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ABSTRACT 
The cellular mechanisms by which antipsychotic medications (neuroleptics) 
produce their therapeutic effects in schizophrenia are largely unknown. 
Although neuroleptic efficacy is attributed to central dopamine D2 andlor 
serotonin 5-HT2 receptor antagonism, clinical improvements in schizophrenia 
are not seen until two or three weeks after daily neuroleptic administration. The 
mechanisms underlying the neuroleptic response must therefore occur 
downstream from initial receptor blockade and be a consequence of continuous. 
chronic neurotransmitter receptor blockade. The goal of the present study was 
to use neuroleptics with varing dopamine vs. serotonergic receptor blocking 
profiles to elucidate some of these intracellular post receptor mechanisms. 
Since both the final steps of dopamine and serotonin synthesis require the 
enzyme aromatic L-amino acid decarboxylase (AADC), the effects of 
neuroleptics on AADC gene (mRNA) expression were examined in PC12 cells 
and compared to their effects on tyrosine hydroxylase (TH; the apparent rate 
limiting enzyme in the synthesis of dopamine) and c-fos (an early immediate 
gene [IEG] known to regulate tyrosine hydroxylase) gene expression. The 
neuroleptics examined did not significantly regulate AADC mRNA in PC12 cells, 
and only haloperidol regulated TH and c-fos mRNA. 
Later in vivo studies in rats showed that acute neuroleptic administration 
increased c-fos mRNA in a number of brain regions, whereas the 
immunoreactivity of a related IEG (delta FosB) was increased upon chronic 
treatment. These studies and a subsequent dose response study 
demonstrated that upregulation of both c-fos mRNA and delta FosB 
imrnunoreactivity was most prominent in dopaminergic projection areas, 
including the striatum and nucleus accumbens. 
Because it has been suggested that neuroleptic treatment might prevent 
neurodegeneration in schizophrenia, the effects of neuroleptics on the mRNA 
expression of neuroprotective target genes of delta FosB were examined both 
in vitro and in vivo. These genes included brain-derived neurotrophic factor 
(BDNF), the neuroprotective enzyme superoxide dismutase (SOD), and the low 
affinity nerve growth factor receptor (p75). While dopamine Dg blockade 
unfavorably regulated BDNF and p75 mRNA, 5-HT2 blockade either had no 
effect on or favorably regulated BDNF, SOD, and p75 mRNA. 
Thus, although very little about the contribution of serotonergic blockade to 
the neuroleptic response was determined in the present study, dopaminergic 
blockade was found to regulate IEGs and several of their target genes. Future 
studies will be needed to understand the role of 5-HT2 receptor blockade in the 
neuroleptic response. 
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The Effects of Some Typical and Atypical Neuroleptics on Gene 
Regulation: Implications for the Treatment of Schizophrenia 
1. INTRODUCTION 
1.1 . Schizophrenia 
Schizophrenia is a serious mental disorder of thought and mood that is only 
partially understood in terms of both its causes and its treatment. It strikes 
approximately 1 % of the population (Sartorious et at., 1972), and its most 
incapacitating forms often escape scientific understanding and remain 
resistant to medical intervention (Keefe et al., 1987). Victims of schizophrenia 
have been estimated to occupy 20% of all psychiatric hospital beds in the 
United States (Roberts, 1990) and 8% of all hospital beds in Canada 
(Statistics Canada, 1991 ), and often do not recover fully from their illnesses. 
1 .I. 1 Definition and clinical presentation 
The symptoms of schizophrenia are traditionally broken down into positive 
(delusions, hallucinations, disorganized1 bizarre behavior), negative (flattened 
affect, limited social adjustment), and cognitive (impaired attention, poverty of 
speech) symptoms (Andreasen et al., 1990; Andreasen, 1994). Vague 
psychiatric symptoms such as social withdrawal, changes in sleep patterns, 
and poor hygiene usually precede the appearance of symptoms that meet the 
DSM IV (1 994) criteria for schizophrenia (Gross, 1997; Parnas, 1999). 
Patients often seek medical attention after a psychotic episode involving one 
or more positive symptoms (McGlashan and Johannessen, 1996). At this 
point in the illness, the patient has often experienced some of the negative and 
cognitive symptoms of the disorder as well (Hafner, 1998; McGlashan, 1998a. 
b). Symptoms usually occur after the onset of adolescence (Hafner et al., 
1993), with men experiencing an earlier onset of the disorder (late teens to mid 
twenties) than women (twenties to early thirties; Seeman, 1997). 
1.1 -2 Treatment and prognosis 
Traditionally, the positive symptoms of schizophrenia usually respond well 
to neuroleptics, while the negative and cognitive symptoms have been difficult 
to treat (Crow, 1980; Andreasen et al, 1990). Prognosis varies, with 
approximately one third of patients responding well to treatment, one third 
having moderate symptom relief accompanied by relapses, and one third 
remaining resistant to treatment (Schellenberg et al., 1994). Older 
dopaminergic blocking neuroleptics such as haloperidol are efficacious in 
treating positive symptoms (Creese et al., 1976), but do not significantly 
ameliorate negative symptoms (Crow, 1985) and may in fact worsen them 
(Finzen, 1991 ; Palao et al., 1994). Traditional neuroleptics may also cause 
significant Parkinson-like motor side effects such as tremor, muscular rigidity, 
and akinesia (Van Putten, 1974; Sovner and DiMasico, 1978). In addition, 
long term treatment with typical neuroleptics can cause tardive dyskinesia 
(TD), a hyperkinetic disorder characterized by abnormal involuntary 
movements of the tongue and mouth (Clemens et al., 1976; Clyne and Juhl, 
1976; Gunne and Barany, 1976; Stimmel, 1976; Burt et at., 1977). Newer 
neuroleptics such as risperidone, quetiapine, sertindole, ziprasidone, 
clozapine, and olanzapine, which block both dopaminergic and serotonergic 
receptors, not only have less severe motor side effects (Roose et al., 1988; 
Meco et al., 1989; Gerlach, 1991 ; lchikawa and Meltzer, 1999), but also 
ameliorate some negative and cognitive symptoms (Bersani et al., 1986, 1990; 
Velligan and Miller, 1999; Remington and Kapur, 2000). Nevertheless, many 
people with schizophrenia never fully recover from the disorder and remain 
resistant to current treatments (Schellenberg et al., 1994). 
1.2 Selected theories of cause and aetiology in schizophrenia 
Although researchers have long searched for a unitary hypothesis of 
schizophrenia, current thought posits that schizophrenia is likely caused by a 
variety of environmental and biological factors. Some suggest that many 
different causes (genetic, environmental, etc.) converge on a common 
pathophysiology (Crow, 1 980). However, most researchers presently agree 
that the clinical symptoms of schizophrenia represent a cluster of related 
disorders that are pathophysiologically heterogeneous (Carpenter and 
Kirkpatrick, 1988) involving a number of neural mechanisms, 
neurotransmitters, and brain regions (Tsuang et al., 1990; Lieberman and 
Koreen, 1993). The following is a brief review of some theories of cause and 
aetiology in schizophrenia. 
1.2.1 Neurotransmitter and receptor theories 
Doparnine (DA), serotonin (5-HTz), glutamatergic, gamma-aminobutyric 
acid (GABA), noradrenaline, acetylcholine and several other neurotransmitters 
and their receptors have all been implicated in the pathophysiology of 
schizophrenia. Levels of these transmitters and/ or their receptors have either 
been found to be altered in schizophrenia or altered by neuroleptic treatment 
(reviewed by Duncan et al., 1999). Current neurotransmitter theories of 
schizophrenia and explanations surrounding the mechanisms of action of 
antipsychotics primarily involve dopamine and serotonin. Since both 
dopamine type 2 (Dp)  and serotonin type 2 (5-HT2) receptor antagonists have 
been successful in the treatment of some patients with schizophrenia, it 
follows that both transmitters are either implicated in the pathology of the 
disorder or can be altered to improve the symptoms of the disease (Huttunen, 
1995). A brief description of the suspected roles of DA, 5-HT and glutamate in 
schizophrenia follows. 
1 -2.1 -1 Dopamine 
The doparnine hypothesis of schizophrenia was the primary theory 
directing schizophrenia research during the past 40 years (Lidow et al., 1998) 
and is still the most comprehensive theory of schizophrenia (Duncan et al., 
1999). This hypothesis is primarily based on two findings (Carlsson, 1988; 
Civelli et al.. 1993): That dopamine agonists such as 3,4- 
dihydroxyphenylalanine (L-DOPA) used to treat Parkinson's disease (Ehringer 
and Hornykiewicz, 1960; Birkmayer and Hornykiewicz, 1 962; Hornykiewicz, 
1966) often result in psychotic side effects (Crowley et al., 1 978), and that 
most neuroleptics, such as chlorpromazine and haloperidol, block 0 2  
receptors and increase brain dopamine turnover (Carisson and Lindquist, 
1963) with a potency that parallels that of their antipsychotic effects (Seeman 
et al., 1975, 1976; Creese et al., 1976; Snyder, 1976). 
Dopamine D2 receptors are found in high concentrations in the caudate 
putamen, nucleus accumbens, and olfactory tubercles primarily as 
autoreceptors on presynaptic terminals (Maeno, 1982; Memo et a!. , 1983; 
Boyson et al., 1986; De Keyser et al., 1988). Findings of elevated striatal D2 
(Mita et al., 1986) and cortical Dq (Seeman et al., 1993; Murray et al., 1995) 
receptors in schizophrenics would support a role of doparnine in 
schizophrenia. It is unclear, however, whether these receptor increases 
actually underlie the pathophysiology of the disorder or if they are due to 
normal compensatory mechanisms of the dopaminergic neuron aimed to 
counteract the doparnine blocking effects of antipsychotic drug treatment 
(Duncan et al., 1999). In addition, initial findings of Dp (Sarkar et al., 1991; 
Catalano et al., 1992) and Dq (DiBella et al., 1996) receptor gene 
poylmorphisms in schizophrenia have not been replicated (Su et al.. 1993; 
Crawford et al., 1996; Ohara et al., 1998). 
After more than forty years of investigation into the dopamine hypothesis of 
schizophrenia, there is still no direct evidence of altered neurotransmission in 
schizophrenia (Duncan et al., 1999). Since most typical 02 receptor blockers 
do not ameliorate the negative and cognitive symptoms of schizophrenia 
(Crow, 1980; Andreasen et al, 1990; Gerlach, 1991 ), the biological correlates 
of schizophrenia are thought to involve more than one transmitter system or 
brain region (Samanin et al., 1978). This is supported by the development of 
highly beneficial antipsychotics such as clozapine, olanzapine, and 
risperidone. These compounds appear to act primarily at sites other than the 
D2 receptor (Iversen, 1985: Meltzer and Nash, 1 99 1 ; Niznik and Van Tol, 
1992). Thus, the hypothesis of excess dopaminergic activity in schizophrenia 
cannot fully account for the disorder's etiology (Reynolds, 1992; DeLecuona et 
al., 1993). 
In recent years, the dopamine hypothesis of schizophrenia has been 
modified to suggest that schizophrenia involves a regulatory imbalance, rather 
than an excess, of doparnine (Davis et al., 1991 ; Grace, 1991 ; Deutch, 1992). 
The positive symptoms of schizophrenia, which have typically responded well 
to classical D2 receptor antagonists, are thought to involve hyperdopaminergic 
activity in mesolimbic structures of the brain, including projections from the 
ventral tegmental area (VTA) to the nucleus accumbens (NuAcc; Grace, 1991 ; 
Duncan et al., 1999). The negative symptoms of schizophrenia are thought to 
involve a relative deficit in dopaminergic activity in the mesocortical system, 
including the medial frontal cortex (mPFC), and the dopamine D l  family of 
receptors (Volkow et al., 1987). In support of a role of hypodopaminergia in 
schizophrenia, Losonczy et al. (I 987) found that a subgroup of schizophrenic 
patients showed clinical improvement in cognitive symptoms in response to 
dopamine agonists such as L-DOPA, methylphenidate, and 
dextroamphetamine. These compounds, however, worsen positive symptoms 
in many patients (Koreen et al., 1997; Szeszko et al., 1999), - further 
illustrating the notion that schizophrenia is pathophysiologically heterogeneous 
and not likely to be understood in terms of a single transmitter system. 
1.2.1 -2 Serotonin 
The hallucinogenic properties of the serotonin (5-HT) receptor antagonist 
lysergic acid diethylamide (LSD) first sparked interest in a serotonergic 
hypothesis of schizophrenia as early as the 1950s (Gaddum, 1953; Wolley and 
Shaw, 1954; Bleich et al., 1991 ). When it was found that other 5-HT 
antagonists lacked hallucinogenic properties and that LSD could also act as a 
5-HT agonist (Van Praag, 1992), the serotonin hypothesis fell into disrepute 
(Iqbal and Van Praag, 1995). Interest in the serotonergic hypothesis was 
rekindled by the finding that newer neuroleptics such as clozapine. 
risperidone, and olanzapine block a greater proportion of serotonergic 
receptors (specifically, type 2a receptors) compared to dopaminergic receptors 
at clinically relevant doses (Meltzer, 1995). 
High densities of serotonin type 2A ( ~ - H T ~ A )  receptors are found in the 
prefrontal cortex (PFC), claustrum, and in platelets (Goodman, 1994). A role 
of serotonin in schizophrenia is supported by post rnortem findings of elevated 
cortical 5-HTza receptors (Mita et al., 1986). These findings, however, may be 
confounded by the 5-HT2 blocking properties actions of neuroleptics, in that 
the 5-HTza receptor upregulation in schizophrenics may be a compensatory 
mechanism to counteract 5-HTza receptor blockade (Duncan et al., 1999). 
Initial findings of 5-HT2 receptor (Erdmann et al.. 1996; lnayama et al., 1996) 
and the serotonin transporter (Dean et al., 1995, 1996; Naylor et al., 1996) 
allelic polymorphisms in schizophrenics have not been replicated (Ishigaki et 
al., 1996; Hawi et al., 1997; Verga et al., 1997; Stober et al., 1998; He et al., 
1999). Some investigators have found increases in blood serotonin levels in 
schizophrenics (Todrick et al., 1960; Garelis et al., 1975), but others have not 
replicated these results (Fefdstein et al., 1959; Halevy et al., 1965). 
Although the role of serotonin in schizophrenia is unclear, it has been 
proposed that newer neuroleptics treat the negative symptoms of 
schizophrenia via their 5HT2 receptor antagonism (Gelders et al., 1989). 
Serotonin 5-HT2 receptor antagonists, such as ritanserin, reduce negative 
symptoms in schizophrenia (Bersani et al.. 1986; Ugedo et al., 1989; Kay and 
Sandyk. 1990) without the extrapyramidal side effects (ESP) often associated 
with D2 receptor blockade. The reduction of negative symptoms by such 5- 
HT2 blockers is thought to be due to the removal of serotonergic inhibition on 
VTA dopaminergic neurons which project to the PFC (Ugedo et al, 1989; Chen 
et al, 1992). This means that 5-HT2 receptor blockade will increase 
doparninergic transmission to the PFC where a hypodopaminergic state is 
hypothesized to exist in schizophrenia (Losonczy et al., 1987). Thus, the 
removal of serotonergic inhibition on mesocortical pathways by 5-HT2 
antagonists may increase the doparninergic activity of the mesocortical path- 
ways to reduce negative symptoms, which may in turn inhibit the dopaminergic 
activity of the mesolimbic system (and reduce positive symptoms). 
Both D2 and 5-HT2 receptor antagonists have been successful in the 
treatment of symptoms in many patients with schizophrenia. Even if these 
transmitter pathways cannot be directly implicated in the disorder, it is well 
known that they can be altered to improve the symptoms of the disease in 
about two thirds of all patients (Andreasen and Black, 1997). 
1.2.2. t Glutamate 
The discovery by Kim et al. (1 980) of low glutamate in the cerebrospinal 
fluid (CSF) of schizophrenics first sparked interest in a glutamatergic 
hypothesis of the disorder (Olney and Farber, 1995). Although this particular 
finding was not consistently replicated (Perry, 1982), indirect evidence exists 
to support N-methyl-D-aspartate (NMDA) glutamate receptor hypofunction 
(i.e., decreased function and efficiency) in schizophrenia. The cyclohexamine 
anesthetics phencyclidine (PCP) and ketamine are noncompetitive antagonists 
of the ionotrophic NMDA glutamate receptor, and produce behaviours similar 
to those of schizophrenia (Cohen et al., 1962; Javitt and Zutikin, 1991 ; 
Malhotra et al., 1997). These agents also exacerbate symptoms in those with 
schizophrenia (Ital et al., 1967), whereby ketamine will produce hallucinations 
and delusions mimicking those previously experienced by the patient (Lahti et 
al., 1995; Duncan et al., 1999). Since symptoms of schizophrenia are not 
usually seen before adolescence, it is also interesting that ketarnine only 
produces psychosis in post-adolescent children and adults but not young 
children (Reich and Silvay, 1989), suggesting that neurodevelopment of 
glutarnate and glutamate-related pathways during adolescence have a role in 
the development of schizophrenia. 
Although cortical messenger ribonucleic acid (mRNA) levels of the NR2D 
subunit of the NMDA receptor have been reported to be increased in 
schizophrenia (Akbarian et al., 1996), while hippocampal glutamatergic GIuR1 
and GluR2 receptor subunit mRNA has been reported to be decreased 
(Harrison et al., 1991 ; Eastwood et al., 1995), these results may be 
confounded by neuroleptic treatment. Increased NR20 subunit mRNA could 
also be interpreted as a compensatory mechanism to combat NMDA receptor 
hypofunction. It has been hypothesized that cortical NMDA receptor 
hypofunction produces the positive symptoms and hyperdopaminergia of 
schizophrenia because it can increase dopaminergic neurotransmission from 
the VTA to the NuAcc via a removal of GABA-mediated inhibition of 
dopaminergic neurons (Freeman and Bunney, 1984; French et al., 1991 ). 
Interactions between dopamine and glutamate relevant to schizophrenia are, 
however, just beginning to be understood. Specifically, cortical dopaminel 
glutamate interactions are thought to underlie several positive and negative 
symptoms of the disorder (Moghaddarn et al., 1997; Sulzer et al., 1998; Moore 
et al., 1999), especially those such as hallucinations, delusions, and thought 
disorders which are thought to be exacerbated by stress (Finlay and Zigmond, 
1997). These neurotransmitter interactions are likely to be the focus of much 
future schizophrenia research. 
1.2.2 Theories of neuropathology 
Although several neuropathological findings have been reported in 
schizophrenia, few are specific to the disorder and even fewer are consistently 
replicated. Investigators have attributed the inconsistencies to the structural 
brain abnormalities of schizophrenia being subtle rather than large (Jeste and 
Lohr, 1989; Fukuzako et at., 1995). to the heterogeneity of the clinical 
presentations of the disorder (Tsuang et al., 1990). and to differences in 
methodology (And reasen and Black, 1997). 
Although not exclusive to schizophrenia, significant reductions in volume 
have been found in the hippocampus (Jeste and Lohr. 1989; Bogerts et al., 
1990; DeLisi et al., 1997), the thalamus (Andreasen et al., 1990; Pakkenberg, 
1990, 1992, 1993), and the prefrontal cortex (PFC; Rajkowska et al., 1994) 
accompanied by ventricular enlargement (Weinberger et al., 1979, 1982; 
Bogerts et al., 1985; Brown et al., 1986; Crow et al., 1989; Suddath et al., 
1989; Dauphinais et al., 1990; Raz and Raz, 1990; DeGreef et at., 1992) in 
those with the disorder. These findings suggest that neuronal atrophy andlor 
cell loss occurs at some point previous to, during, or after the acute clinical 
phase of the disorder. Because post mortem analysis of schizophrenic tissue 
is usually performed after a long course of illness andlor drug treatment, it is 
difficult to ascertain if this tissue loss occurred predominantly during prenatal 
neurodevelopment, at the time of symptom onset, or throughout the course of 
the illness. Thus, it is unknown whether neurodevelopmental and/or 
neurodegenerative processes underlie the neuropathology of schizophrenia, or 
if reductions in brain volume are reflective of reduced cell numbers, atrophy of 
schizophrenia are often pitted against neurodegenerative theories, it is likely 
that schizophrenia involves both processes, as outlined in the next two 
sections. 
1.2.2.1 Neurodeveloprnental theories 
The neurodevelopmental hypothesis of schizophrenia is currently the most 
widely accepted theory of the pathogenesis of schizophrenia (Duncan et al., 
1999). It poses that a genetic defect or environmental insult experienced by 
the fetus in the second trimester of pregnancy initiates the cascade of events 
leading the development of schizophrenia (Murray and Lewis, 1987; 
Weinberger, 1987; Bogerts, 1993; Jones and Cannon. 1998). The symptoms 
of schizophrenia are not often seen until adolescence, primarily because the 
neural pathways normally required to execute the brain functions that are 
abnormal in schizophrenia are not recruited until the development of executive 
cognitive function at puberty (Weinberger, 1987). The adolescent onset of 
schizophrenia may seem to contradict a neurodevelopmental hypothesis since 
one might expect a preterm insult to have immediately apparent behavioral 
and/or physical consequences. The finding that the dissociative anesthetic 
ketarnine produces hallucinations only in post pubertal adolescent and adults, 
but not children (Reich and Silvay, 1989), suggests that the anatomical 
substrates for psychosis do not develop until puberty. 
Several clinical findings in schizophrenics support these developmental 
theories. For example, neurological soft signs including motor and cognitive 
abnormalities are often found in children who go on to develop schizophrenia 
(Erlenmeyer-Kimling and Cornblatt. 1987; Green et al., 1989; Walker and 
Lewine, 1990; Done et al., 1994; Jones and Cannon, 1998) and other 
neurodevelopmental disorders such as autism (Goodman et at., 1994; Rodier 
et al., 1997). Schizophrenics also possess a greater number of minor physical 
abnormalities than the general population (Lane et al., 1996, Trixler et al., 
1997, lsmail et al., 1998; Bassett and Chow, 1999; Torrey, 1999) which 
include such physical anomalies as clinodactyly (adduction of the distal 
phalanx of the fifth digit, i.e., a bent baby finger) and minor abnormalities of the 
ears, mouth and eyes (Akabaliev and Sivkov, 1998). Although lacking in 
clinical significance, these minor physical abnormalities are thought to reflect 
subtle errors of developmental migration that correlate with neuro- 
developmental abnormalities (Buckley, 1998). Since the prominence of minor 
physical abnormalities in schizophrenia has been associated with the severity 
of negative symptoms and with lower premorbid functioning (Buckley et al., 
1994; Waddington et at., 1999). it is possible that the degree of mismigration is 
also related to the severity of these symptoms. 
Neuropathological findings in schizophrenia such as reduced brain volume 
and ventricular enlargement have traditionally been attributed to abnormal 
neurodevelopment during the second trimester of pregnancy (Bogerts. 1993; 
Harrison, 1995). Some researchers have found that these decreases in brain 
volume are stable and do not change throughout the illness (Fukuzako et al., 
1995). Specific cytoarchitectural changes in the cingulate cortex (Benes et al., 
1991 ), the entorhinal cortex (Arnold et al., 1991 ), the parahippocampal cortex 
(Jakob and Beckman, 1986), the frontal lobes (Akbarian et al., 1993), the 
hippocampus (Iritani et al., 1999), and alterations of prenatal forms of neural 
cell adhesion molecules ("NCAMs"; Vawter et al., 1998) that suggest neuronal 
mismigration andlor a failure of "inside out" migration during neuro- 
development in the second trimester of pregnancy, provide even more 
evidence of the neurodeveloprnental basis to this disease. Some laboratories 
have, however, not replicated these findings of altered neuronal migration 
(Akbarian et al., 1996). Nevertheless, both animal models of schizophrenia 
which mimic such prenatal cytoarchitectural changes (Lipska et al., 1993) and 
NCAM knockout mice (Wood et al., 1998) consistently show the anatomical 
and behavioural abnormalities that characterize the disorder and support a 
role of neurodevelopment in schizophrenia. 
The most convincing evidence of a failure of inside-out migration during 
neurodevelopement in schizophrenia comes from studies of "Reeler" mice and 
the reelin gene (Gonzalez et al., 1997). In Reeler mice, the loss of the reelin 
protein causes a failure of "inside-out" migration in the cortex and produces a 
disorganized "outside-in" pattern of neuronal migration (Caviness and 
Sidman, 1973; Caviness and Rakic, 1978; Goffinet, 1979; Caviness, 1982) 
similar to that seen in the brains of some schizophrenics (Fatemi et al., 1999). 
The Reeler mouse shows some behavioral similarities to schizophrenia, such 
as an impaired prepulse inhibition of startle (Tueting et al., 1999). In addition, 
reelin mRNA is decreased in the prefrontal cortex, hippocampus, temporal 
cortices, caudate, and cerebellum of schizophrenics, while reelin protein is 
also decreased in the temporal cortex (Impagnatiello et al., 1998) in 
comparison to controls. Although some sort of neurodevelopmental insult is 
thought to underlie most forms of schizophrenia, the mechanism of action is 
still unknown, and is certainly not currently amenable to treatment. 
1 -2.2.2 Neurodegeneration in schizophrenia 
As previously discussed, neurodevelopmental theories of schizophrenia 
posit that neurodeveloprnental insults during the second trimester of 
pregnancy produce the disarrayed or "dysconnected" neuronal circuitry which 
underlie the disorder, and that overt symptoms emerge only when these 
disordered pathways are recruited at adolescence. While few investigators 
would deny that neurodevelopmental abnormalities underlie the disorder, 
many would argue that these neuronal changes are not static but 
progressively worsen throughout the course of the illness. There is much 
clinical and anatomical evidence to suggest that some aspects of 
schizophrenia involve an active neurodegenerative component which starts 
prior to the onset of the symptoms and continues throughout the disorder 
(Woods, 1998). This includes the observations which are described below: 
Symptoms of schizophrenia worsen over time (section 1.2.2.2.1). 
Early intervention with certain neuroleptics improves long term 
outcome (section 1.2.2.2.2). 
Some anatomical changes in schizophrenia are ongoing throughout 
the course of the illness (section 1.2.2.2.3). 
1.2.2.2.1 Symptoms of schizophrenia worsen over time 
Traditionally, the term "neurodevelopmental" has been used in the literature 
to describe events occurring in fetal and perinatal life and not those of 
adolescence. The neurodevelopmental hypothesis of schizo-phrenia as such 
therefore explains a good deal of the initial patho-physiology of the disorder, 
but does not explain why some symptoms continue to worsen and become 
more irreversible after key neuro-developmental periods (i.e., post 
adolescence; McGlashan, 1998a, b). 
Although negative and cognitive symptoms often tend to progress as the 
patient ages, the positive symptoms of schizophrenia generally remain stable 
or regress with age (Waddington et al.. 1997 a,b). It is thus thought that the 
negative and cognitive symptoms of the disorder may be characterized by a 
neurodegenerative process, which is supported by several findings. For 
example, cross-sectional studies have shown that negative but not positive 
symptoms significantly worsen with age and duration of the illness 
(Waddington et al., 1997a,b) in both younger (Peralta et al., 1995) and older 
(Arnold et al., 1995; Davidson et al., 1995) patients. McGlashan and Fenton 
(1992) found that negative, but not positive, symptoms were variable early in 
the course of the illness. Since this deterioration of negative symptoms occurs 
long after initial neurodevelopmental periods, and since negative symptoms 
are particularly difficult to treat (Crow, 1980), it is possible that an ongoing 
neurodegenerative process accompanies and underlies the progressive 
worsening and seeming irreversibility of these symptoms. 
Like the negative symptoms, cognitive symptoms have been found to 
worsen with time (Arnold et al., 1995; Delisi et al., 1995; Delisi, 1996; Davidson 
and McGlashan, 1997)' especially in patients who do not have marked 
cognitive dysfunction at the beginning of such longitutindal studies (Harvey et 
al., 1995; 1996). Bilder et al. (1 992) found that cognitive deterioration 
continued in young patients after the first episode of psychosis, and in a 
nineteen year longitudinal study it was found that the participants had a seven 
times greater chance of developing psychosis if cognitive abilities declined 
from childhood to adulthood (Kremen et al., 1998). Since cognitive decline is 
integral to many post pubertal neurodegenerative disorders such as 
Alzheimer's disease, Huntington's disease, and even Parkinson's disease 
(which also affect brain circuitry purported to be altered in schizophrenia), it 
would not be surprising if the cognitive deficits accompanying schizophrenia 
are also characterized by neurodegeneration. 
1.2.2.2.2 Early intervention with neuroleptics improves long term outcome 
Many clinicians attest that some of the symptoms of schizophrenia not only 
worsen over time (McGlashan and Fenton, 1993; DeQuardo, 1998) but that 
untreated schizophrenia can eventually develop into a more permanent 
(reviewed by Waddington et at., 1 998a,b; 1 997a.b; Fenton and McGlashan, 
1994) and less treatable state (Waddington et al., 1991, 1995, 1997a,b, 1998, 
1999; Wyatt et al., 1991 a, b; 1995; 1997; Falloon, 1992; Loebel et al., 1992; ; 
McGlashan and Fenton, 1992,1993; McGlashan, 1996a, b; McGlashan and 
Johannessen, 1996; McGorry, 1998). Studies addressing the abilities of 
neuroleptics to arrest progression of some symptoms of the disorder were 
done as early as 1968 at a time when the efficacy of neuroleptic treatment was 
still in question (Wyatt, 1995). May et al. (1 976a,b, 1981) found that patients 
who received antipsychotic treatment required fewer days of rehospitalization 
two years following the initial discharge. This was supported by later studies by 
McGlashan and Fenton (1 992) and Fenton and McGlashan (1994) who found 
that negative symptoms worsened in schizophrenic patients over a course of 
five years and then became stable and more resistant to treatment. Davidson 
et al. (1995) reviewed eight years of outcome in schizophrenia and also found 
that a longer duration of untreated psychosis was associated with negative 
symptoms and poor outcome, and Rzewuska (1 994) found that the duration of 
untreated psychosis during the first year of illness was a clear predictor of long 
term outcome in the disorder. Thus, there is clear evidence that symptoms of 
schizophrenia continue to worsen long after the onset of adolescence and the 
onset of the disorder. 
I .2.2.2.3 Anatomical evidence of neurodegeneration in schizophrenia 
Due to the absence in schizophrenia of markers of neurodegeneration such 
as gliosis (Nieto and Escobar, 1972; Stevens, l982), neuro-degenerative 
theories of schizophrenia have been few. While one group has found evidence 
of gliosis in schizophrenia (Arnold et at., 1995; Arnold and Trojanowski, 1996) 
this has not been consistently replicated (Roberts et al., 1986; 1987; Bogerts et 
al., 1990; Falkai et al., 1999). The absence of gliosis does not, however, 
necessarily rule out a neuro-degenerative process. For example, apoptotic 
cells are cleared within 24 to 48 hours after death and do not leave traces of 
gross morphological damage (Cotman and Su, 1996). Schizophrenia has 
been said to be an absolute deterioration from previous levels of functioning 
(Miller, 1989), resulting in the irreversibility of symptoms. If 
neurodevelopmental pathological changes are already present before the 
onset of schizophrenia, yet as the disorder progresses symptoms become less 
reversible, it is quite possible that these symptoms become less treatable 
because they are in part caused by neurodegeneration such as neuronal 
atrophy or cell death which occurs during the course of the illness. 
Anatomical and imaging studies of schizophrenia support a role of 
neurodegeneration in the disorder (DeLisi et al., 1995; Coyle, 1996; Nair et al., 
1997). For example, many authors have reported that ventricular enlargement 
progresses over the course of the illness (Woods et al., 1990; DeLisi et al., 
1995, 1997). While progressive ventricular enlargement is thought to play a 
role in other psychiatric disorders, it is likely that it is the most severe in 
disorders which are difficult to treat, including schizophrenia and advanced 
manic depression. 
A progressive reduction in size of several brain structures has also been 
found in schizophrenia (Delisi et al., 1995). Using MRI, Jacobsen et al. (1998) 
found that there was a progressive decrease in the size of temporal lobe 
structures over the course of the illness in childhood schizophrenia, and DeLisi 
(1 997) also found progressive hippocampal atrophy over the course of the 
illness, regardless of the age of onset. Superior temporal gyrus (O'Donnell et 
al., 1995) and frontal lobe (Turetsky et al., 1995) volumes have been found to 
decrease with age and duration of the illness, and Waddington et al. (1991) 
found that the progressive ventricular enlargement accompanying 
schizophrenia correlated with increasing age and the later prominence of 
cortical atrophy. 
There are many clinical correlates to anatomical findings in schizophrenia 
suggesting neurodegeneration. Not only do imaging and neuropsychological 
studies suggest that ongoing neuronal atrophy accompanies schizophrenia 
(Turner et al., 1986; Waddington et al., 1991; Delisi et al, 1997), but several 
investigators have found that such atrophy is associated with poor outcome 
(Woods et al., 1990; Woods and Yurgelun-Todd, 1991 ). Delisi (1 996) found 
that ventricular enlargement occurred throughout the course of the illness and 
correlated with symptom severity. Frecksa et al. (1 994) found that patients 
with a predominance of negative and cognitive symptoms showed a greater 
increase in ventricular size on computerized tomography (CT) scans in 
comparison to controls. Arnold et al. (1995) found that "patients with marked 
cognitive deterioration over time showed more gliosis restricted to the 
subiculum and orbitofrontal cortex than did otherwise similar patients without 
such cognitive impairment", suggesting that there are specific subtypes of 
schizophrenia which are more likely to be characterized by neurodegeneration. 
1.2.2.3 Theories of neurodegeneration in schizophrenia 
The mechanisms of neurodegeneration in schizophrenia are unknown. It is 
possible that neurodegeneration during the active phase of psychosis is 
facilitated by several factors including the underlying neurodevelopmental 
pathology, select environmental insults at adolescence, and the biological 
process of psychosis itself. There are many types of neurodegeneration, some 
of which include cell death (necrosis, gliosis, apoptosis), neuronal atrophy 
(withdrawal of axons. dendritic shortening), and cell membrane damage 
(oxidation). Most of these types of neurodegeneration have been implicated in 
schizophrenia, as will be discussed below. 
1.2.2.3.1 Cell death as intrinsic to schizophrenia 
Although some investigators have reported evidence of gliosis in 
schizophrenia (Arnorld et al., 1995), gliosis does not seem to play a primary 
role in the disorder. Some authors (Margolis et al., 1995; Olney and Farber, 
1995; Coyle, 1996) have hypothesized that programmed cell death (apoptosis) 
may be intrinsic to schizophrenia, but since apoptotic cells are cleared within 
24 to 48 hours of the initiation of cell death (Vincent, 1995; Benjamins and 
Nedelkoska, 1996; Cotman and Su, 1 996), subtle ongoing apoptosis in 
schizophrenia would be almost impossible to detect by current methods. Other 
investigators have found that apoptosis occurs in projection sites of lesioned 
ventral hippocampus in rat models of schizophrenia (Khaing et al., 1999; Ashe, 
2000), suggesting that damage to one brain region can cause cell death in its 
projection neurons (such as those affected in schizophrenia). Cell counts of 
entire brain regions in schizophrenia suggest some degree of cell loss (see 
Bogerts et al., 1983; Benes et al., 1986; Pakkenberg, 1990, 1992, 1993). 
Unless mutant genes directly implicated in apoptosis (such as Bcl-2, p53, etc.) 
can be identified as altered in schizophrenia, investigators must focus on other 
signs of impending cell death (such as reduction of dendritic and axonal 
extensions) to support this hypothesis (see Cattsa and Catts, 2000 for a review 
on the potential role of p53 in schizophrenia). 
1.2.2.3.2 Neuronal atrophy and cell death are due to excessive 
prepubertal synaptic pruning 
According to Huttenlocher (1 979), synaptic density peaks during 
childhood, declines 30 - 40% during adolescence, and stabilizes in adulthood. 
Specifically, cortical development during adolescence is characterized by the 
substantial reductions of synapses (Hoffman and McGlashan, 1997). Since 
large-scale neuronal losses do not normally occur during adolescence (Mani et 
al., 1986), synaptic elimination at puberty is suspected to limit and refine 
connectivity between neurons (Huttenlocher, 1979). 
Feinberg (1 982) was the first investigator to suggest that schizophrenia 
occurs due to excessive pruning and synaptic elimination during adolescence, 
and that symptoms of schizophrenia do not appear until puberty due to the 
redundancy of synapses until pruning during adolescence. Many studies 
suggest that excessive synaptic pruning during adolescence is associated with 
schizophrenia (Hoffman and Dobscha, 1989; Keshavan et al., 1994; Garey et 
al., 1995; Glantz and Lewis, 1995; Margolis et al., 1995; Olney and Farber, 
1995; Selemon et al., 1995; Keshavan, 1999). Not only would this theory 
explain a number of anatomical and clinical findings in schizophrenia, but it 
would also explain increased cell packing and decreased neuropil in the 
schizophrenic cortex (Selemon et at., 1995; see figure 1 .I). As reviewed by 
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Figure 1 .I. Schematic diagram of normal and schizophrenic cortices 
reproduced from Selemon et al., 1995. Neurons are smaller and 
neuropil is reduced in the schizophrenic coxtex. Although the relative 
number of neurons in the schizophrenic vs. control corticies appear to be 
"increased" per square unit of measure, it is more likely that there is either 
no change or is a reduction in cell numbers in the entire cortical area. 
Waddington et al. (1 997a, b), the brain regions where normal neuronal atrophy 
is seen are the same places where changes in schizophrenia are seen, and 
some have suggested that neurotrophin deficits could contribute to such a 
process (Bayer and Falkai, 1997). Thus, excessive synaptic pruning at 
adolescence might not only underlie neuronal atrophy in schizophrenia but 
may set up a compromised neural circuitry in the disorder which is more 
susceptible to neuronally damaging insults such as stress. 
1.2.2.3.3 Neuronal atrophy and cell death are due to the toxic process of 
psychosis 
The theory that neuronal atrophy and cell death in schizophrenia are due to 
the toxic processes of psychosis is quite similar to the hypothesis of excessive 
synaptic pruning. This hypothesis does not, however, propose that 
schizophrenia itself is characterized by abnormal synaptic pruning, but that the 
neuronal atrophy and cell death seen in the disorder are either caused by other 
factors extrinsic to the disorder such as stress (Nuechterlein et al., 1992) and 
drug abuse (Kril et al., 1997) or are epiphenomena1 (Harrison, 1995) to the 
disorder (a result of psychosis). Synaptic pruning at adolescence may 
otherwise be normal. In other words, the additional reduction of neuropil in 
schizophrenia is not intrinsic to the disease process per say, but occurs either 
because stress will cause further neuronal damage on an already 
compromised neuronal circuitry (caused initially by neurodevelopmental 
abnormalities) and/ or because the process of psychosis itself (especially the 
positive symptoms) is excitotoxic to the brain and thus worsens negative 
symptoms by causing cell death andl or atrophy in neurons previously made 
vulnerable by neurodevelopmental abnormalities. This hypothesis is supported 
by findings of increased adult forms of serum (Lyons et al., 1988) and CSF 
(Polkorak et al., 1995) NCAM, as this form of NCAM "has been found to be 
shed from tissues damaged by an ongoing disease process1* (Waddington et 
al., 1997a, b). 
1.2.2.4 Summary 
On the whole, anatomical findings in schizophrenia imply that in addition 
to a probable neurodevelopmental defect in the disorder, there is a 
neurodegenerative component associated with symptom onset (Coyle, 1996; 
Deiisi, 1997) that is positively affected by neuroleptic treatment (May et al.. 
1976a,b, 1981 ; McGlashen and Fenton, 1992; Fenton and McGlashen, 1994). 
Anatomical and clinical findings suggest ongoing neurodegeneration in 
schizophrenia. Although the neurodevelopmental hypothesis in part explains 
the initial pathophysiology of schizophrenia, it does not explain why these 
symptoms continue to worsen and become more irreversible at key 
neurodevelopmental periods such as adolescence. This not only suggests 
progressive neurodegeneration in schizophrenia, but that some neuroleptics 
may in part arrest this process. 
The neurodegenerative hypothesis of schizophrenia can be summarized as 
follows: schizophrenia begins prenatally and progresses until reaching a 
critical threshold, typically in the second or third decade of life. Progressive 
brain volume loss is maximal in the first two decades and slows down with 
age. The tissue loss does not involve persistent gliosis, and damaged 
neurons may be removed by excessive neuronal apoptosis. Most likely, 
normal pruning at adolescence reduces connectivity in the pre-schizophrenic 
brain to levels which are now insufficient for normal neurotransmission, and 
additional neuronal atrophy and or cell death due to stress (Uno et al., 1989; 
Watanabe et al., 1992; Stein-Behrens et al., 1994) may cause further damage 
an already compromised circuitry. Increasing evidence that early intervention 
with neuroleptics can improve long term outcome demands that the molecular 
mechanism(s), by which neuroleptics could do this be elucidated, and is one of 
the primary foci of the present study. Thus, the apparent superior clinical 
efficacy of these neuroleptics may be due in part to their neuroprotective 
capabilities and their abilities to prevent further neurodegeneration in 
schizophrenia. 
1.3 Treatment of schizophrenia 
Although neuroleptic treatments for schizophrenia continue to improve, it is 
difficult to design efficacious medications for a disorder which is so poorly 
understood. Also, a neuroleptic which treats the majority of symptoms in the 
majority of patients is yet to be discovered (reviewed by Ayd, 1991; Lehrnann 
and Ban, 1997). 
1.3.1 History 
The first efficacious treatment of the disorder was described by Sen and 
Bose in (1931), who reported treating insanity with the plant Rauwolfia 
serpentina (as cited in Bhatara et al., 1997). It is known today that there are 
several active alkaloids in this plant which produce similar antipsychotic 
effects. The use of this particular alkaloid, which is now known as reserpine 
(Giachetti and Shore, 1978; Guo, 1 996), fell out of favor as other 
antipsychotics became available (Ayd, 1991 ). In 1951, Laborit and Huguenard 
administered the phenothiazine derivative chlorpromazine to presurgical 
patients as an anesthetic (Shen, 1999). Observations by Delay et al. (1952) of 
the mood stabilizing effects of chlorpromazine the led them to systematically 
test its effects in schizophrenics (Delay et al., 1952; Ayd, 1991 ). They found 
that while chlorpromazine could reduce psychotic and delusional symptoms, it 
did not affect "deficiency" (negative) symptoms (Delay et al., 1952). 
The next landmark in the treatment of schizophrenia came with the 
synthesis of the butyrophenone haloperidol in 1958 by Bert Hermans of 
Janssen Pharmaceutica (Ayd, 1991 ; reviewed by Granger, 1999). Intended as 
an analgesic, Paul Janssen nevertheless arranged for psychiatrists to test 
haloperidol on patients before animal studies were complete (Ayd, 7991 ). Its 
subsequent clinical success precipitated the further development of many 
classes of neuroleptics including the azaphenothiazines, thioxanthines, 
benzoquinolizines, diphenylbutylpiperidines, and other butyrophenones and 
phenothiazines (Lehmann and Ban, 1997), as well as the dibenzodiazepine 
derivative clozapine, which was first used in clinical practice in 1972 (Hector, 
1998). 
With the exception of clozapine, these neuroleptics all produced Parkinson- 
like motor extrapyramidal side effects (EPS), a side effect that, up until the 
19703, was taken as a mark of neuroleptic efficacy (Guo. 1996). The 
discovery that these neuroleptics blocked D2 receptors with a potency that 
paralleled that of their antipsychotic effects (Creese et a!, 1976; Seeman et al, 
1976; Snyder, 1976), their ability to produce EPS, and the observations that 
the DA agonist amphetamine casued psychosis (Crowley et al., 1968; Espelin 
and Done, 1968) led researchers to form the initial dopamine hypothesis of 
schizophrenia. Clinical observations, however, that clozapine was efficacious 
in treating schizophrenia without producing EPS brought into question the 
necessity of EPS to predict the potency of neuroleptics (Stille and Hippius, 
1971 ; Burki et al., 1973; Matz et al., 1974) and had researchers asking if the 
DA hypothesis could fully account for the symptoms, pathophysiology, and 
treatment of the disorder (Burki et al., 1975; Alpert and Friedhoff, 1980). 
Clozapine was thus called an "atypical" neuroleptic because it did not produce 
EPS as did the other "typical" neuroleptics of the 1970's (Lehmann and Ban, 
1997). 
1.3.2 The concept of typicality vs. atypicality 
Although clozapine could treat the negative symptoms of schizophrenia, it 
carried with it a small risk of the fatal blood disorder agranulocytosis 
(Idanpaan-Heikkila et al., 1 975; Baldessarini and Frankenburg, 1991 ). In 
addition, in some patients, clozapine did not completely ameliorate the positive 
symptoms of the disorder, suggesting that some D2 blockade was still 
necessary for the treatment of positive symptoms. On the other hand, typical 
neuroleptics like haloperidol did not completely treat the negative symptoms of 
the disorder (Strauss and Carpenter, 1977). They also produced motor side 
effects that not only reduced compliance (Van Putten, 1974; Sovner and 
DiMascio, 1978) but were sometimes, as in the case of tardive dyskinesia, 
irreversible (Cadet et al., 1986; Cadet and Lohr, 1989; Cadet and Kahler, 
1994; Rotrosen et al., 1996). In the 1 9801s, pharmaceutical companies 
competed to produce a neuroleptic that would treat the positive, negative, and 
cognitive symptoms of schizophrenia without producing EPS or causing fatal 
blood dyscrasias, and the distinction between typical vs. atypical became the 
most popular way to characterize neuroleptics and guide their development. 
Because it was found that clozapine blocked 5-HT2 receptors to a much 
greater extent than D2 receptors, pharmaceutical companies aimed to design 
atypical neuroleptics with this receptor blocking profile. This led to several 
definitions of typical and atypical neuroleptics, as are described below 
(Lehmann and Ban, 1997): 
a. Neuroleptics which cause EPS are called "typical", whereas neuroleptics 
which produce minimal EPS are called "atypical" (Fog, 1967; Matz et al., 1974; 
Mercugliano et al., 1992). "Typical" refers to all the classical neuroleptics 
which have the therapeutic efficacy and side effect profile of haloperidol, while 
neuroleptics producing a clinical profile similar to ctozapine's would be called 
"atypical" (Lehmann and Ban, 1997). It wasn't until the late 1980's that other 
"atypical" neuroleptics (such as risperidone) became available for clinical use. 
b. Neuroleptics which strongly block Dg receptors in nigrostriatal (mesolimbic) 
pathways and weakly in the nucleus accumbens (mesocortex) are called 
"typical", whereas neuroleptics which weakly block nigrostriatal 0 2  receptors 
and strongly block Dp receptors in the nucleus accumbens are called "atypical" 
(Bunney et al., 1991). 
c. Neuroleptics which block only dopamine D2 receptors are called typical, 
whereas neuroleptics which block both dopamine Dg and serotonergic 5-HT2 
receptors are called atypical (Meltzer, 1993). 
d. Neuroleptics which ameliorate only the positive symptoms of 
schizophrenia are called typical, whereas neuroleptics which ameliorate 
positive, negative, and cognitive symptoms are called atypical. Currently, this 
is the most widely accepted distinction of typical vs. atypical neuroleptics, as it 
does not rely on the receptor blocking properties of the neuroleptic to predict 
its clinical response or its effect on dopaminergic systems (for example, 
remoxipride strongly blocks D2 receptors, but has an "atypical" therapeutic and 
side effect profile). 
1.3.3 Typical neuroleptics used in the present study 
1.3.3.1 Haloperidol 
Haloperidol, a butyrophenone derivative (Janssen and Niemegeers, 1959; 
Divry et al., 1960), is one of the most commonly used "typical" neuroleptics in 
the treatment of schizophrenia. It strongly blocks nigrostriatal dopaminergic 
neurons (Snyder et al., 1973; Seeman et al., 1975). causes significant EPS 
(Divry et al., 1960), weakly blocks serotonergic receptors (Schotte et al., 
1993). and either does not affect or worsens negative and cognitive symptoms 
(Crow, 1980, Van Putten, 1987). At therapeutic doses, it primarily has affinity 
for D2 receptors, followed by alpha1 adrenergic, D l ,  and 5-HT2 receptors 
(Schotte et al., 1996). Haloperidol is often still used as the first line treatment 
for the floridly psychotic patient who visits the emergency room for the first 
time. In light of the development of newer neuroleptics with more favorable 
side effect profiles, haloperidol is used less often, even in the treatment of first 
episode patients. 
Along with a significant risk of producing EPS, haloperidol is highly sedative 
and may cause hyperprolactinemia. In addition, long term haloperidol 
25 
treatment may produce tardive dyskinesia (TD), a potentially irreversible motor 
disorder characterized by involuntary movements of the face, tongue, trunk, 
and extremities (Clemens et al., 1976; Clyne and Juhl, 1976; Gunne and 
Barany, 1976; Stirnmel, 1976; Burt et al., 1977). Although the mechanism by 
which haloperidol causes tardive dyskinesia is unknown, many researchers 
suggest that haloperidol-like neuroleptics cause cell death in the affected 
motor regions (Cadet et al., 1986; Cadet and Lohr, 1989; Lohr et al., 1990; 
Lohr. 1991, 1992). perhaps due to increased free radical formation caused by 
neuroleptic induced increases in dopamine turnover (Stein and Wise, 1971 ; 
Graham et al., 1978; Matsumoto et al., 1983). This is supported by the finding 
of a toxic metabolite of haloperidol (Fang and Gorrod, 1991 ; Fang and Yu, 
1997), increased iron in post-mortem brains of those with TD (Hunter et al., 
1968; Campbell et al., l985), the discovery of a reduced free radical 
scavenging enzyme in patients with neuroleptic induced TD (Yarnada et al., 
1997), and the improvement of TD following treatment with the antioxidant 
vitamin E (Lohr et al.. 1987, 1988; Elkashef et al., 1990; Schmidt et al., 1991 ; 
Egan et al., 1992; Shriqui et al., 1992, Adler et al., 1992; Peet et al., 1993). 
Nevertheless, haloperidol remains an effective treatment for those 
schizophrenics who have predominantly positive symptoms. 
1.3.4 Atypical neuroleptics used in the present study 
The atypical neuroleptics chosen for the present study were primarily 
selected based on their receptor binding profiles. Since efficacious 
neuroleptics bind to Dp and/ or 5-HT2 receptors, three of the neuroleptics used 
(remoxipride, risperidone, ritanserin) were chosen based on their differential 
blockade of these receptors (D2, D215-HT2, and 5-HT2 receptors 
respectively). However, their degree of clinical use, availability for laboratory 
testing, and chemical structures were also considered for their inclusion in the 
planned experiments. Clozapine and haloperidol were chosen due to their 
substantial clinical use and for their different clinical indications in 
schizophrenia, while olanzapine was included in later studies as a comparison 
to clozapine when it became available for laboratory use. 
1 3 4 . 1  Risperidone 
Risperidone is a benzisoxazole derivative which blocks both 5-HT2 and Dg 
receptors at clinically effective doses (Huang et al., 1993). It was the first 
successful new atypical antipsychotic since clozapine and a significant 
improvement over previous neuroleptics (Leysen et al., 1988). Not only can it 
treat both positive and negative symptoms of the disorder, but it produces less 
EPS and does not cause agranulocytosis (Claus et al., 1992; Chouinard et al., 
1993). It is currently considered by many physicians to be first line treatment 
for schizophrenia, and some clinicians report that risperidone can even correct 
pre-existing motor abnormalities (Claus et al., 1992; Chouinard et al., 1993). 
Risperidone binds most strongly to ~ - H T ~ A  receptors, followed by 
noradrenergic alpha1 , Dq, histaminergic, serotonergic type 1A (~HTIA), 
noradrenergic alphap, and D l  receptors (Megens et al., 1994; Leysen et al., 
1992; Schotte et al., 1989). Risperidone and its active metabolite 9- 
hydroxyrisperidone, are equally potent receptor blockers (He et al., 1995). It 
has a narrow therapeutic window, as dose determines its 5-HT2 to Dp receptor 
blocking ratio in vivo (Janssen et al., 1988; Ereshefsky et al., 1993). At 
therapeutic levels, risperidone produces 50% 5-HT2/ 20% D2 blockade at low 
doses to >80% 5-HT2/ >80% D2 blockade at higher doses, roughly 
corresponding to 1-6 mglday (Schotte et al., 1989; reviewed by Grant and 
Fitton, 1994). Lower doses lack efficacy, and higher doses produce EPS 
comparable to those caused by haloperidol (Claus et al., 1992, Chouinard et 
al., 1993). The narrow therapeutic window and dose-dependent variations in 
the relative 5-HT2 to D2 blocking ratio of risperidone make it an excellent 
candidate to study the molecular mechanisms underlying therapeutic efficacy 
vs. side effects. 
1.3.4.2 Ritanserin 
Ritanserin was designed as a pure 5-HT2 receptor blocker a few years 
before the synthesis of risperidone (Leysen et al., 1985) and was used in 
conjunction with haloperidol to treat the negative symptoms of schizophrenia 
(Bersani et al., 1986; Ugedo et at., 1989; Kay and Sandyk, 1990). Its ability to 
reduce haloperidol-induced EPS led to the hypothesis that, at least in 
extrapyramidal motor systems, 5-HT2 receptor blockade could counteract the 
effects of DA receptor blockade. Currently, it has limited clinical use due to 
availability of other compounds which better treat the whole spectrum of 
schizophrenic symptoms. It is still nonetheless a valuable research tool to 
determine the role of serotonin in the action of neuroleptics (Reyntijens et al., 
1 986). 
1 -3.4.3 Clozapine 
Developed in the 1 9 6 0 ' ~ ~  the dibenzodiazepine derivative clozapine was 
the only neuroleptic able to treat the negative symptoms of schizophrenia until 
the advent of risperidone. It has a unique receptor binding profile, with a 
strong affinity for 5-HT2, histaminergic, and noradrenergic alpha1 receptors. 
Clozapine also binds to 5-HTl c, D2, noradrenergic alpha2, cholinergic 
muscarinic, and ~ - H T ~ A  receptors at higher doses, and blocks 04 receptors 
with a potency 5 times greater than D2 receptors (Kapur et al., 1999). 
Clozapine reduces both the positive and negative symptoms of schizophrenia 
(Maj et al., 1974; Meltzer, 1993) without inducing the EPS associated with 
traditional D2 blockers, presumably in part due to its strong ~ - H T ~ A  receptor 
antagonism (Sleich et at., 1988). Although it is arguably still the most potent 
neuroleptic for the refractory, negative symptoms of schizophrenia (Small et 
al., 1987; Kane et al., l988), it is often used only as a last resort due to its 
potential to cause agranulocytosis and the consequent weekly blood 
monitoring required. 
1.3.4.4 Olanzapine 
Olanzapine, a thienobenzodiazepine, was introduced clinically in 1997. 
Structurally similar to clozapine except for a few minor substitutions, it was 
designed to have a clinical efficacy similar to clozapine's without causing 
agranulocytosis (Fulton and Goa, 1997). Unlike any of the other neuroleptics 
tested in the present study, its' strongest affinity is for muscarinic receptors, 
followed by ~ - H T ~ A ,  histaminergic, Dp, Dl, and noradrenergic alpha1 and 
alpha2 receptors (Bymaster et al., 1996; Schotte et al., 1996). It has greater 
Dg receptor blockade than clozapine and can cause EPS, although like 
clozapine it can in some cases reverse particular motor dysfunctions (Littrell et 
al., 1998; O'Brien and Barber, 1998). It treats positive symptoms with the 
same efficacy as haloperidol and treats negative symptoms with an improved 
efficacy (Beasley et al., 1997). Although no direct comparisons have been 
made, many clinicians agree that clozapine is still more efficacious than 
olanzapine in treating the refractory negative symptoms of schizophrenia 
(Sanders and Mossman, 1999). 
1.3.4.5 Remoxipride 
Remoxipride, a benzamide derivative, was released in 1990. It is clinically 
equivalent to haloperidol in its ability to treat primarily the positive, but not the 
negative, symptoms of schizophrenia (Awad et al., 1997; Lapierre et al., 1999). 
Although it is a relatively selective Dq blocker (Ogren et al., 1984), it produces 
EPS only at high doses, the reason for which is unknown (den Boer and 
Westenberg, 1 990; Holm et al., 1993). Remoxipride is no longer used 
clinically because it causes blood dyscrasias such as aplastic anemia 
(Karlsson, 1993; Kewin, 1993; Laidlaw et al., 1993; Philpott et al., 1993). 
Nevertheless, it remains a useful research tool to study the dopaminergic 
mechanisms underlying neuroleptic efficacy that are separate from the 
dopaminergic mechanism thought to underlie EPS. 
1 -4 Candidate genes potentially regulated by neuroleptics 
Efficacious neuroleptics alter both dopaminergic and serotonergic 
neurotransmission. If dopaminergic and/or serotonergic receptor blockade 
were exclusively responsible for treating schizophrenia, one would expect to 
see clinical improvement almost immediately following neuroleptic 
administration (Pickar, 1988; Pickar and Breier, 1989). As clinical 
improvement in schizophrenia is not seen until two or three weeks after 
initiating chronic neuroieptic administration, the neural mechanisms by which 
neuroleptics produce their therapeutic effects must occur downstream from the 
receptor (Duman et al., 1994). Although these mechanisms are presently 
poorly understood, it is thought that the neuroleptic response involves a 
cascade of molecular events starting at the receptor and culminating at the 
nucleus of the neurons that produce long term changes in the expression of 
target genes (Hyman and Nestler, 1993, 1996; see Figure 1.2). 
1.4.1 Signal transduction 
Signal transduction is the term used to describe how cells take an 
extracellular message and convert it into the appropriate intracellular response 
(Chamey et al., 1999). Such responses might include activation or inhibition of 
ion channels, neurotransmitter synthesis and release, or protein synthesis 
(reviewed by Stahl, 1999a-d). Chronic neuroleptic treatment is now known to 
produce long term changes in signal transduction by increasing or decreasing 
the synthesis of several target genes, including enzymes, receptors, and 
growth associated proteins (Hyman and Nestler, 1993), although their actual 
role in the neuroleptic response remains unknown. 
Although neuroleptics have been shown to upregulate the gene expression 
of several proteins relevant to schizophrenia such as the dopamine D2 
receptor, the intracellular events leading up to such neuroleptic-induced 
changes are unknown (Duncan et al., 1999) and alterations in the target genes 
specific to the clinical response of the neuroleprics have not been identified. 
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Figure 1.2: Schematic diagram depicting the intracellular signalling 
pathway for first, second, third and fourth messengem. Taken from Hyman 
and Nestler, 1993 (The Molecular Foundations of Psychiatry. Washington, DC: 
American Psychiatric Press). 
The elucidation of long term changes in signal transduction and the regulation 
of target genes by chronic neuroleptic treatment is therefore the current focus 
of much neuroleptic research (Hyman and Nestler, 1993; 1996). 
1.4.1.1 Dp and 5-HT2 receptor-mediated signal transduction 
The neurotransmitters and peptides which bind to extracellular receptors 
are often referred to as the "first messengers" of the signaling cascade 
(Giacobini, 1976). With respect to neurotransmitter1 receptor initiated signal 
transduction, the extracellular message is detected at the nuclear level only 
after a number of sequential intracellular events take place. Although 
blockade of D2 and 5-HT2 receptors produce opposite effects on intracellular 
signaling cascades, they utilize similar signaling machinery (Charney et al., 
1999). 
Immediately coupled to Dp and 5-HT2 receptors are intracellular coupling 
factors called G-proteins (Battaglia et al., 1984; Titeler et al., 1984; Neve et al., 
1989; Senogles et al., 1990). G-proteins are so named due to their ability to 
bind the nucleotides guanosine triphosphate (GTP), and guanosine 
diphosphate (GDP) (Hyman and Nestler. 1993). The trimeric G-protein does 
not bind to the receptor until it is occupied by its neurotransmitter, at which 
point the GDP-bound alpha subunit of the G-protein is phosphorylated. This in 
turn causes the displacement of GDP by GTP, which then causes the alpha 
subunit to dissociate from the rest of the G-protein (Cassel and Selinger, 1978; 
Cote et al., 1980). This subunit can then either directly mediate ion channels 
or membrane- bound enzymes such as adenylate cyclase (AC) which converts 
adenosine triphosphate (ATP) to the second messenger cyclic adenosine 
monophosphate (CAMP), and phospholipase C (PLC) which converts 
phosphatidylinositol (PI) to the second messengers inositol trisphosphate (IP3) 
and diacylglycerol (DAG) (Arad et al., 1984; Schramm and Selinger, 1984; 
Gonzales and Crews, 1985). 
1.4.1 .I. 1 Specific signaling pathways of dopamine 
The D2 receptor is linked to a GiIGo alpha subunit of its G-protein, 
meaning that the binding of DA to this receptor will either cause an influx of 
potassium (K+) or an inhibition of adenylate cyclase (AC; Neve et al., 1989; 
Senogles et al., 1990). Neuroleptic-induced antagonism of this receptor will 
therefore inhibit K+ influx or stimulate AC. In general, neuroleptic-induced 
activation of AC has been studied in much greater detail than neuroleptic 
induced inhibition of K+ channels (Ahn et al., 1976, Smith et al., 1988; 
Rodriguez-Sanchez et at., 1994). The activation of AC and the subsequent 
increase of intracellular cAMP then causes activation of the phosphorylating 
enzyme cAMP dependent protein kinase (CAMP dependent PK), which 
dissociates the inhibitory regulatory element from the catalytic subunit PKA 
(Gnegy et al., 1 976). 
Not only can PKA phosphorylate and therefore alter the function of a 
number of intracellular proteins, but it can phosphorylate a third messenger 
called the cAMP response element binding protein (CREB; Montminy and 
Bilezikjian, 1987). The CREB protein sits unphosphoryfated on the cAMP 
responsive element on the promoter region of cAMP responsive genes and 
remains inactive until phosphorylated by PKA (Sun and Maurer, 1995). Once 
phosphorylated, CREB can increase the transcription of its target genes 
(Gonzalez et al., 1989). Example of genes containing CRE's and known to be 
subject to increased synthesis by CREB include tyrosine hydroxylase (Kim et 
al., 1993; Lazaroff et al., 1995; Ghee et al., 1998) and the early immediate 
gene (or "fourth messenger1') c-fos (Sassone-Corsi et al., 1 988). 
1.4.1.1.2 Specific signaling pathways of serotonin 
S-HT~A receptors are linked to a Gq alpha subunit of its G-protein, which 
means that the binding of serotonin to this receptor will stimulate PLC activity 
(Roth and Chuang, 1987). Neuroleptic-induced antagonism of this receptor 
will therefore inhibit additional PLC activity, which in the long run will reduce 
the release of Caastores and inhibit the activation of PKA (see Dwivedi and 
Pandey, 1999). Although blockade of 5-HT2 receptors would not be expected 
to cause increases in fourth messengers such as c-fos, the inhibition of 
serotonergic neurotransmission may have effects on downstream neurons in 
which increases in such messengers may be observed (Hyman and Nestler, 
1 993). 
1.4.1.1.3 Fourth messengers: transcription factors1 immediate early genes 
Transcription factors are nuclear proteins which bind specific regulatory 
DNA sequences on target genes to either enhance or inhibit transcription 
(Curran et al., 1988). Immediate early genes (IEG's) are transcription factors 
which are induced rapidly and transiently upon stimulation and are often used 
to trace neuronal activity in the brain (Morgan et a/., 1987: Morgan and Curran. 
1989; 1991). They are induced by a variety of pharmacological, biological, 
and behavioural stimuli. Since the induction of a particular IEG may increase 
or decrease the rate of transcription of various other genes, a factor that 
changes levels of brain IEG's may in part exert its function by changing the 
amount of a particular target gene that is transcribed (Hyman and Nestler, 
1993). 
1.4.1.2 C-~OS 
1.4.1.2.1 Structure and function 
C-fos is an early immediate gene which due to its ability to be induced by a 
wide variety of stimuli is often used as a marker of neuronal activity (Dragunow 
and Fuall, 1989). It is rapidly induced throughout the CNS by a number of 
stimuli, including seizures (Morgan et al., 1987), morphine (Chang et al.. 
1988), caffeine (Nakajirna et al., 1989). cocaine (Brown et al., 1992), 
amphetamine (Nguyen et al., 1992), stress (Duncan et al., 1993), fear (Beck 
and Fibiger, 1995), and nicotine (Paglusi et al., 1996). Its transcription can be 
activated within minutes (Greenberg and Ziff, 1984; Greenberg et al., 1985). 
Its mRNA reaches its highest levels about 30 to 45 minutes following 
stimulation, with peak protein levels occurring about two hours following 
stimulation (Muller et al., 1984). It appears that increases in levels of the c-fos 
gene product (the protein) are primarily regulated at the transcriptional level 
(Greenberg et al., 1986), meaning that its mRNA must first be increased in 
order to elevate its protein levels. 
The c-fos gene encodes a 380 amino acid 55 kDA protein (Fos) which after 
phosphorylation has an apparent molecular weight of 62 kDA (Curran et al., 
1984). After dirnerizing with other proteins in its "leucine zipper" family (Fos, 
Jun, JunB, JunD; Rauscher et al., 1988; Fugii et al., 1991 ), Fos binds to the 
activator protein-1 (AP-1) binding site in the enhancer region of DNA (Chiu et 
al., 1988; Curran and Franza, 1988; Morgan and Curran, 1991 ) and usually 
facilitates the transcription of its target genes [note: FosIJunB dimers have 
been shown in some cases to inhibit transcription (Chiu et al., 1989; Schutte et 
at., 1989)]. It has a CRE (Sassone-Corsi et al., 1 gQO), is phosphorylated by 
CAMP dependent PK and calcium ( ~ a ~ l c a l m o d u l i n  dependent PK (Curran et 
al.. 1987) and inhibits its own transcription when phosphorylated (Schonthal et 
al., 1991). Examples of genes containing AP-1 sites in their promoter regions 
and known to be subject to increased synthesis by Fos include proenkephalin 
(Uhl et al., 1988), neurotensinlneuromedian N (Kislauskis and Dobner, 1 WO), 
and tyrosine hydroxylase (Icard-Liepkalns et al., 1992). 
1.4.1.2.2 Regulation by neuroleptics 
Interest in the role of c-fos in the neuroleptic response first began when it 
was found that a single intraperitoneal (i.p.) injection of haloperidol dose- 
dependently increased striatal c-fos mRNA 30 minutes to one hour after the 
injection (Dragunow et al., 1990; Miller, 1990). This increase could be 
reversed by a Dp agonist (Miller, 1990). Given that haloperidol's propensity to 
cause EPS is linked to its blockade of striatal D2 receptors, many investigators 
proposed that not only could striatal c-fos activation be used to predict the 
EPS liability of neuroleptics, but that neuroleptic-induced c-fos activation in 
other brain regions might be used to help elucidate other neural substrates 
underlying neuroleptic efficacies and side effect profiles. In addition, it was 
thought that, being a transcription factor, the Fos gene might p!ay a role in the 
long term regulation of target genes which contribute to the neuroleptic 
therapeutic response. 
Over the last ten years, a large number of investigators have examined the 
regulation of the Fos family of proteins by neuroleptics (Deutch, 1992; 
Robertson and Fibiger, 1992; Dilts et al., 1993; Merchant and Dorsa, 1993, 
Fibiger, 1994; Fink-Jensen and Kristensen, 1994; Robertson et al., 1994; 
Merchant et al., 1994; Deutch et al., 1995; Deutch and Duman, 1996; Sernba 
et al., 1996; Nomikos et al., A 997; Arnt and Skarsfeldt, 1998; and many 
others). The most interesting findings were that as hypothesized, regionally 
specific induction of c-fos was caused by typical vs. atypical neuroleptics. 
Whereas typical neuroleptics such as haloperidol increased c-fos mRNA 
andlor the Fos protein in the striatum but not the mPFC, the opposite was true 
for atypical neuroleptics such as clozapine that had superior efficacy in treating 
negative and cognitive symptoms (Robertson and Fibiger. 1992). In addition, 
it was found that all neuroleptics increased c-fos mRNA in the nucleus 
accumbens, suggesting that activation of this structure might underlie 
neuroleptic efficacy. Later studies also demonstrated that both typical and 
atypical neuroleptics increased c-fos mRNA in the lateral septa1 nucleus 
(Robertson et al., 1994). 
l.4.1.3 Delta FosB 
1.4.1.3.1 Structure and function 
Delta FosB is a member of the Fos family of transcription factors (Zerial et 
al., 1989). It is a 35 kDA protein that is a splice variant of the 338 amino acid 
FosB gene which encodes both the FosB and delta FosB gene (Mumberg et 
al., 1991, Nakabeppu and Nathans, 1991). The delta FosB protein lacks the 
last 101 amino acids found in the C-terminus of FosB, but the proteins are 
otherwise identical in structure and have similar binding characteristics 
(Nakabeppu and Nathans, 1991). Like c-fos, delta FosB preferably dimerizes 
to the Jun family of transcription factors and binds to AP-1 sites in the 
promoter region of target genes (Zerial et al., 1989). Unlike c-fos, delta FosB 
dimers are not strong activators of transcription and may actually repress 
transcription by competitively inhibiting the binding of transcription activating 
FoslJun dimers (Mumberg et al., 1991; Nakabeppu and Nathans, 1991). In 
addition, as opposed to c-fos, apparent increases (accumulation) of delta FosB 
seem to be primarily regulated by phosphorylation while mRNA levels of delta 
FosB are activated rapidly and transiently (Chen et al., 1997). 
1.4.1.3.2 Regulation by neuroleptics 
Delta FosB has been shown to have not short, but long induction kinetics, 
meaning that it is not rapidly increased in the short term but when increased 
remains elevated for long periods of time. While delta FosB has been shown 
to be upregulated for periods of greater than 3 months after the experimental 
manipulation in certain experimental paradigms (Doucet et al., 19961, 
increases in c-fos have been shown to be desensitized by chronic treatments, 
including chronic haloperidol and clozapine treatment (Merchant et al., 1995; 
Sebens et a!., 1995). Recent studies have shown that chronic (but not acute) 
haloperidol and clozapine administration increases delta FosB in regions 
similar to, although not identical with, those where c-fos mRNA upregulation is 
seen upon acute administration (Hiroi and Graybiel, 1996; Vahid-Anisari et al., 
1996). Since the therapeutic effects of neuroleptics are not seen until after 
several weeks of chronic drug administration (Pickar, 1988; Pickar and Breier, 
1989; Stern et al., 1993), it is of interest that unlike c-fos, neuroleptic induced 
changes in delta FosB follow a time pattern similar to the emergence of the 
therapeutic efficacy of the drug. 
1.4.2 Target genes I: synthetic enzymes 
1 A 2 . l  Tyrosine hydroxylase (TH) 
1.4.2.1 .I Regulation and function 
The enzyme tyrosine hydroxylase (TH) (EC 1 .14.16.2) hydroxylates the 
meta position of tyrosine to form the precursor of DA. 3.4-dihydroxy-L- 
phenylalanine (L-DOPA). It is considered to be the rate limiting enzyme in the 
synthesis of the catecholamines (Spector et al., 1965) DA, noradrenaline, and 
adrenaline (Levitt et al., 1965). It is found in catecholamine-synthesizing cells 
in the central and peripheral nervous systems (Elfvin et al., 1975; Pickel et al., 
1975a, b), and TH mRNA is found in regions such as the substantia nigra. 
ventral tegmental area, and the locus coeruleus (Han et al., 1987), and its 
protein is found in projection neurons of these areas (such as the striatum. 
nucleus accumbens, and cortex/thalamus respectively) as well as in adrenal 
glands and chromafin tissue (Pickel et al., 1975a.b). 
TH is a heavily regulated enzyme. It is activated by phosphorylation by 
either PKA (Lovenberg and Bruckwick, 1975). ~a2+/calmodulin- dependent 
PKll (Vulliet et al., 1984), or PKC (Albert et at., 1984) at specific serine 
residues. It is subject to long term regulation, such as its synthesis being 
increased by nerve stimulation (Thoenen et all 1969) and cold stress (Gordon 
et all 1966). The enzyme is inhibited by its end product (Ikeda et all 1966; 
Nagatsu et al., 1964), is inactivated by CAMP- dependent phosphorylation 
activation (Vrana and Roskoski, 1983) and can autophosphorylate. It has an 
AP-1 site (Icard-Liepkalns et al., 1992) and a CRE (Kim et at., 1993; Lazaroff 
et al.. 1995; Ghee et al.. 1998) site on its promoter and is regulated by Fos 
(Icard-Liepkalns et al., 1 992). 
1.4.2.1.2 TH in schizophrenia 
Although the DA hypothesis of schizophrenia is no longer considered to be 
sufficient to explain schizophrenia, TH is still suspected to play a role in the 
disorder. Many recent investigations of polymorphisms of the TH gene in 
schizophrenia have examined I st intron polymorphisms, microsatellite 
repeats, allele/genotype frequencies, and amino acid substitutions. For 
example, two groups have found that polymorphisms of the 1st intron of the 
TH gene are related to differences in catecholamine turnover (Thipaut et al., 
1997; Wei et al., 1997). Microsatellite DNA tetra repeats (TCAT*)n in the first 
intron have been found to be associated with altered excitability of 
noradrenergic neurons in schizophrenia, and have been found in unaffected 
relatives of patients with schizophrenia (Meloni et al., 1995). Not only have 
others failed to replicate these results (Ishiguro, 1998; Jonsson et al., 1 998), 
but the finding of altered satellite DNA in non-affected relatives suggests that 
disruptions of the TH gene are not sufficient to cause schizophrenia, or that 
TH just happens to be linked to the causative genes. Changes in allele and 
genotype frequencies have not been replicated (Jonsson et al., 1996), nor 
has an amino acid substitution at valine 486 for methionine (Kunugi et al., 
1998) been replicated (Ishiguro et at., 1998). 
Changes in TH enzyme activity and rnRNA/ protein levels in schizophrenia 
are not clear. Higher TH activity has been observed in the caudate putamen 
(CP) of schizophrenics (Toru et al., 1982), but this was not found by Crow et 
al. (1979). While Parkinsonian brains have low levels of TH mRNA in the 
substantia nigra as compared to controls, schizophrenic brains do not show 
these changes, although some schizophrenics have been found to have lower 
TH mRNA relative to DOPA decarboxylase mRNA levels (Ichinose et a!., 
1994). Even if there were consistent findings of altered TH in schizophrenia, 
post mortem analyses of TH protein and mRNA levels may be confounded by 
neuroleptic treatment (see below), and the schizophrenic subjects in the study 
of lchinose et al. (1994) had been treated with neuroleptics. 
'Nucleotide bases of DNA: T= thymine, C=cytosine, A=adenine, G=guanine 
1 A.2.1.3 Regulation by neuroleptics 
Acute administration of neuroleptic drugs such as haloperidol has been 
found to increase TH enzyme activity (Zivkovic and Guidotti, 1974; Zivkovic et 
al, 1974), while chronic neuroleptic treatment can decrease it (Lerner et al, 
1977). Remoxipride (5-1 25 pmollkg imp.) increases striatal DA turnover (as 
indicated by increased 3,4-dihydroxyphenylacetic acid [DOPAC] and 
homovanillic acid [HVA]) and increases the rate of striatal DA disappearance 
following inhibition of TH (Magnusson and Fowler, 1989). 
Acute haloperidol and spiperone have been shown to upregulate TH mRNA 
in mouse striaturn (Cho et al., 1997). Cottingham et al. (1990; 1991), however, 
found no changes in TH mRNA in the substantia nigra (SN), VTA, or locus 
coeruleus (LC) upon acute and chronic haloperidol administration (3 or 19 
days). In addition, Buckland et al. (1 992; 1993) found no effect of 0, 1, 2, 4, 
8, 16. or 32 day haloperidol, loxapine, sulpiride, or clozapine treatment on 
whole brain TH mRNA. Levinson et al. (1998) found that haloperidol 
withdrawal downregulates nigral TH IR increasingly over time, demonstrating 
that continued neuroleptic administration is required to maintain induction of 
TH IR. This, along with the mRNA data, suggests that DA receptor blocking 
neuroleptics may increase transcription of TH mRNA, that this may translate to 
protein, and that withdrawal of neuroleptics stops this upregulation. It is 
interesting that chronic antidepressant treatment has a differential effect on 
TH, whereby it downregulates TH mRNA (Nestler et al., 1990) and alters 
different aspects of monoamine synthesis (Moret and Britey, 1992). 
1.4.2.2 Aromatic L-amino decarboxylase (AADC) 
1.4.2.2.1 Regulation and function 
Both DA and 5-HT synthesis require the enzyme aromatic L-amino acid 
decarboxylase (AADC) (EC4.1.1.28) for decarboxylation of the amino acids L- 
DOPA and 5-hydroxytryptophan (5-HTP; Lovenberg et al., 1962; Christenson 
et al., 1972). AADC is found throughout the central and peripheral nervous 
systems in catecholamine- and serotonin-containing neurons (Hokfelt et al., 
1973). AADC mRNA is located in those brain areas that contain dopaminergic 
and serotonergic cell bodies (Coge et al., 1990; Tisson et al., 1991; Eaton et 
al., 1992, 1993) such as the SN, CP, LC, raphe nuclei, brain stem, the nuclei 
of the hypothalamus, the limbic system, as well as in the circumventricular 
organs and the pituitary gland (Black and Geen, 1975; Saavedra, 1977). Both 
AADC mRNA (Li et al., 1992) and protein (Juorio et al., 1993) have been 
found in glial cells, where AADC is proposed to decarboxylate stray L- amino 
acids (Berry et al., 1996). 
Since the brain has relatively high activity of AADC and the concentrations 
of L-DOPA and 5-HTP are lower than the Michaelis Menten Constant (Km) of 
the enzyme, it has been assumed that the enzyme is not rate limiting, at least 
with respect to the synthesis of DA and 5-HT (Dairman et al., 1971; Bowsher 
and Henry, 1986). This assumption has been supported by the apparent 
absence of DA or 5-HT decreases following AADC inhibition (Brodie et al, 
1962). It is likely, however, that AADC is the rate limiting factor in the 
treatment of Parkinson's disease with L-DOPA (Gjedde et al., 1993). The 
finding that brain AADC is rate limiting for the synthesis of the trace amines 
such as phenylethylamine and tryptamine (Lovenberg et at., 1962; Boulton, 
1976) and is regulated by DA receptors (Zhu et al., 1992; 1993; 1994 
Hadjiconstantinou et al., 1993) suggests that AADC is a regulated enzyme and 
that its role in rnonoamine synthesis may be more important than once 
believed (re-viewed by Zhu and Juorio, 1995; Berry et al., 1996; Fisher et al., 
2000). 
Dopamine D2 receptor blockade has been shown to increase AADC 
activity (Rossetti et al., 1990: Zhu et al., 1992), while stimulation of this 
receptor has the opposite effect (Hadjiconstantinou et al., 1993, Zhu et al., 
1993). There are many other molecular mechanisms by which AADC is 
regulated (for review, see Berry et al., 1996), and its primary protein structure 
has phosphorylation sites for both PKA and PKC (Kemp and Pearson, 1990) 
which are a part of the signal transduction pathways for dopamine and 
serotonin respectively. 
1.4.2.2.2 AADC in schizophrenia 
AADC is widely distributed in many brain regions, several of which have 
been implicated in the pathophysiology of schizophrenia. Since the 
therapeutic actions of neuroleptics are attributed to their D2 andlor 5-tiT2 
receptor blockade, and since AADC is the final enzyme in the synthetic 
pathway of both of these neurotransmitters, it would not be surprising if AADC 
played a role in the pathophysiology of schizophrenia. No known allele 
polymorphisms of AADC have, however, been identified in schizophrenia, and 
no post mortem changes in AADC mRNA have been found in schizophrenic 
brains (Ichinose et al., 1994), although two allele variants have been found in 
bipolar disorder (Borglum et al., 1999). Although imaging studies have 
revealed increased AADC in the brains of living schizophrenic patients, these 
findings may be confounded by neuroleptic administration (Reith et al., 1994). 
Theories of the possible role of AADC in schizophrenia have rested primarily 
on the effects of various psychoactive drugs on AADC mRNA, as discussed 
below. 
1.4.2.2.3 Regulation by neuroleptics 
An elevated expression of AADC mRNA after neuroleptic expression has 
been found in many paradigms, suggesting that the alteration of its message 
by neuroleptics may contribute to the therapeutic mechanism of these drugs. 
Buckland et al. (1992) found that acute and chronic haloperidol or loxapine 
significantly increased AADC but not TH mRNA over time (1, 2, 4, 8, 16, 32 
days) in whole brain homogenates of rats (sacrificed 4 hrs after last injection, 
injected twice a day) to 240% and 180% of control levels at 32 days. Sulpiride 
(Buckland et al., 1992) and clozapine (30 mglkglday) were without effect over 
the 32 day injection period, demonstrating that only some neuroleptics can 
induce AADC mRNA. 
Activity of AADC is also altered by dopaminergic drugs. Zhu et al. (1 993) 
found that cis-flupenthixol and rernoxipride increased striatal AADC activity 
significantly above controls, while bromocriptine (10mgikg). but not (-)- 
quinpirole or d-amphetamine, decreased AADC activity in comparison to 
controls. These findings together suggest that downregulation of AADC 
mRNA by neuroleptics might cause a compensatory increase in AADC 
enzyme activity. Cho et al. (1997) found that haloperidol and spiperone 
upregulated AADC protein levels and increased enzyme activity, but not AADC 
mRNA levels in the mouse striatum, suggesting that Buckland et a1.k findings 
of neuroleptic induced upregulation of AADC mRNA occurs in brain regions 
other than the striatum. Therefore, regardless of the relative dopaminergic vs. 
serotonergic blockade of a particular neuroleptic, it is possible that a shared 
mechanism of action of neuroleptics is the upregulation of AADC mRNA. 
Interestingly, Buckland et al. (1 996) found that chronic administration of 
the dopamine agonist amphetamine and the GABA agonist vigabatrin 
downregulated AADC mRNA increasingly over 8, 16, and 32 days in the 
hippocampus, olfactory tubercles, hypothalamus, striatum, cerebellum, cortex, 
NuAcc, and PFC, while cocaine (40 and 50 mgikglday) was without effect. 
This led Buckland et al. (1996) to hypothesize that factors which cause 
psychosis decrease AADC mRNA, while those that ameliorate psychosis 
increase AADC mRNA. Buckland et al. (1997). however, found that 32 day 
PCP or LSD administration upregulated AADC mRNA in the striatum, nucleus 
accurnbens, hippocampus, and cerebellum between 50 and 150% over 
controls, demonstrating that psychosis-inducing agents can either upregulate 
or downregulate AADC mRNA. 
1.4.3Target genes II: Selected factors affecting neuroprotection 
Neuroanatomical studies of schizophrenia suggest that progressive 
neuropathological changes (such as neuronal atrophy andlor cell death) occur 
over the lifetime course of the disease (DeLisi et al., 1995; Coyle, 1996; Nair et 
al., 1997). Early intervention with atypical neuroleptics has been shown to 
prevent progression of at least some symptoms, although the mechanisms by 
which neuroleptics may do this remain unknown (Waddington et al., 1991, 
1995, 1 997a,b, 1 998a.b, 1999; Wyatt et al., l99la,b; Falloon, 1992; Loebel et 
al., 1992; McGlashan and Fenton, 1992, 1993; Fenton and McGlashan, 1994; 
McGlashan and Johannessen, 1996; McGlashan, 1996a, b; McGorry, 1998). 
There are at least three mechanisms by which neuroleptics may prevent 
further neurodegeneration in schizophrenia. The potential mechanisms of 
interest in the present study and selected factors which may be involved in 
neuroprotection are as follows: 
Protection against cellular oxidation: superoxide dismutase 
(SOD1 ; section 1.4.3.1) 
Protection against apoptosis: low affinity nerve growth factor 
receptor (p75; section 1.4.3.2) 
Protection against neuronal atrophy: brain derived neurotrophic 
factor (BDNF, section 1.4.3.3) 
1.4.3.1 Superoxide dismutase (SOD) 
1.4.3.1.1 Regulation and function 
A possible target gene of neuroleptic regulation includes the Cu2+lZn2+ 
dependent superoxide dismutase (SOD1, E.C. 7.15.1.6), a 32 kDA 
homodimeric metalloenzyme which reduces cellular oxidative stress and 
neuronal damage via the inactivation of oxygen free radicals (Hark and 
Deutsch, 1972). SOD is a ubiquitous enzyme in all aerobic cells, but has been 
found in greater amounts in large pyramidal neurons of the neocortex and 
hippocampus (Delacourte et al., 1988; Ceballos et al., 1991). There are three 
isozymes of SOD, including the Cu2+/Zn*+ form (SOD1; which exists in the 
cytosol; McCord and Fridovich, 1969), the Mn2+ dependent form (SOD2; 
mitochondrial; Marklund, l982), and an extracellular form (Weisiger and 
Fridovich, 1973). Although there is no known AP-1 site on the SODl 
promoter, the major activator for transcription of SODl is the CCAAT enhancer 
binding protein C/EBP alpha (Kim et al., 1997; Seo et al., 1997). 
SOD reduces reactive oxygen species through the dismutation of 
superoxide anion into molecular oxygen and hydrogen peroxide (McCord and 
Fridovich, 1969; Furuta et al., 1995). A primary target for damage by free 
radicals is the fatty acids which are in cell membranes. In neurons, where 
there are high levels of oxygen consumption, cell membranes are particularly 
susceptible to lipid peroxidation (Furuta et al., 1995). Numerous factors which 
are neuroprotective upregulate SODl activity and/ or transcription, such as 
neurotrophins (Wengenack et al., 1997), L-deprenyl (Li et al., 1998) and 
ginsenosides (Kim et al., 1996). SODl is upregulated by the neurotrophin 
brain derived neurotrophic factor (BDNF) and nerve growth factor (NGF; 
Mattson et at., 1995), and in vivo studies have demonstrated that upregulation 
of this enzyme is neuroprotective in ischemia (Wengenack et al., 1997) and 
glutamate neurotoxicity (Furukawa et al., 1997). Mutant, dysfunctional SODl 
has been associated with motor neuron degeneration resembling amyotrophic 
lateral sclerosis (ALS; Wengenack et al., 1997). Reduced SODl activity has 
been found in ALS (Kong and Xu, 1998) and point mutations in SODl have 
been found in patients with the familial form of this disorder (Deng et al., 1993; 
Rosen et al., 1993). Lifespan is reduced in SODl knockout mice (Schwartz 
and Coyle, 1998). suggesting that this enzyme plays a significant role in the 
aging process as well. 
1.4.3.1 2 SOD in schizophrenia 
Oxidative stress is long thought by many to be involved in the pathology of 
schizophrenia (Lohr, 1991 ; Cadet and Kahler, 1994; Goodman, 1994; Mahadik 
and Gouda, 1996; Mahadik and Mukherjee. 1996; Mahadik and Scheffer, 
1996; Mukherjee et al., 1996; Reddy and Yao, 1996; Baez et al., 1997; 
Smythies, 1997) and tardive dyskinesia (Lohr et al., 1990; Yamada et al., 
1997). There have been findings of increased superoxide anion production by 
neutrophils from the blood of schizophrenic patients (Melamed et al., 1998). 
and Mukherjee et a!. (1996) found that impaired antioxidant systems including 
reduced SOD activity were present at the onset of psychosis. Reduction of 
SODl activity has also been observed to play a role in dopamine- mediated 
neurotoxicity (Greenlund et al., 1995) which may be of significance in the 
hyperdopaminergia of schizophrenia. 
1.4.3.1.3 Regulation by neuroleptics 
SODl is a ubiquitous enzyme and is widely distributed in the central 
nervous system (CNS), including many regions purported to be atrophied in 
schizophrenia such as the hippocampus and cerebral cortex (Lohr et al., 1990; 
Selemon et al., 1995). It is therefore conceivable that upregulation of the gene 
expression of this enzyme by neuroleptics could prevent further free radical 
induced neurotoxicityl neurodegeneration in schizophrenia. It is likely, 
however, that neuroleptics which induce TD (such as strong 0 2  blocking 
neuroleptics like haloperidol) have an opposite effect on SOD1 from 
neuroleptics such as clozapine which appear to reverse TD (Delecluse et al., 
1998; Gao et al., 1998; Karp et al., 1999). Haloperidol decreases SODl 
enzyme activity, and SOD1 activity is decreased in tardive dyskinesia in the 
erythrocytes of haloperidol treated patients (Yamada et al., 1997). Long term 
treatment with the typical neuroleptic chlorpromazine, but not the mood 
stabilizer lithium, decreases SOD1 activity in the brain, liver and erythrocytes of 
rats (Abdalla and Bechara, 1994), further suggesting that reduced SOD1 
activity is associated with D2 receptor blockade. Haloperidol has been 
specifically shown to create reactive oxygen species (ROS; Sagara, 1998; Yao 
et al., 1998)' while Behl et al., (1996) have demonstrated that oxidative stress- 
resistant cells are protected against haloperidol-induced neurotoxicity. 
1.4.3.2 The low affinity nerve growth factor receptor (p75) 
1.4.3.2.1 Regulation and function 
A second candidate gene includes the low affinity nerve growth factor 
receptor (p75), a 75 kDA transmembrane cytokine receptor-like protein which 
constitutively induces neural cell death in the absence of its primary ligand, 
nerve growth factor (NGF) (Thoenen and Barde, 1980; Levi-Montalcini, 1987; 
Greene and Kaplan, 1995; Kaplan and Miller. 1997; Muller and Clos, 1997). 
The expression of p75 receptor mRNA in adults is primarily limited to the 
medial septa1 nucleus and the nucleus of Broca's diagonal band (Vazquez and 
Ebendal, 1991 ). 
The p75 receptor has been nicknamed the "death" receptor. While cultured 
rat pheochromocytoma (PC12) cells normally do not need NGF to suwive, 
treatment of such cultures with NGF causes the induction of the p75 receptor. 
Induction of p75 is thought to make these neurons "dependent" on NGF, 
because if the NGF is withdrawn, the PC12 cells will die. This is supported by 
the finding that both the rate and extent of PC12 cell death following NGF 
withdrawal is determined by the degree of p75 expression (Barrett and 
Georgiou, 1996). In addition. both the antisense blockade of its mRNA 
(Barrett and Georgiou, 1996) and the inhibition of its function by antibodies 
(Rabizadeh et al., 1993; Farde et al., 1996) have been associated with 
reduced cell death in PC1 2 cells. Conversely, the p75 gene has an AP1 site 
on its promoter as well as many others, but is more likely regulated by c-jun 
than c-fos. Its primary transcription factor is Zif268/Egr-1 (Nikam et al., 1995). 
1.4.3.2.2 Structure of neurotrophins and their receptors 
The p75 receptor will bind all members of the neurotrophin family with an 
equal affinity (Lipton and Kalil, 1995); these include the prototypical NGF, 
brain-derived neurotrophic factor (BDNF), and the more recently discovered 
neurotrophin-3 (NT-3) and neurotrophin-4/5 (NT-4/5) (Snider and Johnson, 
1989; Snider, 1994). All members of the neurotrophin family are 12 kDa basic 
proteins that share significant structural homologies (Hofer et al., 1990; 
Maisonpierre et al., 1991 a), including several similar amino acid sequences 
surrounding the neurotrophins' six conserved cysteine residues and a 48% 
amino acid homology between the three neurotrophins (Maisonpierre et al., 
1991 b). Neurotrophins are produced by the cleavage of larger precursor 
protein with the mature protein, corresponding to the C-terminal half of the 
precursor (Darling et al., 1983), but all are products of separate genes 
(Maisonpierre et al., l 9 9 l  a). Regardless, mature forms, tissue distribution and 
neuronal specificities of the neurotrophins are conserved across mammals 
(Maison pierre et al., 1991 a). 
Although each neurotrophin preferentially binds to its receptor as a 
homodimer, there is some overlap in receptor binding, and NT-3/ BDNF 
heterodimers (Philo et a!., 1994) do bind to both TrkB and TrkC receptors in 
vitro (Arakawa et al., 1994). Though the function of p75 is unclear, it is 
thought that in addition to playing a direct role in cell death, it may enhance 
dimerization of the neurotrophins (see Carter and Lewin, 1997 for review and 
illustration) and post receptor neurotrophin signaling (Davies et al., 1993; Verdi 
et al., 1994). 
1.4.3.2.3 p75 in schizophrenia 
There are no reports of alterations of p75 in schizophrenia. It is highly 
possible, however, that p75-positive neurons and their targets are altered in 
the disease. As previously discussed, the expression of p75 receptor mRNA 
in adults is primarily limited to the medial septa1 nucleus 
and the nucleus of Broca's diagonal band (Vazquez and Ebendal, 1991 ). 
These nuclei of the basal forebrain contain cholinergic neurons which 
project to the hippocampus and cerebral cortex (Ebendal, 1992), two areas 
which are found to be reduced in volume in schizophrenia. The atrophy of 
these neurons would result in decreased input to the hippocampus and cortex, 
which could exacerbate, temporarily or permanently, the positive, negative, 
and cognitive symptoms of schizophrenia, and/ or contribute to the 
degeneration and death of target neurons. Interestingly, the expression of p75 
in cholinergic neurons is associated with Alzheimer's disease (Woolf et al., 
1989) and R-amyloid toxicity (Rabizadeh and Bredesen, 1994), demonstrating 
that the alteration of p75 can play a role in the deterioration of cognition. 
1.4.3.2.4 Regulation by neuroleptics 
Little research has been done on the effects of neuroleptics on p75. 
Pollmacher et al. (1 996; 1997) found that chronic treatment with clozapine, but 
not with haloperidol, increased the plasma level of p75 as well as that of tumor 
necrosis factor-alpha (TNF-alpha), soluble TNF receptors p55 and slL-2r. 
(Note: These studies were done to determine if clozapine-induced fever was 
associated with these measures; but the increases were independent of prior 
or concurrent medication and also occured in patients who did not experience 
clozapine-induced fever). The authors concluded that "haloperidol (but not 
clozapine) is unlikely to confound the results of studies investigating disease- 
related alterations in the levels of a broad range of cytokines and soluble 
cytokine receptors in schizophrenia". In the aforementioned study, it was 
undetermined how plasma p75 levels correlated with the effects of the 
neuroleptics on schizophrenic symptomotology. 
1.4.3.3 Brain derived neurotrophic factor (BDNF) 
1.4.3.3.1 Distribution of BDNF and its receptor (TrkB) in the CNS 
Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin 
family of growth factors (Barde, 1989). In vivo, three isoforms of TrkB are 
generated by differential splicing - one having full function and two having 
truncated receptors lacking kinases (Mocchetti and Wrathall, 1995). BDNF is 
the most abundant neurotrophin in the brain, with highest levels in 
hippocampus, cerebral cortex, and forebrain cholinergic synaptic targets 
(Philips et al., 1990; Maisonpierre et al., 1991 b; Marty et al., 1996). 
Distribution of BDNF is more widespread in the brain than that of other 
neurotrophins, and high levels of BDNF mRNA and protein have been 
observed in neurons of the hippocampus, including pyramidal, hilar, and 
granule cells of the dentate gyrus, and in scattered cells in the amygdala, and 
in the cingulate, parietal, and entorhinal corticies (Hofer et al., 1990; 
Maisonpierre et al., 1991a). TrkB mRNA is widely distributed, and is found in 
high quantities in the olfactory system, cerebral cortex, hippocampal formation, 
amygdala, and cerebellar cortex (Masana et al., 1993) in the adult rat brain. 
Interestingly, it is often these brain regions that are the most vulnerable to 
insults such as ischemia, glutamate toxicity, and glucose deprivation and are 
altered in schizophrenia (Mattson et al., 1995; Selemon et al., 1995). 
1.4.3.3.2 Function 
BDNF is not only involved in the survival of adult neurons, but is also 
involved in embryonic growth and development in the CNS. Tissue culture 
studies have helped establish the role of BNDF and its receptor in embryonic 
development (Barbacid, 1994; Ernfors et al., 1994; Snider, 1994; Eide et al., 
1996). For example, disruption of BDNF or trkB genes produces a loss of 
sensory neurons in mice (Snider, 1994). BDNF promotes neurite extension of 
rat cerebellar cells in culture, suggesting that it is important in the maturation 
and maintenance of differentiated cells (Hughes et al., 1993) BDNF has also 
been shown to enhance NMDA receptor maturation in cultured mouse 
cerebellar granule cells (Allsopp et al., 1995). 
There is clear evidence that growth factors such as BDNF increase survival 
and help protect neurons from ischemic (Beck et al., 1994; Tsukahara et al., 
1994), glutamatergic (Mattson et al., 1995), and hypoglycemic (Mattson et ai., 
1993) insults. Specifically, via stimulation of SOD1 activity, BDNF prevents 
neurons from the above listed neuronal insults (Mattson et al., 1995). In 
summary, these findings indicate that BDNF is necessary to neurons 
throughout the life cycle. 
BDNF has an AP-1 site on its promoter (Hayes et al., 1997) and there is 
some evidence to suggest that BDNF can be induced as an early immediate 
gene. Hughes et al. (1993) found that hippocampal focal brain injury 
transiently increases BDNF mRNA but that this increase was not blocked by 
the protein synthesis inhibitor cycloheximide. BDNF immunoreactivity is also 
seen in the cytoplasm of cholinergic neurons where the mRNA has not been 
detected, suggesting that some BDNF enters the nucleus to regulate 
transcription. Genes with BDNF binding sites have not been identified. 
However, it is possible that BDNF influences the transcription of other 
neuroprotective genes via stabilization of a common transcription factor/ DNA 
binding domain complex, by removing1 adding inhibition of transcription starts, 
or simply by binding to the genome itself. Marsh et al. (1993) have 
demonstrated that BDNF administration to cultured hippocampal neurons will 
stimulate auto-phosphorylation of TrkB within five minutes, allowing rapid 
phosphorylation of effector proteins, which suggests that BDNF can quickly 
alter protein conformation and function. 
1.4.3.3.3 BDNF in schizophrenia and regulation by neuroleptics 
Neurotrophins such as BDNF are involved in the creation, maintenance, 
and growth of neuritic processes and thus have the ability to regulate synaptic 
connectivity. Inadequate trophin supply will lead to either neuronal atrophy, 
shrunken processes, or in extreme cases, cell death and will thus disrupt 
neurotransmission. Interestingly, BDNF is decreased by factors correlated 
with the onset of first episode psychosis such as stress (Smith et al., 1995) 
and estrogen withdrawal I menopause (Singh et al., 1995). and is increased by 
factors associated with the clinical treatment of schizophrenia (such as 5-HT2 
receptor blockade and ECT treatment; Vaidya et at., 1997; Nibuya et al., 
1995). In addition, reduced hippocampal BDNF mRNA (Brouha et al., 1996) 
and an allele variant of the BDNF gene (Vicente et at., 1996) in schizophrenia 
suggests that disruptions of BDNF may play a role in the etiology of this 
disorder by compromising neuroplasticity or altering normal 
neurotransmission. In addition, given the role of BDNF in the normal 
maturation of the brain, disruptions of this neurotrophin could also underlie 
some of the neurodevelopmentat abnormalities of schizophrenia as well as 
many other aspects of the disease. Thus, BDNF is a prime candidate on 
which to study the effects of neuroleptics. 
1.5 Present study 
Schizophrenia is a severely dehabilitating mental disease that is poorly 
understood in terms of its causes, etiology, and treatment. While newer 
"atypical" neuroleptics generally cause fewer side effects and successfully 
alleviate symptoms in a greater number of patients than did previous 
treatments, all antipsychotics still carry a high risk of causing significant 
adverse side effects, and approximately one quarter of all patients do not find 
any symptomatic relief with today's neuroleptics. Moreover, the 
neurodevelopmental abnormalities which are thought in part to underlie the 
disorder are not currently amenable to pharmacological correction. At the 
present, the greatest hope for improving the treatment of schizophrenia is 
through improving the efficacy of neuroleptics. 
Although it is known that neuroleptics antagonize a wide variety of 
neurotransmitter receptors (such as dopaminergic, serotonergic, adrenergic, 
muscarinic, and histaminergic receptors), it is not known why neuroleptics 
must be administered for at least two to three weeks before a therapeutic 
effect is observed. This delay in action suggests that the molecular 
mechanism underlying the therapeutic efficacy of neuroleptics lies beyond the 
receptor (Hyman and Nestler, 1993; 1996). We (and many others) thus 
propose that neuroleptics exert their effects by altering the gene (mRNA) 
expression of key proteins downstream from the receptor. Such mechanisms 
likely include long term changes in gene regulation in the affected neurons and 
in the amount of protein expressed by these genes (Duman et al., 1994; 
1997). Thus, the central goal of this project is to try to elucidate the effects of 
neuroleptics on the mRNA expression of three selected groups of candidate 
genes, which include: 
1. Early immediate genes (genes that are rapidly transcribed and translated 
upon activation) including c-fos and delta FosB. 
2. Target genes of the early immediate gene family including: 
a. enzymes in the synthetic pathways of the neurotransmitters doparnine 
and/ or serotonin, includina aromatic L-amino acid decarboxvlase and tvrosine 
hydrox~lase. 
b. genes involved in the survival of neurons, including the neuroprotective 
enzyme su~eroxide dismutase, the low affinitv nerve arowth factor receptor, 
and the most abundant growth factor in the brain, brain derived neurotro~hic 
factor. 
The neuroleptics used in the present study were chosen in order to have a 
wide representation of neuroleptics with primarily Dq blocking activity, mixed 
Dq/ 5-HT2 receptor blocking activity, selective 5-HT2 blocking activity, and 
prototypical typical and atypical neuroleptics and included the following: 
1. Remoxipride (a dopamine 02 blocker) 
2. Risperidone (a D2/ serotonin 5-HT2 receptor blocker) 
3. Ritanserin (a 5-HT2 blocker) 
4 Haloperidol (a strong D2/ moderate noradrenergic receptor blocker) 
5. Clozapine (a 5-HT2/ Dq receptor blocker) 
Figure 1.3 outlines the flow and direction of the present study. As 
previously discussed, transcription factors such as c-fos and delta FosB which 
are known to be upregulated by neuroleptic treatment may possibly regulate 
the long term gene expression of either or both of the two sets of indicated 
target genes. 
1.6 Hypotheses 
Both dopaminergic and serotonergic pathways have been implicated in the 
pathophysiology of schizophrenia, and current research suggests that 
efficacious neuroleptics reduce the symptoms of schizophrenia, at least in 
part, via DA2 and/or 5-HT2 receptor antagonism. Since current 
neuroleptics pharmacologically manipulate dopaminergic and serotonergic 
systems, and since dopaminergic vs. serotonergic blockade produces some 
similar, but many different, effects clinically, the following three hypotheses 
with respect to each factor chosen for examination are proposed: 
1. Neuroleptics will alter the gene expression of proteins downstream from 
the receptor. 
2. Neuroleptics will upregulate c-fos mRNA and delta FosB 
immunoreactivity upon either acute or chronic administration. 
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Figure 1.3. Flow and direction of present study. Transcription factors such 
as c-fos and delta FosB are increased upon neuronal stimulation and can 
regulate the gene expression of many target genes. These genes include a 
number of candidate genes thought to be involved in the neuroleptic response, 
as illustrated in the above diagram. 
3. Target genes of the Fos family of transcription factors (such as AADC, 
TH, SOD1, p75, and BDNF) will also be altered by neuroleptic treatment. 
Specifically, we hypothesize: 
That all neuroleptics will upregulate TH and AADC mRNA in a similar 
manner in PC1 2 cells. 
That atypical, but not typical, neuroleptics will regulate protective genes 
in a positive manner. 
Early immediate gene expression will be associated with the regulation 
of these target mRNAs. 
2. MATERIALS AND METHODS 
For list of chemicals used and company addresses, please see 
Appendix A. 
2.1 Cell culture: The PC1 2 rat pheochromocytoma cell line 
2.1.1 History and development 
PC12 cells were derived from epinephrine- and norepinephrine- producing 
chromaffin cells from adrenal medullary pheochromocytoma tumors (Greene 
and Tischler, 1976, 1982). As tumor cells, PC1 2 cells continually replicate and 
provide a self propagating system in which to study catecholamine synthesis, 
release, and metabolism. The PC12 rat pheochromocytoma cell line was 
developed in the 1970's by Greene and Tischler (1 976). When it was 
discovered that the neurotrophin nerve growth factor (NGF) could stimulate 
neurite outgrowth, these investigators determined the culture conditions 
necessary to propagate these cells in order to further study neuronal 
differentiation (Greene and Tischler, 1976). PC1 2 cells contain all the 
machinery required for the synthesis of dopamine and norepinephrine 
including TH, AADC, and dopamine 8-hydroxylase (Itoh and Ohmori, 1973; 
Chalfie and Perlman, 1976; Greene and Tischler, 1976). Undifferentiated 
PC1 2 cells have Dq (Greene and Tischler, 1976). 5-HT2 (Humblot et al., 1997) 
and p75 (Loeb et al., 1991 ) receptors and express both c-fos and SOD1. 
Currently, PC 12 cells are widely used as a model for the study of 
catecholamines as well neuronal differentiation and cell death (reviewed by 
Greene and Tischler, 1982; Stepfanis et al., 1997). 
2.1 -2 Preparation of cell culture materials 
All manipulations were performed using sterile technique and performed in 
a class II laminar flow hood. Nanopure water was used in all solutions and 
buffers and was prepared by the experimenter with the use of a Barnstead RO 
Pure and Nanopure II system with an organic cartridge. This process removes 
organic compounds and ionic particles. The plates and flasks used to grow 
PC1 2 monolayers were collagen coated to enhance adhesion to the inner cell 
culture walls. Collagen was diluted 1 OX with sterile, autoclaved nanopure 
water and poured as a thin layer onto the inner flask surface. The flasks were 
capped and ieft overnight. The following day, the remaining collagen was 
poured out of the flasks and reused twice before discarding. To coat six-well 
plates, 1 mL of 1 OX diluted collagen was placed in each well and the wells 
were covered for at least 4 hours. After removing the excess collagen, the 
plates were left open to dry for 2 hours in the hood under ultraviolet (UV) light 
to kill any bacterial growth in the wells of the plates. The plates were covered 
and sealed with parafilm until use. 
2.1.3 Preparation of culture and conditions 
The PC1 2 cell line was obtained from American Type Culture Collection 
(Rockville, Maryland) and cultured in RPMl 1640 medium (developed at 
Roswell Park Memorial institute by Moore et al., 1966a,b) containing 5% fetal 
- 
calf serum and 10% horse serum, 0.03% glutarnine plus 100 unitslml 
penicillin and 100 pglmL streptomycin as described in protocols provided by 
supplier. One (1)mL 2M NaOH was added to 1 L of medium after the addition 
of the serum to raise the pH of the medium back up to approximately 8.0. 
Stock solutions of penicillin (5% in sterile nanopure H20), streptomycin (5% in 
sterile nanopure H20), and 3% glutamine were made in advance and filtered 
with a 0 . 2 ~  Nalgene Millipore filter. Aliquots were stored at -20°C until use. 
Celts were thawed from -70°C in 8-10 mL of medium in a 37°C water bath. 
Incubations were carried out at 37°C in 95% humidified air with 5% C02. The 
culture medium was initially changed after 3 days, and the old medium was 
discarded. To ensure the discarding of dead cells (which do not stick to the 
collagen coated walls) the flask was gently shaken before removing the old 
media. Viable cells adhering to the collagen were then haversted by forcefully 
pipetting at once approximately 20 mL of medium against the flask surface for 
approximately one minute. Using a 10 mL syringe and a 22.5 gauge needle, 
cell clumps were broken up into individual cells by pulling the mixture up into 
the syringe and quickly forcing the cells out through the needle against a new, 
sterile tissue culture plate. This was repeated 10 times. The cell suspension 
was then divided between three new collagen- coated flasks, and 20 mL of 
flesh medium was added to each flask. The cells were allowed to grow for 
three days before the medium was changed. The medium was subsequently 
changed twice a week by removing the old media and adding 20-24 mL of 
fresh media. 
2.1.4 Plating procedure 
To plate cells, the cells were removed from the 20 mL flasks and were 
separated through a 22.5 gauge needle as previously described. When 
placed into 1200 mL of serum-free medium, the cells from about ten 20 mL 
flasks provided enough cells to reach a density of 200,000 to 500,000 
cells/ml. Four (4)mL of medium was then plated into each well of the 6-well 
poly-l-lysine coated plates. After a three day incubation period, (which allowed 
for the newly plated cells to grow and adhere to the flask) the medium was 
carefully removed and replaced with 3 mL of serum-free RPMl medium. 
2.2 Animals 
2.2.1 Handling and housing 
Male Wistar rats (215-260 g, Charles River Canada, Montreal. Quebec) 
were individually housed under a 12: 12-hour 1ight:dark cycle with food and 
water ad libitum. All procedures involving animals were performed in 
accordance with the Canadian Council on Animal Care guidelines and were 
approved by the University of Saskatchewan Animal Care Committee. 
All animals were allowed 3 days to settle after being transported to the 
animal housing facility before being exposed to contact with the experimenter. 
Animals were handled for 4 days to allow them to become accustomed to the 
future injection protocol. Animals were also transported to the injection room 
and handled once daily for 3 days prior to receiving actual injections. The 
animals were allowed one hour to settle after being moved to the injection 
room. 
2.3 Preparation and administration of drugs 
All drugs were freshly prepared as needed for the experiments. For 
chronic animal experiments, fresh drug solutions were prepared as follows 
every 3 to 4 days and were stored in a refrigerator at 4°C until use. The 
following drugs were used in both cell culture and/or animal experiments: 
remoxipride, risperidone, ritanserin , haloperidol, clozapine, and olanzapine 
(see Appendix A for source of drugs). 
2.3.1 Cell culture 
All drugs were dissolved in 1 mL Aristar grade ethanol and sterile filtered 
through a 0.2y Nalgene microfilter. This solution was then serially diluted in 
sterile 0.9% NaCl 4 times by a factor of 10 (dilutions = 1 : 10, 1 :100, 1 :I 000, 
1 : 10000). Final drug concentrations were calculated using the following 
formula: 
1 M drug concentration = molecular weight of drua X culture well volume 
volume of drug added 
1 pM drug concentration = molecular weioht of drucl X 3000 uU 25 uL 
1,000,000 
The cells that had been plated in 6-well plates were treated 3 days later 
with the various neuroleptics. Drug concentrations for cell culture experiments 
were chosen based on those reported in the literature for similar studies. The 
neuroleptics were administered to cells using a 25 pL repeat Eppendorf 
pipette. Cells were harvested at time points ranging for 0.5 hours to 48 hours 
at doses ranging from 0.01 pM to 250 pM. 
2.3.2 Animal experiments 
All drugs were dissolved in 0.8% glacial acetic acid in 5% glucose (5mg 
glucose in lOOmL sterile nanopure H20). Due to solubility problems, clozapine 
was made up in 1.5 times the volume of the other neuroleptics and was 
therefore injected as 50% more volume. Final drug doses were calculated as 
mglkg. Neuroleptics were given in amounts approximately four times greater 
than the mglkg human dose and were similar to neuroleptic doses reported in 
the literature traditionally in animal studies. 
For acute injection experiments, at least 3 animals per group received a 
single i.p. injection of either vehicle (0.8% glacial acetic acid in 5% glucose), 
remoxipride, risperidone, ritanserin, haloperidol, or clozapine at various doses 
corresponding to a range of high, moderate, and low clinical doses. For 
chronic and chronic challenge injections, three animals per group received 
daily imp. injections of either vehicle (0.8% glacial acetic acid in 5% glucose, 
remoxipride (3 mglkg), risperidone (1 mg/kg), ritanserin (2 mglkg), haloperidol 
(1 mg/kg) or clozapine (20 mg/kg) for 20 days (olanazapine was only included 
in later studies when it became available in the last 3 years for laboratory 
study), with challenge animals receiving an additional injection 30 minutes 
before sacrifice. In the dose-response study, 3 animals per group received 
daily i.p. injections of either vehicle (0.8% glacial acetic acid in 5% glucose), 
risperidone (4.1 1 , 0.67, or 0.067 mglkg), or haloperidol (1 mglkg) for 20 days. 
Animals were sacrificed and perfused as described below. The injection 
volume ranged from 250-350uL of solution, depending on the weight of the 
animal (mg/kg). 
2.4 Tissue preparation for analysis of mRNA and protein 
All reagents used for the analysis of mRNA were of molecular biology 
grade to ensure a ribonuclease RNAse-free environment. Nanopure water 
treated with the RNAse inhibitor diethylpyrocarbonate (DEPC: 1.1 Gmglml) was 
used in all experiments. DEPC-treated water was made by dissolving 4 mL 
DEPC in 4L nanopure Hz0 and autoclaving it for thirty minutes with the caps 
loosened. 
For analysis of mRNA in PC12 cells. the medium was removed from the 
plate after each time point and replaced with 1.25 mL GlTC buffer (4 M 
guanidinium isothiocyanate, 5 mM sodium citrate, 0.5% N-lauroylsarcosine, 
0.1 M t3-mercaptoethanol, adjusted to a pH of 5.5 with sodium acetate to 
pH=6.0). Plates were stored at -20°C until the total cellular and tissue RNA 
was extracted. 
Animals required for analysis of brain tissue mRNA only were sacrificed by 
stunning and decapitation. For northern blot analysis, brain regions were 
dissected out over ice, were placed in plastic 15mL Falcon centrifuge tubes 
and stored on dry ice. Three ml GlTC buffer was then added to each tube. 
Regions for disection were defined as in Horn et al. (1974). Samples were 
homogenized in the GlTC buffer and stored at -70°C until the extraction of 
RNA. 
The brains to be used for in situ hybridization were quickly rinsed in saline, 
quick frozen in a dry ice1 isopentane slurry at -50°C and stored at -70°C until 
sectioning. Animals required for analysis of both mRNA and protein were 
sacrificed by anesthesia with Nembutal (50 mglkg, i-p.), were transcardially 
perfused with 0.1 M Na-K phosphate buffer (PBS; pH 7.4) and the brains were 
then fixed by perfusion with 4% paraformaldehyde (PFA) in 0.1 M PBS. Brains 
were post-fixed in a 4% PFA solution at 4°C for 4 hours, cryoprotected in 30% 
sucrose (30mg sucrose in 100 mL sterile DEPC-treated H20) at 4°C for at 
least 2 days (or until the brains had sunk to the bottom of their container), 
quick frozen in a dry ice/ isopentane slurry at -50°C and stored at -70" until 
sectioning. 
2.5 Preparation of templates and probes for northern and in situ 
hybridization 
2.5.1 Templates prepared by PCR (c-fos) 
2.5.1.1 Principles of PCR 
The polymerase chain reaction (PCR) allows the amplification (i-e., the 
rapid, exponential increase) of a specific, short strand of DNA which, when 
"amplified", can be used for a variety of applications. The reaction simply 
requires that a DNA template, buffer, the appropriate primers, and a 
polymerase lacking 3' to 5' exonuclease activity be added at the beginning of 
the reaction and cycled through temperatures sufficient for DNA denaturation 
(94-95"C), primer annealing (37-7Z°C), and primer extension (72°C) (Saiki et 
al., 1988). Unlike older DNA amplification methods, PCR allows the 
amplification of a single molecule of DNA template without its introduction into 
Escherichia (E.) coli (Davis et al., 1994). In addition, whereas polymerases 
previously used in such amplifications were destroyed by temperatures 
required for denaturation, use of the thermostable Taq polymerase (from the 
hot spring residing bacteria Thermus aquaticus) allowed repeated amplification 
without having to add new polymerase after each denaturation step. Since 
PCR can amplify as little one DNA molecule, the presence of only a single 
DNA species is crucial for purity of amplification. 
2.5.1.2 Preparation of c-fos probe 
Two 48 base oligonucleotide primers (designed by Dr. Xin-Min Li, Dept. 
Psychiatry, University of Saskatchewan) based on the rat c-fos complementary 
DNA (cDNA) were synthesized on a PCR-MATE Applied Biosystems 391 DNA 
synthesizer. Primer-1 was 5' GGG ATT TAG GTG ACA CTA TAG AAC TTA 
AAT GCT TTT AT1 GAC AAT GAC AAT GTA 3' and primer02 was 5' CTG 
TAATACGACTCACTATAGGGTGGTCTGAATGTTCTGACATTAACA 
3'. Synthesis and further amplification was performed for 30 cycles 
(denaturation: 94°C for 2 minutes, annealing: 65°C for 1 minute, extension: 
72°C for 1 minute) using a DNA thermal cycler (Perkin ElmerICetus) and 
Perkin ElmerlCetus GeneAmp PCR Core Reagents. The reaction mix 
included 2.5 U/lOO pL AmpliTaq DNA polymerase; 200 pM each for dATPl 
dCTP, dGTP, and dTTP; 1x PCR buffer (500 mM KCI. 100 mM Tris-HCI (pH 
8.3))' 1.0 -4.0 mM MgCl2, 5ng/ 100 pL template (rat c-fos cDNA), and 0.2- 1.0 
pM each of primer 1 and primer 2 in a total volume of 100 pL. 
2.5.2 Templates derived from plasmids (general procedure) 
2.5.2.1 Preparation of media 
The media (LB, or Luria-Bertani media) used to grow untransformed, 
transformed and transfected Escherichia coli (E. coli) contained 209 bacto- 
tryptone.lOg bacto-yeast, and 209 NaCl made up to 2000 ml with nanopure 
water. The pH was adjusted to 7.4 with 1 M NaOH. To make agar plates, 159 
agar was added to half of the mixture. The medium was then autoclaved, left 
to cool to room temperature, and had ampicillin (AMP) added to a portion of it. 
Stock solutions (1 000x) of AMP were made by adding 50 rng AMP per 1 mL 
Hz0 and filtering the solution with a 0 . 2 ~  Nalgene Millipore filter. Aliquots were 
stored at -20°C until use. 
2.5.2.2 Transformation of bacteria 
The E. Coli strain JM109 was streaked onto antibiotic-free LB plates and 
left overnight to incubate in a dry chamber at 37°C. The following day, one 
colony was selected to grow in 40 mL of antibiotic-free LB liquid media in a 
flask in a shaking water bath at 37°C until the rate of growth of the colony 
reached log phase kinetics. This was determined by measuring the optical 
density (OD) of the bacterial solution at 600nm until it reached an OD of 0.3 to 
0.5. This process usually took between 3 to 7 hours. 
The bacterial colony was centrifuged at room temperature at 1500g for 
approximately 5 minutes until a pellet became visible. The excess fluid was 
discarded and the cells were resuspended in 20 rnL of 50 mM CaC12 in order 
to make the cells competent for transfection. After sitting on ice for 30 minutes 
the cells were spun as previously for 5 minutes at 4°C. The cells were 
resuspended in 4 mL CaC12 and stored at 4°C until use. 
Dry plasmid DNA conferring probe sequences for various genes was mixed 
in nanopure Hz0 at a concentration of 1-2pg per 50pL (for details of the 
plasmid vectors used and the restriction cuts, please see sections 2.5.3 and 
2.5.4). Plasmid DNA was mixed with competent cells in ratio of 1 :2000. The 
mixture was stored on ice for 30 minutes and then heat shocked at 42°C for 2 
minutes. One (1)mL of LB medium (without antibiotic) was added and mixed 
in a shaking water bath at 37°C for 45 minutes to allow for the expression of 
the antibiotic resistance gene for AMP contained within the newly inserted 
plasmid. 
2.5.2.3 Plating of cells and selection of culture 
The bacteria were then grown on both ampicillin negative (AMP-) and 
ampicillin positive (AMP+) agar (inverted) plates overnight at 37°C. Only 
bacteria containing the plasmid would be resistant to the ampicillin, and 
therefore only transformed bacteria could grow on the AMP+ plates. Wild type 
(untransformed) bacteria were grown on AMP+ plates as a negative control. 
To ensure that the colony selected for the plasmid miniprep consisted of 
transformed bacteria, a single colony that was not touching or growing on top 
of any other colonies was selected from the AMP+ plate. 
2.5.2.4 Amplification and preparation of plasmid DNA 
To amplify the plasmid of interest, a single colony of bacteria transfected 
with the probe coding AMP-resistant plasmid was grown in 100 mL liquid 
AMP+ LB media overnight at 37°C in a shaking water bath (Maniatis et al., 
1982). This was then centrifuged at 2000Xg, the supernatant was discarded, 
and the pellet was resuspended in 450 pL of glucose buffer (25 mM Tris [tris 
{hydroxymethyl) aminomethane], pH 8.0; 50 mM glucose, 10 mM EDTA 
[ethylene diaminetetraacetic acid]). This was followed by the addition of 1.2 
mL 0.2M NaOH with 1 % sodium dodecyl sulfate (SDS) to lyze the bacterial cell 
membrane and free the plasmid DNA. The solution was centrifuged for 10 
minutes after the addition of 900 pL ice cold potassium acetate solution (29.49 
potassium acetate, 11.5 mL glacial acetic acid to 100 rnL H20). The 
supernatant was saved and the precipitate discarded. After adding 1.5 mL 
isopropanol to the supernatant, the mixture was stored at -20°C for at least 15 
minutes and was then centrifuged for 15 minutes at 12,0009. The pellet was 
resuspended in 400 VL of TrisIEDTA buffer (TE) buffer (1 0 mM Tris pH 7.4; 
0.1 mM EDTA pH 8.0), and 40uL 3M sodium acetate. 
2.5.2.5 Purification of DNA 
A phenol1 chloroform extraction was used to partially purify the plasmid 
DNA. Volumes in a ratio of 25:24:1 of saturated salt (ss)-phenol: chloroform: 
isoamyl alcohol were mixed and vortexed, followed by centrifugation. The 
phenol was buffered to prevent DNA damage from oxidized materials in the 
phenol. During the purification, proteins denature and collect in the lower 
organic (phenol) phase, while nucleic acids remain in the aqueous phase. 
The top aqueous layer was saved followed by the addition of approximately 
2.5 volumes of 95% ethanol to the top aqueous layer and the mixture was 
stored at -20°C overnight. After being centrifuged for 10 minutes at 4"C, the 
supernatant was discarded, excess salt was removed from the remaining 
pellet with 80% ethanol, and the mixture was recentrifuged for 2 minutes. The 
pellet was left to airdry overnight and was resuspended in 5OpLTE buffer the 
following morning. 
To further purify the plasmid DNA and remove E. cob DNA, the total DNA 
was run on a 0.8% agarose gel in 100 mL 1X TAE (Tris acetate/ EDTA) buffer 
(1 -6 M Tris base, 0.8M sodium acetate, 40 mM EDTA, adjusted to pH 7.2 with 
acetic acid) and 10 mglml of ethidium bromide (an intercalating agent). The 
gel loading solution contained (in 10 rnL) 5 rnL glycerol, 250 pL 40X TAE 
buffer, 1 mL saturated brornophenol blue, 1 mL10% suspension xylene cyanol, 
and 2.75 mL H20. The part of the gel containing the plasmid DNA was cut out 
and purified using a Geneclean II kit (Promega). Purity was confirmed by mini- 
gel electrophoresis. 
2.5.2.6 Restriction digest of plasmid DNA 
Restriction endonucleases (RE's) are enzymes found in bacteria that, by 
recognizing and cutting specific sequences in double-stranded DNA, protect 
the bacteria from foreign DNA (Zielinski et al., 1999). Most RE's cut at 
recognition sequences 6 to 8 base pairs long, many of the recognition 
sequences being palindromes (a sequence which is mirrored on both strands 
in the 5' --> 3' direction). Molecular biologists have presently identified over 
600 "type II" RE'S which, unlike other types of RE'S, do not require adenosine 
triphosphate (ATP) for cleavage and cleave close to or at the recognition 
sequence (Davis et al., 1994). These RE's are commercially available for 
applications including the analysis of chromosome polymorphisms and the 
recombination of DNA (Maniatis et al., 1982). 
To run an analytical digest, 1 pL (0.2 to IOU) of the appropriate RE(s), 1 pL 
(0.1 to 0.5 pg) of the plasmid to be cut, I pL of the appropriate buffer, and 7pL 
Hz0 were incubated at 37°C for 1 hour. After stopping the reaction by 
incubation at 65°C for 2 minutes, the sample plus an equal volume of loading 
buffer was run for 1 hour on a 1 % agarose gel at 75 mV against a DNA marker 
to confirm probe length and that the plasmid had been cut in the proper 
location. 
To determine the concentration of plasmid DNA, 4 pL of the solution 
containing the plasmid DNA was added to ImL H20, was mixed, and added to 
a crystal cuvette for measurement under UV light at 260 nM on a Beckman Du 
460 spectrophotometer and the concentration calculated using the following 
equation: 
Concentration of Nucleic Acid (DNA or RNA) in w/pL=- 
Absorption at 260 nrn (A260) X extinction coefficient X 'dilution factor 
'Dilution factor = 
Total volume of solute in cuvette (mL) 
Volume of nucleic acid measured (pL) 
Concentration of DNA (pg/pl)=- 
Absor~tion at 260 nm (14260) X 50 un/ rnL X 1 mL 
4 PL 
The extinction coefficient of DNA is 50 pg/mL, 40 pglml for RNA and 30 pg/pL 
for oligonucleotides. Extinction coefficients correspond to nucleotide 
concentrations that produce an optical density of 1.0 at A260 (Davis et al.. 
1 994). 
2.5.3 Labeling cDNA probes: TH, AADC, SOD, p75, cyclophilin 
The cDNA probes were radiolabled by random primer synthesis with [a-32P] 
dCTP as described by Fainberg and Vogelstein (1983) using a random primer 
6 8 
kit from Boehringer Manheim. Briefly, the probe template (50 nglpL) single 
stranded or double stranded DNA was denatured at 95°C for at least 5 
minutes and quickly placed on ice to prevent renaturation. Once denatured, 
single stranded DNA acts as the template to synthesize the radiolabeled 
probe. The reaction mixture contained 2 pL of random hexonucleotide primers 
(0.5 M Tris-HCI, 1 M MgC12), 1 mM dithiothreitol (DTT), 2 mg/mL bovine serum 
albumin, hexanucleotides @ 62.5 A260 units/ml (pH 7.20, 1 pL (2U) Klenow 
fragment, 5 pL 'P dCTP (50 pCi) and 3 pL dNTPYs (dATP, dGTP, dTTP) each 
at a concentration of 0.5 mM, and was incubated with 25 ng denatured 
template DNA made up to 19 pL with sterile redistilled Hz0 for at least 1 hour 
at 37°C. The reaction was stopped with 10 pL 0.01 M EDTA followed by the 
addition of 130 VL STE buffer (NaCI-Tris-EDTA Na2 buffer, pH 7.4). The 
probe was column purified with Bio-Spin 30 chromatography columns 
according to the manufacturer's instructions. Salmon sperm DNA (1 mg/mL) 
which had been heat denatured was added to block non-specific polar groups 
on the membrane and was added in an amount to bring the solution up to 
500pL. The mixture was then alkali denatured with 0.1 volumes 3N NaOH for 5 
minutes. followed by the addition of 0.05 volumes 1M Tris-HCI, pH 7.2 and 0.1 
volumes 3N HCI. 
SOD1 cDNA was kindly provided by Dr. J. T. Coyle (Harvard Medical 
School, Boston, Massachusetts, USA). AADC and TH cDNA were obtained 
from rat adrenal gland total RNA by RT-PCR (Li et al., 1992). The p75 cDNA 
probe (from rat complementary RNA [cRNA]) was from Dr. Ron Lindsay 
(Regeneron Pharmaceuticals, ferrytown, New York, USA) and the cyclophilin 
probe was from Dr. Barry Kosofsky (Harvard Medical School. Boston, 
Massachusetts). SOD1, cyclophilin, and AADC cDNA were placed in PGEM-3 
inserted into JMI 09 E.Coli. SOD1 cDNA was cut with Pstl , cyclophilin was 
cut with BamHI, and the AADC cDAN was cut with EcoR1 and Pstl . 
2.5.4 Labeling cRNA probes: c-fos, BDNF 
The cRNA probes were radiolabelled with either [a -"PI or [a using a 
transcription kit from Boehringer Manheim. Briefly, the template coding for 
probe sequences was first inserted into a plasmid between two promoter 
regions which code for the start site of transcription of selected DNA- 
dependent RNA polymerases, including SP6, T7, and T3 RNA polymerases 
(SP6 polymerase is from the Salmonella bacteriophage SP6, while 17  and T3 
polymerases are from the E. Coli bacteriophages T3 and T7). The plasmid 
was cut with the appropriate restriction enzyme at one of the promoter regions 
to define the 3' end of the transcription unit for the synthesis of the antisense 
probe. In vitro transcription was started with 0.5 pglpl ternplatelcut plasrnid, 2 
pL 10X buffer, 1 pL of 1 :50 CTP, 3pL NTP (ATP, GTP, UTP) each at a 
concentration of 10pM, and the mixture was incubated at 37°C for at least 2 
hours. The RNA polymerase was heat denatured (65°C) for 15 minutes and 
1 pl (10 U) deoxyribonuclease (DNase) was incubated with the mixture for one 
hour at 37°C to digest the template cDNA. After the addition of 10pl 0.1 
EDTA and 65 p1 STE buffer, the probes were column purified with Bio-Spin 30 
Chromatography Culumns according to the manufacturer's instructions. 
Unincorporated nucleotides are retained in the column while the longer, 
synthesized transcripts pass through the column and are collected for use in 
either the northern or in situ hybridizations. 
To measure the specific activity of labeled probes, 1 pl of each purified 
probe was added to 10 ml of scintillation fluid and counted as counts per 
minute (cpm)/pg on a Beckman LS 5000TD scintillation counter. To be used 
for in situ hybridization experiments, probes needed to label between 5 X 1 Os 
to 2 X 106 cpm/ml (% incorporation could be calculated by spectrophotometry). 
The probe for c-fos (antisense SP6) routinely labeled at counts lower than 
the other RNA probes, so two variations in the procedure were performed to 
increase the specific activity of the probe. While double labeling with [35S] CTP 
and ATP did not seem to increase specific activity, reduction of the amount of 
cold CTP (1 :I 00 vs. 1 :50) did seem to increase specific activity by a factor of 
1.5 times. 
The BDNF cRNA probe (from rat cRNA) was the gift of Dr. Ron Lindsay 
(Regeneron Pharmaceuticals, Terrytown, New York, USA). The BDNF probe 
template (1 127 base pairs) was inserted in the Bluescript SK- from Lamba Zap 
II, with the mRNA sequence starting at 14 nucleotides after an ECOR-1 linker 
and ending at 1108 base pairs before the ECOR-1 linker between promoter 
regions for T7 and T3 (Maisonpierre et at., 199ia,b). The antisense probe to 
detect mRNA was generated using a T7 promoter. The transcription region 
was defined by cutting the inserted plasmid just before the start site of the T3 
promoter with the BAM HI restriction endonuclease. To generate a template 
for a sense strand, the plasmid was cut just before the T7 promoter with the 
Xho I restriction endonuclease. Both endonucleases are non-cutters of the 
BDNF coding region and cut at only one site in the polycloning region of the 
plasmid. The c-fos probe was not placed in a plasmid, but linked to an SP6 
promoter region for probe synthesis and was used immediately after its 
symthesis by PCR. 
2.6 Estimation of mRNAs by northern hybridization 
The northern hybridization is one of the most useful methods available to 
estimate the amount of RNA in target cells and tissues. The amount of mRNA 
present of a particular gene in a given tissue can provide useful information 
about the conditions in a cell that can increase or decrease its availability to 
serve as the template for the protein it encodes. Although the northern blot 
hybridization cannot provide information about the cellular location of a 
particular mRNA, it can be used to quickly estimate if a particular treatment will 
have an effect on a target mRNA is a particular tissue. 
2.6.1 Isolation of mRNA 
Total cellular RNA was prepared from treated cells by extraction in GfTC 
buffer and collected by ultracentrifugation (21 hours, 32,000 revolutions per 
minute [rpm], Beckman) under vacuum through 5.7 M cesium chloride (CsCI: 
95.97 g CsCI, 0.83 mL 3M sodium acetate. 2000 mL DEPC-treated H20). 
After being filtered through a 0.8 pM Millipore filter, the CsCl solution was 
transferred into 2L bottles, treated with 1 mL DEPC, left overnight and placed in 
a shaker bath in a fume hood at 60°C to get rid of the DEPC. 
The RNA was chloroform-extracted, ethanol-precipitated, resuspended in 
DEPC treated water, and stored at -70°C until use. RNA was measured 
spectrophotometrically by absorbance at 260 nm. The purity of RNA was 
checked by the ratio of the UV absorbance at 260nml280nm which was about 
1.8. Ethidium bromide staining of the sample trackings indicated that the 
samples were not degraded. 
The total RNA was denatured at 65°C for 15 minutes in MOPS (3-(N- 
morpholino) propanesulfonic acid) buffer (200 mM MOPS, 50 mM sodium 
acetate, 10 mM EDTA, pH 7.0) containing 50% formamide and 2.2M 
formaldehyde to keep the RNA denatured. Total RNA was separated by 
electrophoresis in a 1 .O% agarose gel containing MOPS buffer and 2.2M 
formaldehyde. Following electrophoresis, a picture of the 18s and 28s RNA 
bands were taken to ensure standardization of gel loading (see below). The 
RNA was transferred to nylon membranes and the membranes were cross- 
linked in a UV Stratalinker 2400. Membranes were visualized under UV light 
to ensure adequacy of transfer. 
2.6.2 Principles of hybridization 
Hybridization techniques rely on the ability of a labeled single stranded 
DNA or RNA probe to form selective homo- (DNAIDNA, RNNRNA) or 
heteroduplexes (RNNDNA) with a target DNA or mRNA, and on the creation 
of conditions which remove excess or background labeled nucleotides and 
allow the desired duplex to remain for detection. RNNRNA hybrids are the 
most stable, followed by RNAfDNA and then DNAfDNA interactions. This 
means that RNA probes will bind more tightly to mRNA than will DNA probes 
during the detection of mRNA by northern hybridization and will thus require 
more stringent wash conditions to remove excess probe. 
Other factors affect the stability of duplexes. The "melting temperature", or 
Tm, of such nucleotide duplexes is defined as the temperature at which half of 
the nucleotides in a duplex melt or lose their pair bonding capacity. Since GC 
pairs have three hydrogen bonds, while AT(1Uracil) bonds only have two, 
duplexes with a higher GC content have a higher Tm, and thus need a higher 
temperature wash to lower the stability of and thus "melt" nucleotide duplexes. 
The average Tm is 85"C, and northern hybridization wash conditions are 
typically 20°C lower than the Tm. In addition, the higher the degree of 
complementarity between duplexes, the more stable the duplex. This factor 
allows the specific probe/ target mRNA hybrid to remain while non-specific 
duplexes can be washed out of the membrane. 
Salts such as NaCl stabilize nucleotide duplexes by interacting with 
negatively charged phosphate groups on the nucleotide backbone. At room 
temperature, DNA will completely denature in water, but will remain double 
stranded at a salt concentration of 2.0 to 6.0 M. A 0.15 M salt solution will 
lower the Tm by 20°C. The lower the salt concentration of the wash conditions 
and the higher the "stringency" (the ability to disrupt nucleotide duplexes) of 
the wash, the more nucleotidelprobe interactions are disrupted (nonspecific 
duplexes are washed out first). Forrnarnide disrupts hydrogen bonds and thus 
can be added if high temperature and low salt concentrations fail to sufficiently 
remove undesired probe and excess nucleotides from the membrane. Thus, 
wash conditions can be altered based on the composition of the particular 
probe used. 
2.6.3 Procedure 
Filters were prehybridized at 60°C for 2 hours with prehybridization solution 
containing 10% dextransulfate, 5X SSPE [(sodium chloride1 sodium phosphate 
buffer; 5 X Denhardt's solution (0.1 % Bovine Serum Albumin (BSA), 0.1 % 
Ficoll, 0.1 % polyvinylpyrrolidone)], 0.5% SDS, and denatured salmon sperm 
DNA (200 pglml). Hybridization was performed at 60" C for 18 hours. After 
hybridization, membranes were washed at room temperature twice in 2 X 
SSPE-0.1 % SDS, once in 0.1 X SSPE-0.1% SDS at 60°C, and once in 0.7 X 
SSPE-0.1% SDS at 60°C. The membranes were washed and exposed to X- 
Omat AR film with intensifying screens at -70°C to obtain autoradiograms. The 
autoradiograms were scanned with a computerized densitometer (Du 640, 
Beckman) for quantitative estimations, and the signals were adjusted 
according to the signals of rehybridization with a cyclophilin probe. 
2.6.4 Variations of wash conditions 
Both TH and AADC probes required a higher stringency wash. Incubations 
and washes were performed at 65"C, and longer wash times at 0 . 1 ~  SSPE 
were employed to acquire membranes with low enough counts for 
autoradiography. The c-fos RNA probe required a low stringency wash at 
60°C with reduced wash times at the lower salt concentrations. The SOD and 
p75 probes required wash conditions similar to but slightly less stringent than 
that of AADC and TH. The BDNF probe required incubation at 68°C with long 
washes with low salt concentrations at anywhere between 68 and 72°C. 
2.6.5 Autoradiography and exposure times 
After washing, membranes were exposed to X-Omat AR Kodak film with 
intensifying screens, at -70°C to obtain autoradiograms. Exposure time for the 
development of measurable autoradiographs ranged from 0.5 hours to 10 
days. In general, each probe had an optimal development time, with TH 
autoradiographs requiring the shortest exposure times, and c-fos 
autoradiographs requiring the longest exposure times. 
2.6.6 Standardization of gel loading 
There are two methods commonly employed to ensure that the amounts of 
total RNA run on an electrophoretic gel are equal to one another: intensity of 
18sI 28s bands, and hybridization to housekeeping genes such as R-actin and 
cyclophilin. When intercalated with ethidium bromide, 18s and 28s structural 
RNAs can be visualized in a gel under UV light. If the amount of total RNA 
loaded into each lane of the gel is equal, the intensity of the 18s and 28s 
bands under UV light should be equal. If they are not equal, band intensities 
can be measured and loading can be standardized in comparison to the 
controls. The disadvantage of this procedure is that it does not take into 
account the possibility of uneven transfer of RNA to the membranes during the 
transblot procedure. Membranes can be visualized under UV light and the 
image transferred to a computer-based image analysis program, but such 
images are not always sufficient for such analysis. 
Housekeeping genes are those genes whose protein product is 
constitutively expressed and is resistant to induction of its production by 
intracellularl and or extracellular inputs. Hybridization of a housekeeping gene 
such as R-actin or cyclophilin to the same membrane probed for the mRNA to 
be measured, accounts for the possibility of uneven transfer and is even a 
better control if hybridized to the membrane at the same time as the other 
probe, which is only possible if the mRNA species migrate at a far enough 
distance from the housekeeping gene being measured. In practice, it is 
probably safe to use a housekeeping gene if it is first established that the 
experimental manipulation does not regulate the housekeeping gene used, 
which can in part be established by a comparison to 18 and 28s intensities. If 
the experimental condition regulates the housekeeping gene, it would be 
necessary to find a different housekeeping gene and/ or standardize to the 18 
and 28s bands. 
In the present study, efforts were made to standardize all membranes to 
cyclophilin mRNA. If hybridizations to cyclophylin were faulty or if treatments 
altered cyclophilin mRNA, standardizations to the 18s and 28s were employed. 
2.6.7 Quantification of Autoradiographs 
2.6.7.1 Quantification program and preparations of linearity standards 
Autoradiographs from membranes were scanned with an Acer Acer310P 
scanner and analyzed using an IBM compatible version of NIH Image (Scion 
Image). Since film can become "maxed out" or saturated, it is possible to be 
unable to record further radioactive signal. Film actually has three ranges of 
linearity and it is ideal to measure film densities in the middle and most 
dynamic range. 
When choosing a radioisotope for a particular application, one must 
consider the degree of resolution desired and the amount of time one is willing 
to wait for a result. If one wants quick results and the resolution of the film 
image obtained is not a primary concern (such as in a northern blot), a high 
beta-emitting radioisotope such as 32P is a good choice. If resolution is 
important, as it would be in an in situ hybridization, a radioisotope with a lower 
emission energy such as is neccessary to ensure a more detailed film 
image; although some films may need up to 3 week exposure periods to 
produce a quantifiable image. 
There are several methods available to ensure the linearity of 
autoradiographic signals, including the use of commercial 'H-polymer 
standards (Geary et al., 1985), but 3H autoradiography has the disadvantage 
of requiring weeks to obtain quantifiable radiographic signals due to the 
relatively low emission energy of 'H (Nazarali et al., 1989). For northern blot 
analyses where the strong beta emitter 32P is often used as the radiolabel, 
simple standards can be prepared by applying differing concentrations of 32P 
to nylon membranes and including these membranes in the film cassette with 
the probed membranes of interest. Standardization of autoradiography with 
35S in situ hybridization (ISH) requires the use of brain paste standards or 
commercially available calibrated I4C or 1251- polymer standards (Davenport 
and Hall, 1998). In the present study, ''S brain paste standards were made by 
the present investigator as outlined in section 2.8.4.1. 
2.6.7.2 Positive controls 
Since one of the mRNAs probed for in the present study (c-fos) is usually 
undetectable in control conditions, positive controls were employed. Male 
Wistar rats were injected with 10 mglkg kainic acid and were observed for 2 to 
6 hours for signs of seizure using Racine's rating scale (Racine and Burnham, 
1984). In addition, at the onset of the present study, it was known that acute 
haloperidol treatment (1 mglkg, animals sacrificed 30 to 45 minutes after a 
single i.p. injection) would significantly increase striatal c-fos mRNA over 
controls. If an ISH did not produce positive results with the kainate- and 
haloperidol-treated animals, it could be concluded that the ISH did not work. 
Conversely, if these positive controls yielded significant c-fos mRNA labeling 
but changes were not observed in the other sections, we could be certain that 
the negative results (i.e., the absence of signal) were true lack of gene 
induction and not merely "false negatives". 
2.7 Preparation of tissue for in situ hybridization analysis 
2.7.1 Poly-L-lysine coating of slides 
Melvin Freed microscope slides were placed in slide racks (19 per rack) 
and cleaned in 6N HCI for 112 hour. The slides were rinsed in tap water for 
approximately one hour and left to soak in nanowater overnight. The slides 
were dried at 60°C overnight, allowed to cool to room temperature, and 
soaked in a 10 fold dilution of poly-L-lysine in DEPC water for 112 hour. After 
being dried at 60°C overnight, the slides were allowed to cool, were dipped in 
poly-L-lysine again for one half hour, and dried overnight. Precautions were 
taken to ensure an RNAse-free environment. Slides were stored at 4°C up to 
one month until use. The poly-L-solution was stored at 4°C and reused once 
before being discarded. 
2.7.2 Sectioning 
The cryostat temperature was kept at -18°C or lower to prevent the 
activation of RNAses (especially in fresh frozen tissue). The slides being used 
were also kept at this temperature in the cryostat. Brains to be sectioned were 
taken from the -70°C freezer and left covered in the cryostat chamber for 
about 2 hours to equilibrate to the chamber temperature. Coronal sections for 
ISH were cut at either 12 or 20 pm. Sections from different experimental 
conditions were put on each slide, and the relative position of each 
experimental group was rotated to ensure that samples from one experimental 
group did not always end up on the same position on the slide (this control is 
particularly important for emulsion analysis, since the top section on the slide 
spends less time in the emulsion than the bottom slide). The slides were kept 
covered in the chamber and sections were cut as quickly as possible to 
prevent drying of tissue. Sections were stored at -20°C until 
immunohistochernistry, in situ hybridization, and/or prehybridization (for fresh 
frozen tissue). 
2.7.3 Prehybridization 
Sections from fresh frozen tissue must be prehybridized with 
paraformaldehyde in order to preserve tissue and prevent the breakdown of 
RNA. However, fixation time must be limited to that time which provides good 
tissue morphology but still allows an acceptable signal-to- noise ratio after in 
situ hybridization. Sections were carefully warmed to room temperature and 
placed in 4% paraformaldehyde (PFA) for 5 minutes, and washed in 1 x PBS 
(phosphate buffered saline; 0.01 M Na2HP04, 0.01 M NaH2P04, and 0.26 M 
NaCl pH= 7.4 in DEPC-treated water) for 2 and then 3 minutes. In order to 
block polar and charged groups on the sections (which would cause non- 
specific binding of probe), the sections were placed in 1 X (0.1 M) 
triethanolamine-HC (TEA; NaCI, 0.1 M triethanolamine, adjusted to pH 8.0 
with NaOH) for 10 minutes, 1 X TAEI 0.25% acetic anhydride for 10 minutes, 
2X SSC for 5 minutes, 70% ethanol for 1 minute, 80% ethanol for 1 minute, 
95% ethanol for 2 minutes, and 100% ethanol for 1 minute The lipids were 
then extracted from the sections in chloroform 2X 5 minutes, 100% ethanol 
for 1 minute, and 95% ethanol for 1 minute. Slides were allowed to dry on the 
bench at room temperature for at least an hour before being seaied in airtight 
slide boxes and stored at -20°C. 
2.8 Estimation of mRNA by in situ hybridization 
In situ hybridization is often used to localize results found by northern blot 
analysis in the brain. The principles of nucleic acid binding for in situ 
hybridization are similar to those for northern hybridizations (see section 
2.6.6). 
2.8.1 General procedure 
Special care must be taken to prevent endogenous RNAse enzymes in the 
brain tissue from degrading the mRNAs we wished to measure. Sections were 
removed from storage at -20°C and allowed 1.5 hours to warm to room 
temperature (to prevent tissue damage from frost). The hybridization buffer for 
in situ hybridization contained 0.6M NaCI, 0.08M Tris buffer pH 7.5, 0.004M 
EDTA, 0.1% sodium pyrophosphate, 10% dextran sulfate, 0.2% SDS, 0.02% 
heparin NaCI, and 50% ultraformamide, which was made in advance and 
stored in aliquots at -20°C until use. This was added 10:1 to the 
radiolabelled RNA probe (1.0-3.0 X 106 cpm), was boiled for 5 to 10 minutes, 
placed on ice, and had 100 mM DTT added to prevent oxidation. 
Approximately 40 to 45 pL of the hybridization solution was added to each 
slide. The slides were coverslipped, placed in a polystyrene box containing 2 
pieces of Whatman filter paper soaked with 2X SSCf 50% formamide (2X SSC 
made from 20X SSC stock: 3M NaCI, 0.3M sodium citrate, adjusted to pH 7.0 
with 1 M HCI), and incubated overnight at 50°C for at least 18 hours. 
The following day, the sections were soaked for 10 minutes in 2X SSC 
buffer at room temperature, and the coverslips were then carefully removed. 
Sections were washed for 3X 5 minutes in 2XSSC buffer, treated with 10 
mg/mL RNAse in 500 mL RNAse buffer (0.3M NaCI, 0.01M Tris buffer pH=8, 
and 0.005M EDTA pH=8) for 30 minutes, washed in RNAse buffer for 30 
minutes, and washed in 2XSSC for 5 minutes. Depending on the radioactivity 
left on the slide, the sections were washed at varying degrees of time, 
temperature and SSC concentrations. A series of trials were performed to 
determine the appropriate wash conditions. For BDNF, sections were washed 
in 2X SSC at 60°C for 30 minutes and 0.2X SSC at 60°C for 30 minutes. For 
c-fos, sections were washed in 2X SSC at 50°C for 15 minutes and 0.2X SSC 
at 50°C for 10 minutes. Sections were dried in ascending ethanol 
concentrations (50, 70, 90, 95% ethanol/ 0.3M ammonium acetate) and 
allowed to air dry for at least one hour prior to exposure to film andlor 
emulsion. 
2.8.2 Variations in procedures 
Due to the initial weak signal obtained from tissue probed with the 35S- 
radiolabelted c-fos probe, a competition assay was performed to determine if 
the appropriate probe concentration was being used. When it was verified that 
the probe concentration being used was appropriate, other variations in the 
procedure were undertaken to increase the c-fos hybridization signal. The 
substitution of "P for 35S allowed for a stronger signal. In some experiments, 
the section thickness was increased from 12 to 20 VM which also increased 
the signal. Conditions were othenvise varied in a manner similar to that of the 
northern hybridizations. C-fos probes required incubation at 50°C, less RNAse 
A treatment and fewer, shorter washes than did BDNF (incubation at 54"C, 
high RNAse A treatment, longer post hybridization washes). Longer 
incubation times (up to 24 hours) provided stronger signals on 
autoradiographs. 
2.8.3 Autoradiography and exposure times 
Exposure time for the development of measurable autoradiographs ranged 
from 1.5 days to 2 weeks. In general, each probe had an optimal development 
time. BDNF autoradiographs produced clear, strong signals in as little as 1.5 
hours, while c-fos-generated autoradiographs took up to 2 weeks for 
development and had significant background. After development times of two 
weeks, background often became too dark for adequate measurement. 
2.8.4 Quantitative analysis 
2.8.4. I Preparation of brain paste standards 
Standards which have been calibrated to brain paste standards are 
commercially available (Nazarali et at., 1989). Although 14C commercial 
standards are available for calibration of 35S autoradiographic signals, "S 
brain paste standards were made by the present investigator for calibration 
and were verified to be linear on a Molecular Dynamics Phosphoimager 
System. Briefly, brain paste standards were prepared by weighing out 
approximately 150 mg rat brain which had been ground into a paste. After 
choosing a desired concentration (dpmlmg) of 35S to be present in each of 14 
brain pastes (which included dilutions in concentrations from 50, 100, 200 
dpmlmg to 409,600 dpmlmg), these dilutions were added in equal volumes to 
the pastes and mixed well. The pastes were frozen in Eppendorf tubes, 
removed and mounted for sectioning while frozen, and cut at the same tissue 
section thickness (12 pM) as the tissue sections being analyzed for in situ 
hybridization autoradiography, with one section from each of the 14 brain 
pastes being present on each slide. A brain paste slide was included with 
slides being exposed to film for quantification to ensure that the 
autoradiographs were in a linear range. 
2.8.4.2 Positive controls 
Positive controls with kainic acid-treated and haloperidol-treated animals 
were employed as described section in 2.6.7.2. 
2.8.4.3 lmaging system 
In situ hybridization data were analyzed using an lmage 1 system 
(Universal lmaging Corporation) and NIH image. Two density measurements 
were made in each region measured on each side of the section. Sections 
from different drug conditions but that were similar anatomically were 
represented in the analysis at least in triplicate. Gray scale values were 
calibrated by 35S brain paste standards on lmage 1 and the data was 
converted to disintegrations per minute (dpm)/mm? 
2.8.5 Photographic emulsion 
Photographic emulsion is indicated when either cellular localization of 
signal is required or the structure containing the desired signal is too small to 
measure by film autoradiography. Kodak NTB2 photographic emulsion was 
diluted 1 :I with nanopure water in a dark room one day previous to the 
procedure (this allows bubbles to rise out of the dilution) and stored at 4'C in 
tinfoil-wrapped 50mL Falcon tubes in a radioactivity-free refrigerator. The 
following day, the water bath was warmed to 42'C and the emulsion was 
squeezed out into a copland jar in the waterbath. Slides to be dipped were 
placed in peel-aways. A test slide was first dipped to ensure that there were 
no bubbles. The slides were dipped for 3 seconds and allowed to dry for at 
least 2 hours. Test slides for early, middle, and late development times were 
also prepared. The slides were then placed in light-tight boxes with desiccant 
and stored at 4°C until development. After development (2 minutes in Kodak 
developer, 30 seconds in water, 3 minutes in Kodak fixer prepared according 
to the manufacturer's instructions) the sections were counterstained with 
cresyl violet. 
2.9 lmmunohistochemistry 
2.9.1 Procedure 
lrnmunostaining was performed as described by Hiroi and Graybiel (1 996) 
with a polyclonal antiserum against FosB/ delta FosB (Santa Cruz 
Biotechnology, Santa Cruz, CA; kindly donated by Dr. X. Zhang) on free 
floating sections at 1 : 1500. Sections were stained by the avidin-biotin (ABC) 
technique. Sections were rinsed for 10 minutes in 0.01 M phosphate buffered 
saline (PBS; 0.9% NaCI, 0.1 M KH2PO4, 0.lM NazHP04) containing 0.2% 
Triton X-100 (PBS-TX), were treated for 10 minutes with 3.0 % Hz02 in PBS- 
TX to prevent endogenous peroxidase activity, were blocked for 3 hours in 5% 
normal goat serum in PBS, and were incubated with the primary antisera (anti- 
rabbit) at 4°C for 15 hours in 0.01 M PBS, 0.8% Triton X-100, and 1 % normal 
serum. 
The appropriate concentration of the primary antibody was determined 
using two sets of concentration gradients on both the tissue of interest and a 
positive control tissue (kainate-treated animals). The first gradient included 
ratios of primary antibody: PBS of 1 :100, 1 :500, 1 :1000, 1 :5000, 1 :10000. The 
best concentration from this trial along with two concentrations below and two 
concentrations above were then employed to find the best primary 
concentration in this range. Too low a concentration obviously produces a 
weak signal, while a too high concentration is wasteful and may cause the 
primary to compete with itself for binding. 
2.9.2 Variations in procedure 
Variations in TritonX-100 concentrations were also employed. Triton 
solubilizes cell membranes and enhances the ability of the primary antibody to 
bind to its target protein. If the Triton concentration was too low, 
immunoreactivity was significantly reduced. Although tissue morphology is 
disrupted by Triton, there was not much difference in tissue preservation at 0.2 
vs. 0.8% TritonX-100. In addition. various incubation times were employed to 
determine the best incubation period for the primary antibody. Longer 
incubation times disrupted tissue morphology regardless of triton 
concentrations, but produced better immunoreactivity. Thus, an 0.8% Triton 
solution and the shortest incubation times possible were used due to its ability 
to improve primary antibody binding. Sections were washed 3X 10 minutes in 
PBS-TX and then incubated with the goat-anti-rabbit secondary antiserum 
(1 :500, Vector) for 1 hour (in PBS-TX, 1 % normal serum). The concentration of 
the secondary antibody and incubations times were determined in a manner 
similar to that of the primary antibody. 
The sections were again washed in PBS-TX and subsequently incubated 
with the avidin-biotin-peroxidase complex (1 : 150, Vectastain Kit) for 45 
minutes in PBS. Longer incubations in the tertiary produced excessive 
background staining. Horseradish peroxidase conjugated with biotin was 
developed with diaminobenzidine (DAB) in the presence of Hz02 (0.001 %) in 
Tris-HCI buffer (0.1 M). The sections were washed 1 X 10 minutes Tris-HCI, 1 X 
10 minutes tap water, and were mounted on slides using gelatin-chrom-alum. 
Sections were then dried through ascending alcohols, cleared with xylene and 
coverslipped . 
Control sections receiving no primary antibody and no secondary antibody 
were included to ensure that there are no non-specific interactions of DAB with 
the tissue. A secondary antibody and tertiary only control ensured that there 
was no non-specific binding of the secondary that could be mistaken for 
primary antibody binding, and indicated whether or not tissue blocking was 
sufficient (blocking must be sufficient to block non-specific binding but low 
enough to permit the binding of the primary antibody). It was also discovered 
through a number of experiments that the immunohistochemistry worked much 
better on free floating sections vs. those mounted on poly-L-lysine coated 
slides. The reason for this is unknown, but might have been due to a reduced 
opportunity for primary antibody penetrance on mounted sections. 
2.9.3 Quantitation 
The number of FosB1 delta FosB-positive neurons in the medial prefrontal 
cortex (400 X 600 pm, mPFC), dorsolateral striatum (DLStr), mediolateral 
striatum (MLStr), and nucleus accumbens (NuAcc) was quantified by image 
analysis using Northern Eclipse software (Empix Imaging, Inc.). Areas 
counted were chosen as defined by Robertson et al. (1994). Total area 
counted for the mPFC and NuAcc was 400 X 600 pm2, while total area for both 
striatal regions was 800 X 1200 pm2. Two measurements on each section 
and its replicate were performed. In order to confirm that staining was nuclear, 
several sections were checked to ensure that the staining being counted 
disappeared in and out of focus through the tissue. 
2.10 Statistical analysis 
All results were analyzed by one or two way analysis of variance performed 
using the CLR ANOVA program (Clearlake Research. Houston, TX, U.S.A.). 
In the presence of significant F values, individual comparisons between means 
were made using Newman-Keuls test. 
3. RESULTS 
3.1 The effects of neuroleptic administration on c-fos and monoamine 
synthetic enzymes (TH and AADC) mRNA in PC12 cell culture 
3.1 . I  The effects of remoxipride, risperidone, ritanserin, haloperidol and 
clozapine on TH and AADC mRNA after 0.5, 1, 2, 6, 12, 24, and 48 hours in 
culture, as determined by northern blot analysis in PC1 2 cells 
Initial experiments examined the effects of remoxipride, risperidone, and 
ritanserin administration to PC12 cells at 1, 6, and 24 hours at concentrations 
of 0.1. 1.0, and 10.0 (2.0 for ritanserin) pM on TH and AADC mRNA. No 
statistical differences were found, so further studies were performed using a 
wider range of doses and time points. Doses ranged from 0.01 to 250 pM and 
time points ranged from 0.5 to 48 hours. Since haloperidol and clozapine are 
considered clinically to be prototypical 'typical" and "atypical" neuroleptics 
respectively, they were included in subsequent studies as a comparison to the 
three other neuroleptics and were examined at a greater number of time 
points*. The following neuroleptics were used at the following doses: 
Remoxipride: 0.01, 0.1, 1.0, 10.0, 100.0 pM 
Risperidone: 0.01, 0.1, 1.0, 10.0, 100.0 pM 
Ritanserin: 0.01, 0.1, 1.0, 2.0, 10.0 pM 
Haloperidol: 0.01, 0.1, 1.0, 10.0, 100.0 pM 
Clozapine: 0.25, 2.5, 25.0, 250.0 pM 
-------------------------------------------------------------------------------------------------------- 
'Note: Olanzapine was only used in later PC12 studies involving SOD and p75 mRNA. 
Data for these experiments are seen in figures 3.1 to 3.1 0. All doses and 
time points presented in these figures represent an n of 3 or greater. 
3.1.2 The effects of remoxipride, ritanserin and clozapine on TH and 
AADC mRNA at 1, 6, and 24 hours 
Figures 3.1 to 3.6 illustrate that incubation of PC12 cell cultures with 
neither remoxipride, ritanserin, nor clozapine had any statistically significant 
effect on AADC and TH mRNA. Incubation of PC1 2 cells with 0.1, 1 -0, or 10.0 
UM of remoxipride for 1, 6 and 24 hours produced no effects of dose [F(3,24) = 
1.17, p = 0.341 or time [F(2,24) = 0.1 1, p = 0.0981 nor were there any 
interactions of dose and time (F(6.24) = 0.51, p = 0.791 on AADC mRNA, as 
disclosed by a two way ANOVA (Figure 3.1). Figure 3.2 demonstrates that 
there were no effects of remoxipride on TH mRNA at these doses [F(3,24) = 
1 .16, p = 0.351 and time points [F(2.24) = 0.1 1, p = 0.901, nor were there any 
interactions of time and dose tF(6.24) = 0.66, p = 0.681 as revealed by a two 
way ANOVA. 
Likewise, incubation of PC1 2 cells with 0.1, 1 .O, and 2.0 VM of ritanserin 
produced no effect of dose [F(3,24) = 1.27, p = 0.311 or time [F(2,24) = 0.05, p 
= 0.961 on AADC mRNA nor was there any interaction of dose and time 
[F(6,24) = 0.26, p = 0.951 on AADC mRNA, as disclosed by a two way ANOVA 
(Figure 3.3). Figure 3.4 demonstrates that there were no effects of ritanserin 
on TH mRNA at these doses (F(3,24) = 0.50, p = 0.681 and time points [F(2,24) 
= 0.20, p = 0.83],], nor were there any interactions of time and dose [F(6,24) = 
0.28, p = 0.941, as revealed by a two way ANOVA. 
Although an initial trend was observed for clozapine to upregulate AADC 
and especially TH mRNA at 1 hour, none of these results were statistically 
significant (see Figures 3.5 and 3.6). lncubation of PC12 cells with 2.5 or 
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Figure 3.1. The effects of remoxipride on AADC mRNA in PC12 cells as 
determined by northern blot analysis. PC12 cells were treated with 0.1, 1 .O, 
or 10.0 VM remoxipride and harvested at each time point (n=3). Results are 
expressed as percent control k S.E.M. 
0 Control 00.1 pM 
Figure 3.2. The effects of remoxipride on TH mRNA in PC12 cells as 
determined by northern blot analysis. PC1 2 cells were treated with 0.1, 1 .O, 
or 10.0 y M  rernoxipride and harvested at each time point (n=3). Results are 
expressed as percent control f S.E.M. 
0 Control 00.1 pM H1.0 pM 2 . 0  pM 
Figure 3.3. The effects of ritanserin on AADC mRNA in PC12 cells as 
determined by northern blot analysis. PC1 2 cells were treated with 0.1, 1 .O, 
or 2.0 pM ritanserin and harvested at each time point (n=3). Results are 
expressed as percent control f S.E.M. 
Control 00.1 pM 
Figure 3.4. The effects of ritanserin on TH mRNA in PC12 cells as 
determined by northern blot analysis. PC1 2 cells were treated with 0.1, 1.0. 
or 2.0 VM ritanserin and harvested at each time point (n=3). Results are 
expressed as percent control 2 S.E.M. 
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Figure 3.5. The effects of clozapine on AADC mRNA in PC12 cells as 
determined by northern blot analysis. PC1 2 cells were treated with 2.5 or 
25.0 pM clozapine and harvested at each time point (n=3). Results are 
expressed as percent control k S.E.M. 
0 Control 
Figure 3.6. The effects of clozapine on TH mRNA in PC12 cells as 
determined by northern blot analysis. PC12 cells were treated with 2.5 or 
25.0 VM clozapine and harvested at each time point (n=3). Results are 
expressed as percent control k S.E.M. 
25.0 pM clozapine produced no effect of dose [F(2,18) = 0.27, p = 0.771 or time 
[F(2,18) = 1 -60, p = 0.231. nor was there an interaction of dose and time 
[F(4,18) = 0.42, p = 0.791 on AADC mRNA, as disclosed by a two way ANOVA 
(Figure 3.5). Figure 3.6 demonstrates that there were no effects of clozapine 
on TH at these doses [F(2,18) = 0.1 9, p = 0.831 and time points [F(2.18) = 
2.81, p = 0.091, nor were there any interactions of time and dose mRNA 
[F(4,18) = 0.71, p = 0.591, as revealed by a two way ANOVA. 
To ensure that an effect of clozapine on AADC and TH mRNA did not occur 
between 1 and 12 hours, a subsequent experiment was performed which 
included a 2 hour time point. One and two way ANOVAs in subsequent 
experiments demonstrated that AADC and TH mRNA levels returned to control 
levels by 2 hours (data not shown). 
3.1.3 The effects of risperidone on AADC and TH mRNA at 1, 6, 
and 24 hours 
Figures 3.7 and 3.8 illustrate that incubation of PC12 cell cultures for 1 
hour with risperidone significantly upregulates AADC and TH mRNA, but that 
this effect is attenuated by 6 and 24 hours respectively. Although incubation of 
PC1 2 cells with 0.1, 1 .O, or 10.0 pM risperidone produced no effect of dose 
[F(3,24) = 2.42, p = 0.09) on AADC mRNA, there was an effect of time [F(2,24) 
= 7.31, p = 0.0031, as disclosed by a two way ANOVA (Figure 3.7), whereby 10 
pM risperidone upregulated AADC mRNA at one hour to 135% of control 
values (post hoc by Newman Keuls, ~ ~ 0 . 0 5 ) .  There were no interactions of 
dose and time [F(6,24) = 1.02, p = 0.441 as revealed by the two way ANOVA. 
Figure 3.8 demonstrates that incubation of PC12 cell cultures with 1 or 10 
pM risperidone produced significant increases in the levels of TH mRNA that 
were observed at 1 hour. Although incubation of PC12 cells with 0.1, 1.0, or 
10.0 pM risperidone produced no effect of time [F(2,24) = 2.99, p = 0.071 on 
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Figure 3.7. The effects of risperidone on AADC mRNA in PC12 cells as 
determined by northern blot analysis. PC12 cells were treated with 0.1. 1.0, 
or 10.0 VM risperidone and harvested at each time point (n=3). Results are 
expressed as percent control S.E.M. 
significantly different from controls, pc0.05. 
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Figure 3.8. The effects of risperidone on TH mRNA in PC12 cells as 
determined by northern blot analysis. PC1 2 cells were treated with 0.1, f .O, 
or 10.0 pM risperidone and harvested at each time point (n=3). Results are 
expressed as percent control f S.E.M. 
significantly different from controls, pc0.05. 
TH mRNA, there was an effect of dose [F(3,24) = 5.33. p = 0.0061 on TH 
mRNA as disclosed by a two way ANOVA (Figure 3.8). whereby 1.0 and 10.0 
pM risperidone significantly upregulated TH mRNA at one hour to 124% and 
141 % respectively of control values (post hoc by Newman Keuls, pe0.05). No 
interaction of dose and time [F(6,24) = 1 -96, p = 0.1 11 was observed. 
3.1.4 The effects of haloperidol on AADC and TH mRNA at 1, 2, 12, and 
24 hours in PC1 2 cells 
Figures 3.9 and 3.10 demonstrated that while incubation of PC1 2 cell 
cultures with 1.0 or 10 pM of haloperidol produced no significant increases in 
AADC mRNA, significant increases in the levels of TH mRNA were observed at 
2 and 12 hours of incubation. Figure 3.9 shows that incubation of PC1 2 cells 
with 1.0 or 10.0 p M  haloperidol produced no effect of dose [F(2,24) = 0.22, p = 
0.801 or time [F(3,24) = 1.41, p = 0.271 on AADC mRNA, nor was there an 
interaction of dose and time [F(6,24) = 0.63, p = 0.701, as disclosed by a two 
way ANOVA. Although statistically nonsignificant, the apparent increase in 
AADC mRNA at 2 hours seems to be followed by a compensatory decrease at 
12 hours (Figure 3.9). 
Incubation of PC1 2 cell cultures with 1 or 10 pM of haloperidol produced 
significant increases in the levels of TH mRNA that were observed at 2 and 12 
hour time points (Figure 3.10). A two way ANOVA disclosed an effect of dose 
[F(2,24) = 6.51, p = 0.006. an effect of time [F(3,24) = 12.14, p = 0.00006], and 
an interaction of dose and time [F(6,24) = 3.04, p c 0.031, whereby 1.0 and 
10.0 pM risperidone upregulated TH mRNA at 2 hours to 134% and 132% 
respectively of controls, and at 12 hours to 21 1 % and 222% respectively of 
control values (post hoc by Newman Keuls, p~0.05). Levels of TH mRNA 
returned to control levels by 24 hours. 
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Figure 3.9. The effects of haloperidol on AADC mRNA in PC12 cells as 
determined by northern blot analysis. PC12 cells were treated with 1.0 or 
10.0 p M  haloperidol and harvested at each time point (n=3). Results are 
expressed as percent control k S.E.M. 
0 Control 
Figure 3.10. The effects of haloperidol on TH mRNA in PC12 cells as 
determined by northern blot analysis. PC1 2 cells were treated with 1.0 or 
10.0 VM haloperidol and harvested at each time point (n=3). Results are 
expressed as percent control i S.E.M. 
significantly different from controls, p4.05. 
Since these results did not support the hypothesis that the neuroleptics used 
in the present study would regulate AADC mRNA, no further studies of the 
effects of these neuroleptics on TH and AADC mRNA were performed in PC12 
cells or in animal studies. 
3.1 .5 The effects of remoxipride, risperidone, ritanserin, haloperidol and 
clozapine on c-fos mRNA at 0.5, 1 .O, and 2.0 hours as determined by northern 
blot analysis in PC1 2 cells 
Figure 3.1 1 shows representative autoradiographs of the effects of the five 
neuroleptics on AADC. TH, and c-fos mRNA. Although a clear trend was 
observed for a high dose of haloperidol (100 pM) to upregulate c-fos (and TH) 
mRNA but not AADC mRNA, no effects of the other neuroleptics on c-fos 
mRNA were observed. Interestingly, any trends of neuroleptic -induced 
increases in c-fos mRNA appeared to be paralleled by changes in TH but not 
AADC mRNA. Due to the low expression of c-fos, these data were not 
statistically analyzed. 
3.2 The effects of neuroleptic administration on c-fos mRNA and 
delta FosB 
The effects of acute, chronic, and chronic/challenge neuroleptic 
administration on c-fos mRNA were examined in vivo with the previously 
mentioned neuroleptics at various doses in the striatum, hippocampus, nucleus 
accumbens, and frontal cortex by northern blot, film, and emulsion analysis, as 
described below. In summary, strong Dp receptor blocking neuroleptics. 
including haloperidol and risperidone, upregulated striatal c-fos mRNA, while 
the other neuroleptics tested did not. Risperidone, clozapine, and haloperidol 
appeared to increase c-fos mRNA in the nucleus accumbens, while none of the 
neuroleptics tested changed c-fos mRNA in the frontal cortex or hippocampus. 
TH mRNA 
AADC mRNA 
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Figure 3.1 1. Representative autoradiographs of the effects haloperidol on 
TH, AADC, and c-fos mRNA in PC12 cells. Only TH mRNA continues to be 
upregulated at 12 hours. 
3.2.1 Northern blot analysis of the effects of acute moderate and high 
dose neuroleptic administration on c-fos mRNA 
The effects of the acute. single dose administration of some 
neuroleptics on the expression of c-fos mRNA were examined in the rat 
striatum, hippocampus, nucleus accumbens and frontal cortex by northern blot 
analysis. The rats were sacrificed 45 minutes following the i.p. administration 
of remoxipride (3 mglkg), risperidone (3 mg/kg), ritanserin (3 mglkg), 
haloperidol (3 mg/kg), clozapine (30 mg/kg) or an equal volume of vehicle. 
Haloperidol produced a significant increase in the striatal expression of c-fos 
mRNA that was 200% of the values of the vehicle control group, as disclosed 
by one way ANOVA [F ( W 2 )  = 7.97, p < 0.00162] (Fig. 3.12). but no changes 
were observed after administration of any of the other drugs. Risperidone did 
show a strong tendency to upregulate striatal c-fos mRNA, but statistical 
significance was not reached on the post-hoc Newman Keuls test. 
The neuroleptics produced no changes in c-fos mRNA in the 
hippocampus, as disclosed by one way ANOVA [F (5.12) = 2.34. p c 0.1061. 
Although risperidone and haloperidol seemed to upregulate hippocampal c-fos 
mRNA (see Figure 3.12). statistical significance was not reached due to high 
variation. For the nucleus accumbens, samples from three animals (n=l) was 
pooled in order to have enough sample with which to run a northern blot - thus 
classical statistics could not be run on this sample. These values were used 
as positive controls to compare the present data to that found in the literature, 
which states that both haloperidol and clozapine upregulate c-fos rnRNA in the 
nucleus accumbens. All five neuroleptics tested increased c-fos mRNA in the 
nucleus accumbens over controls, with the largest increases being for 
haloperidol (240% of control levels), clozapine (204% of control levels), and 
risperidone (1 35% of control levels). 
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Figure 3.12. The effects of acute high dose neuroleptic administration on 
c-fos mRNA in rat striatum, nucleus accumbens, and hippocampus by 
northern blot analysis. Northern blot data for c-fos mRNA. Animals were 
sacrificed 45 minutes after i.p. injections (acute, high dose condition). Doses 
were 3 mg/kg for all drugs except clozapine (30 mg/kg). For striatum and 
hippocampus, n=3. Results are expressed as percent control f S.E.M. 
significantly different from controls, pc0.05. 
+ Statistical significance not reached due to high variation. 
++ For the nucleus accumbens, n=l,  pooled from three animals in order to 
have enough sample with which to run a northern blot - thus classical statistics 
could not be run on this sample. Values were used as positive controls to 
compare other data to the literature. 
In a repeat study, Figure 3.1 3 shows the differential effects of striatal and 
hippocampal c-fos mRNA by risperidone, haloperidol. and clozapine. A one 
way ANOVA and subsequent post-hoc analysis by Newman Keuls revealed 
that both haloperidol (p<0.0001) and risperidone (pc0.05) significantly 
upregulated striatal c-fos mRNA to 519% and 292% of the control values, 
respectively [F(3,8) =20.67, p= 0.0004J. In addition, the upregulation by 
haloperidol of c-fos mRNA was significantly greater than that by risperidone 
(p<0.01). Clozapine did not significantly upregulate striatal c-fos mRNA. No 
significant effects of any of the neuroleptics tested were seen on hippocampal 
c-fos mRNA [F(3,8) =0.43, p=0.74]. These results were similar to those 
illustrated in Figure 3.12. 
Figure 3.14 shows the differential effects of the acute administration of a 
moderate dose of risperidone (1 mglkg), haloperidol (I mglkg), and clozapine 
(15 mglkg) on striatal and frontal cortex c-fos mRNA. A one way ANOVA and 
post-hoc Newman Keuls tests revealed that both haloperidol (p<0.0001) and 
risperidone ( ~ ~ 0 . 0 5 )  significantly upregulated striatal c-fos mRNA to 486% and 
292% of the control values respectively [F(3,8) =20.67, p= 0.00041 while 
clozapine was without effects on these parameters. Statistical significance is 
observed for risperidone due to reduced variability. No significant effects of 
any of the neuroleptics on c-fos mRNA were seen the frontal cortex [F(3,lZ) 
=0.18. p= 0.911. 
Figure 3.1 5 contains pictures of the autoradiographs for the data in 
Figure 3.14 and shows the increased intensity of c-fos but not cyclophilin 
mRNA by haloperidol and risperidone in the striatum but not the frontal cortex 
The intensity of striatal c-fos mRNA is unchanged for clozapine, and none of 
the neuroleptics tested upregulated cyclophilin mRNA in either brain region. C- 
fos data was normalized to cyclophilin mRNA on each nitrocellulose membrane 
(i.e., c-fos and cyclophilin mRNA are measured from the same membrane to 
ensure that RNA was loaded equally for each of the twelve lanes). 
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Figure 3.13 The effects of high dose neuroleptics on c-fos mRNA in rat 
striaturn and hippocampus (repeat study) as determined by northern blot 
analysis. Animals (n=3) were sacrificed 45 minutes after i.p. injections (acute, 
high dose condition). Doses were 3 mgkg for all drugs except clozapine (30 
mglkg). Results are expressed as percent control f S.E.M. 
* significantly different from controls, p<0.001. 
+ haloperidol significantly different from risperidone, pc0.05. 
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Figure 3.14 The effects of acute moderate dose neuroleptics on c-fos 
mRNA in the striatum and frontal cortex as determined by northern blot 
analysis. Animals (n=4) were sacrificed 45 minutes after i-p. injections. 
Doses were 1 mglkg for all drugs except clozapine ( I 5  mglkg). Results are 
expressed as percent control k S.E.M. 
* significantly different from controls, pc0.05. 
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Figure 3.15. Autoradiographs of c-fos mRNA in striatum and frontal 
cortex by northern blot analysis. Animals received acute injections of either 
vehicle (C), 1 rng/kg risperidone (R), 1 mg/kg haloperidol (H), or 15 mglkg 
clozapine (C) and were sacrificed 45 minutes following the injection. C-fos 
mRNA is upregulated by haloperidol and risperidone but not clozapine, and the 
effect is specific to the striatum (not seen in frontal cortex). 
3.2.2 Dose response study to determine the effects of acute neuroleptic 
administration on hippocampal c-fos mRNA 
Figure 3.1 6 shows the results of a dose-response study for the effects 
of neuroleptics on hippocampal c-fos mRNA. This dose-response study was 
performed to determine if trends observed in the hippocampus in initial studies 
could be clarified (see figure 3.12). Animals (n=3) received i.p. injections of 
risperidone (0.5, 1.0, and 1.5 mglkg), haloperidol (0.5, 1 .O, and 1.5 mgkg), or 
clozapine (10, 20, and 30 mglkg) and were sacrificed 45 minutes after i.p. 
injections. No significant differences were disclosed by one way ANOVA for 
any of the drugs tested [risperidone, F(3,8) =0.22, p=0.88; haloperidol. F(3,8) 
=0.21, p=0.89; clozapine. F(3.8) =0.59, p=0.64]. 
A high dose of clozapine (30 mglkg) significantly downregulated 
hippocampal cyclophilin mRNA in comparison to controls and the other two 
doses (p=0.05, see figure 3.1 7), the statistical significance of which even held 
in a one way ANOVA including data for haloperidol and risperidone [F(11,36) 
=2.26; p<0.002; post-hoc by Newman Keuls) to 51 % of control values. This 
trend was also observed in PC1 2 cells treated with high dose clozapine (250 
pM). Individually, neither haloperidol [F(3,8) =0.48, p=0.70] nor risperidone 
[F(3,8) =0.22, p=0.70] significantly altered hippocampal cyclophilin mRNA. 
This effect is not seen in the striatum or cortex (data not shown). High doses 
of clozapine also tended to downregulate cyclophilin mRNA in PC1 2 cells, 
further suggesting the robustness of this finding. 
3.2.3 The effects of acute neuroleptic administration on striatal c-fos 
mRNA as determined by in situ hybridization 
In initial acute experiments, three animals per group received a single i-p. 
injection of either vehicle (0.8% glacial acetic acid in 5% glucose), remoxipride 
(3 mglkg), risperidone (3 mgtkg), ritanserin (2 rnglkg), haloperidol (3 mglkg) or 
Risperidone Haloperidol Clozapine 
0 Control Low Dose I3 Medium I High 
Figure 3.16 Dose-response study for the effects of neuroleptics on c-fos 
mRNA in the hippocampus as determined by northern blot analysis. 
Animals (n=3) were sacrificed 45 minutes after I.P. injections Doses were 1.5, 
1 .O, and 0.5 mglkg for risperidone and haloperidol. Doses were 10, 20, and 30 
mg/kg for clozapine. Results are expressed as percent control k S.E.M. 
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Figure 3.17 High dose clozapine (30 mglkg) significantly downregulates 
hippocampal cyclophilin mRNA as determined by northern blot analysis. 
Animals (n=3) were sacrificed 45 minutes after I.P. injections. Doses were 1.5, 
1 .O, and 0.5 mglkg for risperidone and haloperidol. Doses were 10, 20, and 30 
mglkg for clozapine. Results are expressed aspercent control f S.E.M. 
* significantly different from controls; ~~0.05. 
clozapine (30 mglkg), and were sacrificed 45 minutes after the injection. 
Lower doses were used in subsequent experiments. In these experiments, 
animals received a single i.p. injection of either vehicle (0.8% glacial acetic 
acid in 5% glucose), risperidone (1 mglkg), haloperidol (1 mglkg) or clozapine 
(20 mglkg) and were sacrificed at either 30 or 45 minutes after the injection. 
The autoradiographs shown in Figure 3.18a illustrate an in situ hybridization 
time course study done to determine the time where maximal c-fos stimulation 
would occur in the striatum upon the administration of acute haloperidol. 
Although many investigators doing similar studies used a 45 minute time point 
to examine haloperidol- induced c-fos mRNA in the striatum, future studies 
required that we determined the time point for the strongest induction of c-fos. 
The results in Figure 3.1 8a demonstrate that while c-fos mRNA expression by 
haloperidol is strong at both 30 and 45 minutes, the strongest response was 
observed at 30 minutes. In a separate study (n=3), this was confirmed for both 
haloperidol and risperidone (data not shown). None of the other neuroleptics 
tested showed an induction of c-fos mRNA in the striatum (data not shown). 
The absence of an induction of c-fos was confirmed by the inclusion of positive 
controls in the in situ hybridization (animals receiving a single i.p. injection of 1 
mg/kg haloperidol and sacrificed 30 minutes later; and rats that have kainic 
acid-induced seizures, see section 2.6.7.2 for details). 
Although some initial in situ hybridization studies had suggested that all the 
neuroleptic treatments induced c-fos mRNA in various thalamic nuclei, it was 
later determined that the effect could not be separated out from the large 
induction of c-fos mRNA that was demonstrated by the controls (this problem 
has been observed by other investigators as was confirmed by a personal 
discussion with an associate of Dr. A.Y. Deutch, Yale School of Medicine). 
Thus, these data were not statistically analyzed. The in situ hybridization 
studies also demonstrated that acute neuroleptic administration does not 
induce c-fos mRNA in the hippocampus or prefrontal cortex, and these data 
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Figure 3.1&.ln situ hybridization autoradiographs of c-fos mRNA: 
Time course for haloperidol. 
were not statistically analyzed due to the low levels of c-fos mRNA expression 
in these areas. The absence of response was confirmed by including positive 
controls (sections from animals that had seizures) that showed strong c-fos 
induction in both the hippocampus and prefrontal cortex. 
3.2.4 The effects of chronic and chronic/challenge neuroleptic administration 
on striatal c-fos mRNA by in situ hybridization analysis 
For chronic experiments, three animals per group received daily i.p. 
injections for 19 days of either vehicle (0.8% glacial acetic acid in 5% glucose), 
remoxipride (3 mg/kg), risperidone (I mglkg), ritanserin (2 mgfkg), haloperidol 
(1 mglkg) or clozapine (20 mgfkg), and were sacrificed the next day. For 
chronic/challenge experiments, animals received the same doses and 
injections for 19 days, plus they also received an injection on the next day 30 
minutes before being sacrificed. The chronic/challenge group was included in 
the study to determine if the acute administration of neuroleptics such as 
haloperidol would still induce striatal c-fos mRNA after being chronically 
injected for 19 days. 
The autoradiographs in Figure 3.1 8b illustrate that there was absolutely no 
induction of striatal c-fos mRNA by either injection paradigm. The absence of 
an induction of c-fos was confirmed by the inclusion of the haloperidol and 
kainic acid positive controls in the procedure, and the in situ hybridizations 
were repeated several times. In addition, no induction of hippocampal or 
fronto-cortical c-fos mRNA was observed in either injection paradigms 
(hippocampal data not shown). To further confirm that there was no induction 
of c-fos mRNA, c-fos labeled sections were dipped in photographic emulsion 
and allowed to develop for 6 months. No radioactivity above background was 
detected in any of the aforementioned areas except in the control sections 
(see Figure 3.19). 
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Figure 3.181,. In situ hybridization autoradiographs of c-fos mRNA: 
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Figure 3.19. In situ hybridization emulsion analysis of c-fos mRNA in 
seized rats: No effects of chronic or chronic challenge neuroleptic 
administration. In control section (top photo), the background is blocked out in 
black in order to highlight where c-fos mRNA would be seen in the dentate 
gyrus if there was induction of its mRNA. The second photo shows induction of 
BDNF mRNA in the dentate gyrus of an animal that has experienced a stage 5 
seizure. 
3.2.5 Dose response studies of neuroleptic-induced delta FosB 
immunoreactivity (IR) in the striaturn, nucleus accumbens, and medial 
prefrontal cortex 
Figure 3.20 depicts the areas analyzed for delta FosB irnmunoreactivity 
(see methods for further details). Measurements of delta FosB 
immunoreactivity (IR) as opposed to delta FosB mRNA were taken in 
chronically treated rats on the advice of Dr. Eric Nestler, (Yale University. 
Dept. of Psychiatry) that the mRNA of this gene was not upregulated by 
neuroleptics. In addition, the RNA probes were too small to use in our in situ 
hybridization procedure. 
In general, haloperidol and risperidone increased the number of delta 
FosB positive neurons in striatal regions. while clozapine did not. 
Risperidone, but not clozapine or haloperidol increased delta FosB IR in the 
medial prefrontal cortex, and although there was a trend for all of the 
neuroleptics tested to increase delta FosB IR in the nucleus accumbens, only 
the increases induced by risperidone were statistically significant. 
Since the commercially available delta FosB antibody used in the present 
study recognizes both FosB and delta FosB, a control study was performed to 
determine that the changes detected by the delta FosB antibody were due to 
changes in delta FosB only. Antibodies to FosB and FosB/ delta FosB were 
obtained from Dr. Y. Nakabeppu (Medical Institute of Bioregulation, Kyushu 
University, Fukuoka. Japan) and immunoreactivity detected in samples known 
to be positive for the Santa Cruz antibody were tested with both these 
antibodies. Induction of immunoreactivity was observed with the FosB/ delta 
FosB but not FosB only antibody, demonstrating that the immunoreactivity 
seen with the Santa Cruz delta FosB antibody was due to induction of delta 
FosB alone. This is not surprising. since FosB immunoreactivity does not 
appear to be subject to induction (Robertson et al., 1994). 
Figure 3.20. Regions analyzed for delta FosB immunohistochemistry. 
Modified from camera lucida drawings of respesentative sections form 
Roberston et al. (1994) used to count delta Fos immunoreactivity. A= medial 
prefrontal cortex. B= nucleus accumbus (measured slightly more posteriorly 
than the prefrontal cortex, as indicted by broken lines). C= mediolateral 
striatum, D= dorsolateral striatum. 
(Note: Sections are derived from the Paxinos and Watson Rat Brain Atlas (Znd 
edition. 1986. The first diagram is a representation of a coronal section from 
plate 9, the second diagram being derived from plate 22 as defined in the atlas). 
Table 3.1 reports the effects of chronic neuroleptic administration on delta 
FosB immunoreactivity in the DLStr, MLStr, mPFC and the NuAcc. The data 
were analyzed in two separate groups, each with their own control (which is 
why there are two different values for the control condition). The data in Table 
3.1 show that delta FosB induction in the DLStr is the greatest for haloperidol 
and the high dose of risperidone, as disclosed by ANOVA [F(4,10) =8.803, 
p=0.0029] and a subsequent post-hoc analysis by Newman Keuls (p<0.05). In 
the MLStr, however, the highest dose of risperidone produced the greatest 
increase in delta FosB IR [F(4,lO) =4.848, p=0.0218; p<0.01), followed by 
haloperidol and a moderate dose of risperidone to a lesser extent (p<0.05), as 
revealed by ANOVA and a subsequent test by Newman Keuls. Only the high 
and medium doses of risperidone significantly increased the number of delta 
FosB positive neurons in the mPFC [F(4,10) =3.78, p=0.046; p<0.05), and 
nucleus accumbens [F(4,10) =22.2, p=0.0001; pc0.01 for high dose, pe0.05 
for medium dose risperidone], although haloperidol also tended to increase 
delta FosB immunoreactivity in these areas somewhat. Clozapine did not 
significantly upregulate delta FosB in any of the areas studied. No effects of 
injection stress on delta FosB were observed in comparison to non-injected 
control animats. 
Figure 3.21 illustrates some of the areas where delta FosB was 
upregulated by chronic haloperidol treatment, including the caudate putamen. 
3.3 The effects of neuroleptics on protective factors 
Nylon membranes prepared for the analysis of the effects of neuroleptic 
treatment on TH, AADC, and c-fos mRNA in PC12 cells were reused to 
examine the effects of neuroleptic treatment on p75 and SOD mRNA. Newer 
cell experiments included olanzapine, and these membranes were also probed 
for p75 and SOD mRNA. These olanzapine membranes were not probed for 
TH, AADC, or c-fos mRNA since it was concluded that any such data would 
not add to the previous results of these experiments. 
Table 3.1. The effects of chronic neuroleptic administration on delta FosB 
immunoreactivity in the dorsolateral striatum (DLStr), mediolateral 
striatum (MLStr), the medial prefrontal cortex (mPFC) and the nucleus 
accumbens (Nuacc). 
Control 1 
Haloperidol 
Risperidone High 
Risperidone Medium 
Risperidone Low 
Control 2 
Clozapine High 
Clozapine Medium 
Clozapine Low 
Non-Injected Control 
DLStr 
15k 17 
137* k 46 
148' * 36 
81' & 8 
1 7 i 4  
73* 13 
112k 50 
85 i 27 
86 * 19 
69 * 14 
MLStr 
1524 
86* k 27 
111** 7 
79' * 7 
14k3  
52+ 12 
78 i 37 
48 i 8 
49k 13 
5Oi  17 
NuAcc 
35 *12 
53 * 9 
144** k 6 
8A* k 15 
2 3 k 6  
67* 16 
84 + 22 
81 k 1 9  
64 i 7 
61 k 7  
mPFC 
25 * 7 
42 k 19 
69* k 16 
66' * 9 
39 * 9 
35k10 
37k15 
41 k 8  
33 2 6  
32 2 4 
All values expressed as the number of imrnunoreactive nuclei + S.E.M. Data 
analyzed by ANOVA, post-hoc by Newman Keuls. 
* significantly different from controls, ~ ~ 0 . 0 5 .  
control halo perldol 
Figure 3.21. Delta FosB immunoreactivity in the striatum (caudate 
putamen, CP) and prefrontal cortex (PFC). Large increases in the number of 
delta FosB positive neurons (small black dots) are seen in the CP of haloperidol 
treated vs. control animals. A slight induction of delta FosB immunoreactivity 
can also be seen in the cortical layers of the PFC in haloperidol treated animals. 
3.3.1 The effects of remoxipride, risperidone, ritanserin, haloperidol, 
clozapine, and olanzapine on p75 at 12,24, and 48 hours as 
determined by northern blot analysis in PC12 cells 
No effects on p75 mRNA were seen for remoxipride or ritanserin (data not 
shown). Comparisons were made between the three other drugs (risperidone, 
haloperidol, clozapine) by ANOVA at each of the time points studied. 
Figure 3.22 demonstrates that albeit not significantly, at 12 hours, 
haloperidol (1.0 IJM and 10.0 vM) upregulated p75 mRNA to 166% and 134% 
of control levels, while clozapine (2.5 and 25.0 qM) downregulated p75 mRNA 
expression 78%, and 71% of control values respectively as disclosed by a one 
way ANOVA [F(8,18) =0.43, p=0.89]. These data may not have reached 
significance since two data points only had an n of two (sample lost during 
tissue processing). Figure 3.23. however, demonstrates that these doses of 
haloperidol (1.0 pM and 10.0 pM) downregulated p75 mRNA at 24 hours to 
63% and 58% of control levels, and similarly downregulated p75 mRNA to 
68% and 56% of control levels at 48 hours as revealed by a one way ANOVA 
[F(8-18) =3.57, p=0.012]. Figure 3.24 demonstrates that clozapine (2.5 and 
25.0 pM) ) downregulated p75 mRNA at 24 hours to 68% and 56% of control 
levels, and similarily downregulated p75 mRNA to 65% and 68% of control 
levels at 48 hours as revealed by a one way ANOVA [F(8,18) =5.42, p=O.OOl]. 
Risperidone did not appear to regulate p75 mRNA (data not shown). 
Figure 3.25 demonstrates that incubation with (at concentrations of 10 or 
100 pM) reduced p75 gene expression as disclosed by two way ANOVA 
(Fp, 12 = 17. I?, p < 0.0003). No effect of time ( F ~ J  2 = 2.56, p 4 0.135) or 
interaction between time and olanzapine treatment (F2,12 = 2.49, p < 0.1 25) 
were observed. One way ANOVA disclosed the effect of the olanzapine 
treatment (F2,6 = 16.84, p c 0.004). Significant reductions in p75 gene 
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Figure 3.22. The effects of risperidone, haloperidol, and clozapine on p75 
mRNA in PC12 cells at 12 hours. PC12 cells were treated with two doses of 
the aforementioned neuroleptics and harvested at 12 hours (n=3). Results are 
expressed as percent control k S.E.M. 
* significantly different from controls; pc0.05. 
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Figure 3.23. The effects of risperidone, haloperidol, and clozapine on p75 
mRNA in PC12 cells at 24 hours. PC12 cells were treated with two doses of 
the aforementioned neuroleptics and hawested at 24 hours (n=3). Results are 
expressed as percent control * S.E.M. 
* significantly different from controls; ~ ~ 0 . 0 5 .  
Risperidone Haloperidol Clozapine 
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Figure 3.24. The effects of risperidone, haloperidol, and clozapine on p75 
mRNA in PC12 cells at 48 hours . PC12 cells were treated with two doses of 
the aforementioned neuroleptics and harvested at 48 hours (n=3). Results are 
expressed as percent control f S.E.M. 
* significantly different from controls; pc0.05. 
Figure 3.25. The effects of olanzapine on p75 mRNA at 24 and 48 hrs in 
PC12 cells. PC12 cells were treated with two doses of olanzapine and 
harvested at each time point, n=2, *p ~0.05 PeO.001. Results expressed as 
% control * S.E.M. 
expression were observed 48 hours after incubation with the 10 or 100 pM 
doses by 28 and 71 % of their respective controls. 
3.3.2 The effects of remoxipride, risperidone, ritanserin, haloperidol, 
clozapine, and olanzapine on SOD mRNA at 12, 24, and 48 hours as 
determined by northern blot analysis in PC12 cells 
Figure 3.26 demonstrates that risperidone (albeit at a high dose of 100 pM) 
upregulates SOD mRNA in PC12 cell cultures. Although incubation of PC12 
cells with 1.0 or 10.0 pM risperidone produced no interaction of dose and time 
[F(6,24) = 0.21, p = 0.781 or an effect of time [F(2,24) = 0.25, p = 0.781 on SOD 
mRNA as disclosed by two way analysis of variance (Figure 3-26). there was 
an effect of dose [F(3.24) = 9.67, p = 0.00021. Incubations of 100 pM 
risperidone increased SOD mRNA levels to 162%. 133%. and 151 % of SOD 
mRNA levels in comparison to controls, 10.0 pM risperidone, and 1.0 pM 
risperidone respectively. The high dose of risperidone (100 pM) upregulated 
SOD mRNA at 12. 24, and 48 to 160%, 174%, and 168% respectively of 
control values. 
Figure 3.27 demonstrates that no effects on SOD mRNA were observed at 
any time point for haloperidol [F(8,27) =0.42, p=0.89] by either a one or two 
way ANOVA. Figure 3.28 demonstrates that 25 pM clozapine increases SOD 
mRNA at 48 hours by a one way ANOVA (pe0.05). Figure 3.29 demonstrates 
that incubation of PC12 cells with 10 or 100 pM of olanzapine for 24 or 48 
hours increased SOD1 gene expression as disclosed by two way ANOVA 
(F2.12 = 13.84. p c 0.0008). No effect of time (F2,1 2 = 1.1 0, p < 0.31 ) or 
interaction between olanzapine treatment and time (F2,12 = 0.29, p c 0.75) 
was observed. One way ANOVA showed significant increases in SOD1 gene 
expression observed at 48 hours after treatment with 10 or 100 pM of 
olanzapine that reached 47 and 72 % above their 
Control H1.0 pM l 1 O . O  pM l l 0 0  VM 
Figure 3.26. The effects of risperidone on SOD mRNA at 12, 24, and 48 
hrs in PC12 cells. PC12 cells were treated with three doses of risperidone and 
harvested at each time point (n=3). Results are expressed as percent control 
k S.E.M. 
* significantly different from controls; pc0.05. 
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Figure 3.27. The effects of haloperidol on SOD mRNA at 12, 24, and 48 
h n  in PC12 cells. PC12 cells were treated with three doses of haloperidol 
and harvested at each time point (n=3). Results are expressed as percent 
control * S.E.M. 
0 Control 
Figure 3.28. The effects of clozapine on SOD mRNA at 12,24, and 48 hrs 
in PC12 cells. PC12 cells were treated with three doses of clozapine and 
harvested at each time point (n=3). Results are expressed as percent control 
* S.E.M. 
* significantly different from controls; p~0.05.  
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Figure 3.29. The effects of olanzapine on SOD mRNA at 24 and 48 hrs in 
PC12 cells. PC12 cells were treated with two doses of olanzapine and 
harvested at each time point, n=2, *p e0.05 "pc0.001. Results expressed as 
O h  control k S.E.M. 
corresponding control levels. Figure 3.30 shows representative 
autoradiographs of the induction of p75 and SOD mRNA for clozapine. 
3.3.3 The effects of chronic and acute neuroleptic treatment on 
hippocampal and fronto-cortical BDNF mRNA 
Figure 3.31 demonstrates that acute (45 minute) administration of 
risperidone, haloperidol, or clozapine did not alter either hippocampal or 
fronto-cortical BDNF mRNA [F(5,12)= 0.42, p=0.53], nor were there any trends 
to do so. 
The effects of the chronic administration of remoxipride, risperidone, 
ritanserin, haloperidol, and clozapine on hippocampal and mPFC BDNF mRNA 
are shown in Figure 3.32 and reveal some interesting trends. In hippocampal 
regions, while haloperidol and high doses of atypical neuroleptics 
downregulated BDNF mRNA, the 5-HT2 blocker ritanserin and lower doses of 
atypical neuroleptics upregulated BDNF mRNA. Specifically, for chronic 
injections, in situ hybridization was used to confirm the preliminary results 
achieved by northern blot analysis (it was deemed that the work that went into 
injecting rats for 20 days was better directed to in situ hybridization rather than 
northern blot analysis). 
An ANOVA revealed that although no statistical differences existed 
between the control and drug treatment groups, dentate gyrus BDNF mRNA 
levels were significantly lower in haloperidol vs. risperidone treated rats 
(Newrnan Keuls). Haloperidol significantly downregulates, while ritanserin 
upregulates hippocampal BDNF mRNA (p < 0.05). Haloperidol reduced BDNF 
mRNA to 67% and 76% of control levels in the dentate and CAI region 
respectively, while ritanserin increased CAI BDNF mRNA to 124% of control 
levels. Risperidone and clozapine either did not significantly alter hippocampal 
BDNF mRNA, or slightly upregulated it. Clozapine significantly upregulated 
BNDF mRNA in the mPFC (p c 0.01). F Values: Dentate, F(5.12) = 3.299, 
1 hour 2 hours 12 hours 
Figure 3.30. Represenative northern blot autoradiographs for the effects 
of clozapine on p75 mRNA. Clozapine downregulates p75 mRNA at not one 
or two hours of incubation, but after 12 hours of incubation at all three doses 
used. 
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Figure 3.31. The effects of acute neuroleptics administration on 
hippocampal and prefrontal cortical BDNF mRNA by northern blot 
analysis. Animals were sacrificed 45 minutes after i.p. injections. Doses were 
1 mglkg for all drugs except clozapine (1 5 mglkg). Results are expressed as 
percent control * S.E.M. 
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Fig lure 3.32. The effects of chronic neuroleptic administration on 
hippocampal and mPFC BDNF mRNA as determined by northern blot 
analysis. Animals received i.p. injections for 19 days and were sacrificed 18 
hours after the last injection. Results are expressed as percent control f 
S.E.M. 
significantly different from controls; pc0.05 
+ haloperidol significantly different from risperidone, pe0.05. 
p c. 0.042; CAl , F(5,12) = 6.969, p < 0.0029; CA3, F(5.12) = 2.240, p c 
0.1172); mPFC, F(5.15) = 8.76, p < 0.001). 
3.3.4 Dose response studies of the effects of neuroleptics on hippocampal 
BDNF mRNA 
Figures 3.33 and 3.34 show the results of a dose response study with 
neuroleptics. Rats were treated with either vehicle, haloperidol (1 mgikg i.p.), 
risperidone (0.066, 0.67, 4.1 1 mglkg i.p.), or clozapine (1 -3 mglkg, 9.0 mgikg, 
30.0 mglkg i.p.) daily for 20 days (n=3). These doses were chosen on the 
basis of ex-vivo receptor occupancies in the rat brain (Schotte et al., 1993). 
An additional group of rats receiving no injections were used to control for 
injection stress. Haloperidol significantly decreased hippocampal BDNF 
mRNA (p < 0.05) to 64% and 74 of controls in the dentate and CAI 
respectively. While higher doses of risperidone tended to downregulate BDNF 
mRNA (75% of control levels), lower doses of risperidone and clozapine 
tended to upregulate BDNF mRNA only in the CAI region (dopaminergic 
blockade seems to downregulate, while serotonergic blockade tends to 
upregulate hippocampal BDNF mRNA). Statistical significance for many of 
these findings might be expected to be attained with an increased n. 
Representative autoradiographs are shown in Figures 3.35 and 3.36. 
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Figure 3.33. Dose-response study for the effects of chronic risperidone 
and haloperidol administration on hippocampal BONF mRNA by in situ 
hybridization (note: dose-response is for risperidone only, only one dose of 
haloperidol was used in this experiment). Animals were injected with vehicle, 
haloperidol (1 mglkg i.p.) or risperidone (0.066. 0.67, 4.1 1 mglkg i.p.) daily for 
twenty days. Data analyzed by ANOVA, post-hoc by Newman Keuls (n=3). ). 
Results are expressed as percent control k S.E.M. 
significantly different from controls; pe0.05. 
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Figure 3.34. Dose-response study for the effects of chronic clozapine 
administration and non-injected controls on hippocampal BDNF mRNA by 
in situ hybridization. Animals were injected with vehicle, clozapine ( A  .3. 9.0, or 
30.0 mglkg i.p.) daily for twenty days or received no injection. Data analyzed by 
ANOVA, post-hoc by Newman Keuls (n=3). Results are expressed as percent 
control * S.E.M. 
* significantly different from controls; pc0.05. 
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Figure 3.35. Autoradiographs of hippocampal BDNF mRNA. Preliminary 
study, n=3. Haloperidol significantly downregulated, while ritanserin 
upregulated, hippocampal BDNF mRNA as determined by in situ hydridization 
autoradiography. 
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Figure 3.36. Autoradiographs of hippocampal BDNF mRNA in dose- 
response study. No significant differences as determined by in situ 
hybridization film autoradiography are observed between the controls and the 
non-injected controls. High dose risperidone tends to downregulate 
hippocampal BDNF mRNA, while low dose clozapine may upregulate BDNF 
mRNA in the dentate. 
4. DISCUSSION 
Since both dopamine Dq and serotonin 5-HT2 receptor blockers 
ameliorate symptoms of schizophrenia (Bersani et al., 1986; 1990; Roose et 
al., 1988; Meco et al., 1989; Huttunen, 1995), it was hypothesized in the 
present study that examining the differential effects of D2, 5-HT2, and D2/5- 
HT2 receptor antagonists on various biochemical parameters and brain 
regions would contribute to our understanding of their varied efficacies and 
side effect profiles. It was found that the neuroleptics used in the present 
study did alter the gene expression of various target proteins in vitro and in 
vivo upon acute and chronic administration. In addition, neuroleptics with 
different therapeutic efficacies and side effect profiles activated gene 
expression in different brain regions. 
4.1 Neuroleptics do not upregulate TH, AADC, or c-fos mRNA as 
hypothesized in PC12 cells 
4.1.1 Regulation of TH mRNA in PC1 2 cells 
Since D2 blockers have been shown to upregulate TH mRNA in vivo 
(Cho et al., 1997). it was expected in the present study that haloperidol, 
risperidone, and rernoxipride would also upregulate TH mRNA in PC12 cells. 
It was found that two of the neuroleptics used which could strongly block D2 
receptors did upregulate TH mRNA in vitro; risperidone (Figure 3.7) at one 
hour, and haloperidol (Figure 3.9) at 2 and 12 hours respectively. Since 
ritanserin and clozapine primarily act on serotonergic receptors, it was not 
surprising that these two neuroleptics did not upregulate TH mRNA (Figures 
3.3, 3.5). 
While these findings suggest that D2 blockade could be responsible for the 
upregulation of TH rnRNA, additional results obtained suggest that other 
factors may be involved in this upregulation. Both risperidone and haloperidol 
block a number of neurotransmitter receptors other than D2 receptors (Leysen 
et al., 1992; Huang et al., 1993; Schotte et al., 1993; 1996; Megans et al., 
1994). In addition, remoxipride did not upregulate TH mRNA and was the 
most selective 02 blocker used in the present investigation (Wadworth and 
Heel, 1990). Although risperidone significantly upregulated TH mRNA at two 
doses (10 and 1.0 pM) at one hour (Figure 3.7), the significance of this finding 
is limited due to the short duration (< 6 hours) of the response. Given that 
Buckland et al. (1 992, 1993) did not find that either acute or chronic 
neuroleptic administration altered whole brain TH mRNA, the results in the 
present study may not be all that surprising. 
The finding that neither remoxipride nor ritanserin altered TH mRNA 
suggests that neither D2 or 5-HT2 blockade alone is sufficient to regulate the 
gene expression of this enzyme. Therefore, the upregulation of TH mRNA by 
haloperidol and risperidone is not dependent on either D2 or 5-HT2 blockade 
alone. The finding that clozapine does not regulate TH mRNA suggests that 
the combination of D2 and 5-HT2 blockade is not sufficient to induce TH 
mRNA. Thus, a receptor that is blocked by haloperidol and risperidone, but not 
the other neuroleptics tested might be involved in the induction of TH mRNA. 
An alternative explanation for the effects of these neuroleptics on TH 
mRNA might be regulation of sigma receptors. These receptors are found on a 
number of cells in the CNS, and are found on PC12 cells (Yang et al., 1989; 
Morio et al., 1994). Although their function is poorly understood, sigma 
receptors are regulated by haloperidol and risperidone but not by ritanserin, 
remoxipride, or clozapine (Clissold et al., 1992; Nakata et al., 1999). Since 
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remoxipride is quite specific for Dp receptors, especially in comparison to other 
neuroleptics (Ogren et al., 1983; Wadworth and Heel, 1990). but has little 
effect on sigma receptors in comparison to haloperidol and risperidone 
(Ericson and Ross, 1992; Lang et al., 1994; Okuyama, 1999), it is possible that 
remoxipride's failure to induce TH mRNA is due to its relative lack of sigma 
activity. In support of a role of sigma receptors in the regulation of TH, drugs 
active at sigma receptors have been found to increase rat striatal TH enzyme 
activity (Weiser et al., 1995). 
4.1 -2 Regulation of AADC mRNA in PC1 2 cells 
As both Dg and 5-HT2 receptor blockers ameliorate the symptoms of 
schizophrenia (Bersani et al., 1986, 1990; Roose et al., 1988; Meco et al., 
1989; Huttunen, 1995) and since AADC is required for the synthesis of both 
DA and 5-HT (Lovenberg et al., 1962; Christenson et al., 1972). it was 
hypothesized in the present study that all neuroleptics would regulate AADC 
mRNA in a similar manner. Although the five aforementioned neuroleptics 
were used at a wide range of doses and time points, few changes in AADC 
mRNA levels were observed. Remoxipride, ritanserin, haloperidol and 
clozapine did not significantly regulate AADC mRNA in PC12 cells (Figures 
3.2, 3.4, 3.6, 3.10), and risperidone significantly upregulated AADC mRNA only 
at the one hour time point. Taken with the TH mRNA results of this study, it 
would appear that in PC1 2 cells, neuroleptics have little if any effect on the 
gene expression of either TH or AADC mRNA. 
4.1.3 Regulation of c-fos mRNA in PC1 2 cells 
It was hypothesized that D2 blocking neuroleptics would upregulate c-fos 
mRNA in PC12 cells. The data are difficult to analyze due to the poor quality 
of the autoradiographs, so the results were assessed to identify any obvious 
trends. Interestingly, any trends of neuroleptic-induced increases in c-fos 
mRNA were paralleled by changes in TH but not AADC. It appeared that the 
haloperidol-induced changes in TH mRNA were preceded and paralleled by 
changes in c-fos mRNA at 1, 2, and 12 hours (data not shown; see Figure 3.1 1 
for representative autoradiographs). Esteve et al. (1995) confirmed that 
haloperidol (albeit at high doses of 100 pM) upregulated c-fos mRNA at 0.5, 1, 
and 2 hours in PC12 cells. The present study also demonstrated that 
haloperidol upregulated c-fos mRNA at !OO 1M (data not shown, see 
representative autoradiographs in figure 3.1 1 ), but these results must be 
treated with caution due to the potential toxicity of the high dose of haloperidol 
used (i.e., at this dose, an increased number of the PC12 cells in the well 
plates became detached from the collagen-coated surface, indicating that 
more cells were dying during the experiment at this dose). 
It is not surprising that it was observed in the present investigation that the 
upregulation of c-fos mRNA preceded that of TH mRNA (Ozaki et al., 1998; 
Yukimasa et al., 1999), since the Fos protein is known to upregulate TH 
mRNA (Icard-Liephalns et al., 1992). One investigator found, in a PC1 2 cell 
culture study of the effects of haloperidol administration on c-fos mRNA, that 
the upregulation of c-fos mRNA was accompanied by a Ca2+ dependent 
increase in AP1 binding activities (Esteve et al., 1995), suggesting that the Fos 
protein could be binding to the API site on the TH promoter (Icard-Liepkalns et 
al., 1992). In the case of risperidone, it is quite possible that any c-fos mRNA 
inducing effects caused by its blockade of Dg receptors would rapidly be 
counteracted by its blockade of 5-HT2 receptors, since inhibition of 5-HT2 
receptors induction by 5-HT2 receptor blockers such as ketanserin and 
mesulergine has been shown to block 5-HT2 induction of c-fos (Humblot et al., 
1997). 
Since the AADC promoter was not well characterized at the time of our 
investigations, it was not known whether or not its promoter region contained 
an active AP-1 site. To date, an active AP-1 site has not been identified on the 
AADC promoter (Raynal et al., 1998). Thus, it is not surprising that changes in 
AADC mRNA do not parallel changes in c-fos mRNA. As AADC protein has 
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phosphorylation sites for both protein kinases A and C which are part of the 
signaling pathways for DA and 5-HT respectively (Kemp and Peanon, 1 WO), 
it is possible Dq and 5-HT2 receptor blockade might regulate AADC at the post 
translational and not the transcriptional level, or that AADC transcriptional 
regulation involves other early immediate genes. 
4.1.4 Summary of in vitro results 
In summary, four general conclusions can be made from the investigations 
with the PC12 cell culture: 
a. The neuroleptics examined do not significantly regulate AADC mRNA in 
PC1 2 cells. 
b. Only haloperidol significantly regulated TH rnRNA. 
c. The induction by haloperidol of c-fos mRNA precedes that of TH mRNA. 
d. The Dp vs. 5-HT2 distinction is not meaningful for neuroleptic regulation 
of TH and AADC mRNA in PC12 cells, and such regulation is more likely to 
involve other receptors such as the sigma receptor. 
Since the working hypothesis of the present study (that neuroleptics would 
regulate AADC and TH mRNA in a similar manner) was not supported by the 
experiments, future in vivo studies were limited to examining the effects of 
neuroleptics on AADC mRNA in situ. Preliminary northern blot and in situ 
hybridization experiments demonstrated that although AADC mRNA could be 
detected in the substantia nigra, this mRNA was difficult to detect in the cortex 
or hippocampus due to its relatively low expression levels in the area. As the 
neuroleptic induced increases in AADC mRNA found by Buckland's group 
(1 993) involved studies that were performed with whole brain homogenates, it 
may be that the changes found by this group might occur in the glia that in 
order to be detected require a tissue sample as large as the entire brain. 
4.2 Regulation of c-fos mRNA and delta FosB immunoreactivity in vivo by 
neuroleptics does not follow expected patterns 
4.2.1 Regulation of c-fos mRNA by acute neuroleptic treatment 
As previously discussed, there is little understanding of the molecular 
mechanisms underlying the therapeutic response and side effect profile of 
neuroleptics, and no common mechanisms of action have been identified to 
date. 
Since the Fos protein was known to be induced by a variety of behavioral 
and psychoactive stimuli (Morgan et al., 1987; Brown et al., 1992; Duncan et 
al., 1993), and transcriptionally regulated by a number of genes (Uhl et al., 
1 988; Kislauskis et al., 1 WO), investigators reasoned that perhaps the 
differential clinical effects of neuroleptics could be mapped by examining early 
immediate gene regulation in various brain regions thought to be involved in 
the clinical efficacies and side effect profiles of neuroleptics (Robertson and 
Fibiger, 1992). The knowledge that the upregulation of such a protein (i.e., a 
transcription factor) could alter the expression of other genes made it an 
attractive candidate to not only track the neuronal substrates activated by 
neuroleptics, but to help elucidate the target genes involved in the neuroleptic 
response. 
Earlier animal studies demonstrated that acute haloperidol administration 
significantly upregulated c-fos mRNA in the striatum (Dragunow et al.. 1 990; 
Miller, 1990; Robertson and Fibiger, 1992). The functional validity of these 
findings at the time was significant because it provided one of the first reliable 
markers of neuronal activity which correlated with the effects of haloperidol in 
the striatum and the production of EPS. At the time the present studies were 
initiated, researchers had established that the typical neuroleptic haloperidol 
and the atypical neuroleptic clozapine increased c-fos mRNA andlor the Fos 
protein in differing brain regions (Robertson and Fibiger, 1992). Therefore, the 
hypothesis was made that the differing mechanisms of action of typical vs. 
atypical neuroleptics could be localized to specific brain regions and that drug 
design could use the c-fos response as a marker for therapeutic efficacy and 
side effect profiles (Robertson and Fibiger, 1992; Merchant and Dorsa, 1993). 
No other neuroleptics besides haloperidol and clozapine at that time had been 
examined for their effects on c-fos mRNA, so this was measured in the present 
study for a number of neuroleptics with a wide range of DA to 5-HT blocking 
properties. 
4.2.1.1 Regulation of c-fos mRNA in the striatum 
It was found in the present study that the acute administration (45 minutes) 
of haloperidol and higher doses of risperidone increased c-fos mRNA in the 
striatum, while remoxipride, ritanserin, and clozapine were without effects in 
this brain region (Figures 3.12 to 3.16). This was confirmed in later studies by 
both northern blot and in situ hybridization studies. Studies conducted in other 
laboratories at this time also demonstrated that all typical neuroleptics 
examined with a high propensity to cause EPS (such as haloperidol) increased 
c-fos expression in the dorsal lateral striatum, whereas atypical neuroleptics 
including risperidone, ritanserin and clozapine did not induce any or as great 
an increase in c-fos mRNA in this region (Robertson et al., 1994; Deutch et al-, 
1995; Deutch and Duman, 1996). 
4.2.1 -2 Regulation of c-fos mRNA in the medial prefrontal cortex and 
nucleus accumbens 
Some investigators had suggested that clozapine was not only unique in its 
ability to treat refractory schizophrenia and the negative symptoms of the 
disorder, but that it alone would elevate c-fos mRNA in the medial prefrontal 
cortex (mPFC) (Merchant et al., 1996). Robertson et al., (1994) however, 
found that a number of atypical neuroleptics in addition to clozapine (such as 
remoxipride and Puperapine, but not risperidone) elevated Fos-like 
immunoreactivity in this region. The present experiments showed no induction 
of c-fos mRNA by clozapine, remoxipride, or any of the other neuroleptics 
tested in this brain region (Figures 3.1 8 and 3-19), and other investigators 
(Hiroi and Graybiel, 1996) have failed to replicate these findings of Robertson 
et al. (1994) in the mPFC. 
These investigators also found that both typical and atypical neuroleptics 
increased c-fos mRNA in the nucleus accumbens (NuAcc) (Robertson et al., 
1994). This is in agreement with the results of the present study which found 
that all the neuroleptics tested elevated c-fos mRNA in the NuAcc (see figure 
3.12). The shared therapeutic molecular mechanism of many neuroleptics was 
thus thought perhaps to involve the modulation of neuronal activity in the 
NuAcc, while neuroleptic induced EPS may be related to c-fos stimulation in 
the striatum (Robertson and Fibiger, 1992). 
4.2.2 Regulation of c-fos mRNA by chronic neuroleptic treatment 
As it turned out, the mechanisms underlying the neuroleptic induction of c- 
fos were more complex than it initially appeared. Other studies demonstrated 
that the initial neuroleptic-induced increases in c-fos mRNA were attenuated in 
rats upon chronic neuroleptic administration and it was found that the c-fos 
induction produced by many types of acute stimuli were also attenuated upon 
long term treatment (Merchant and Dorsa, 1993; Merchant and Miller, 1994; 
Merchant, 1994; Merchant et al., 1996). This finding was difficult to explain 
with respect to the early immediate gene hypothesis of neuroleptic treatment, 
since the therapeutic effects of neuroleptics were not observed until two or 
three weeks of continuous administration. One would conceivably want to 
identify an intracellular factor which is altered by neuroleptic treatment at the 
same time course at which therapeutic efficacies and side effects were 
observed in the clinic. 
In order to determine if the neuroleptic-induced induction of striatal c-fos 
mRNA was truly attenuated or was reduced but not absent followinf repeated 
exposure, rats received either chronic neuroleptic injections for 19 days and 
were sacrificed on Day 20 (1 8 hours after the last injection) or received 19 
days of injections, followed by a further injection on day 20 given 30 minutes 
before sacrifice. Time course studies for the effects of acute neuroleptic 
administration on striatal c-fos mRNA were also performed to determine the 
time point at which maximal induction of striatal c-fos mRNA by haloperidol 
was observed. It was hypothesized that long term changes in c-fos mRNA 
might be not be observed in chronic paradigms because maximal induction of 
c-fos mRNA is seen 30 to 45 minutes following an injection, while c-fos mRNA 
was measured in many chronic paradigms at time points much greater than 
this 30 to 45 minute time range. 
The results obtained by in situ hybridization and emulsion autoradiography 
did not support the working hypothesis of the present study. Not only were 
there were no changes in striatal c-fos mRNA with chronic neuroleptic 
treatment, but the haloperidol treatment lost its ability (produced tolerance) to 
upregulate striatal c-fos mRNA when administered 45 minutes before sacrifice 
after it had been injected chronically for 19 days previous to the last injection. 
The validity of these experiments was confirmed by including tissue samples 
from a group of rats treated with haloperidol and another group of rats that had 
been treated with kainic acid (which causes some of the rats to develop 
seizures) which showed intense activation of c-fos expression in the brain. 
Findings of the absence of c-fos induction with chronic haloperidol treatment 
were confirmed in these in situ hybridizations. No other brain regions showed 
c-fos induction in these injection paradigms in our studies. 
Many of the findings of the present study have been confirmed by others in 
the literature (Merchant et al., 1994; Merchant et al., 1996). Specifically, 
Merchant et al. (1994) found that both chronic clozapine and chronic 
haloperidol administration to rats did not alter c-fos mRNA in the dorsolateral 
striaturn, while 28 day saline injections followed by an acute (1 hour before 
sacrifice) injection of haloperidol resulted in an approximately 150% increase in 
c-fos mRNA over 28 day saline-injected controls. While chronic haloperidol 
administration followed by an acute haloperidol injection was also found by 
these investigators to significantly increase c-fos mRNA above control levels, 
the increase was no more than 10% of controls. Thus, while changes in c-fos 
mRNA imrnunoreactivity may identify the neural structures which are activated 
by neuroleptics, it is not likely that the upregulation of c-fos mRNA parallels the 
time frame in which neuroleptics begin to exert their side effects and 
therapeutic efficacies. 
4.2.3 Regulation of delta FosB by neuroleptics 
The gene expression of early immediate gene delta FosB was the next 
target upon which to examine the effects of neuroleptics because unlike c-fos, 
it had been shown to be upregulated upon chronic stimulation in a number of 
experimental paradigms (Jian et al., 1993; Kelz et al., 1999; Nestler et al., 
1999). This "atypical" early immediate gene is not maximally upregulated upon 
acute stimulation, but instead accumulates over time with increasing 
phosphorylation (Chen et al., 1997). Thus, if the c-fos and delta FosB 
responses are related, it is possible that one of the targets of c-fos is the 
upregulation of phosphorylating enzymes such as the protein kinases which 
phosphorylate proteins and contribute to their cellular longevity (Doucet et al., 
1996; Chen et al., 1997; Nestler et al., 1999). 
It was the hypothesis of the present study that chronic neuroleptic 
administration would upregulate delta FosB in the same brain regions where c- 
fos mRNA is elevated by acute neuroleptic treatment. Vahid-Ansari et al. 
(1 996) have demonstrated that chronic haloperidol and clozapine 
administration increases delta FosB in regions similar to those where c-fos 
mRNA upregulation is seen in the acute state. It was found in the present study 
that haloperidol and risperidone did increase the number of delta FosB 
immunoreactive neurons in the striatum (Table 3.1, Figure 3.21). It is 
interesting that whereas haloperidol and only high doses of risperidone 
increased delta FosB IF? in the dorsolateral striatum (DLStr), haloperidol and 
both high and moderate doses of risperidone increased delta FosB 
immunoreactivity in the mediolateral striatum (MLStr). Since moderate doses 
of risperidone clinically alleviate symptoms of schizophrenia but do not 
necessarily cause EPS (Leysen et al.. 1988). these findings support the 
hypothesis that the motor side effects of neuroleptics are caused in the DLStr 
(which receives projections from the substantia nigra, SN), but that the 
amelioration of positive symptoms in part is related to activity of the MLStr 
(which receives projections from the ventral tegmental area, VTA: Grace, 
1991). 
However, the present investigations demonstrated that while delta FosB 
immunoreactivity followed expected patterns in the DLStr and MLStr, we (and 
others) were unable to replicate findings of clozapine- induced delta FosB IR in 
the medial prefrontal cortex (mPFC) (Table 3.1, Figure 3.21). In fact, induction 
was significant for risperidone, and it seemed that there was some induction of 
delta FosB immunoreactivity in the mPFC. Differences in results could reflect 
different criteria applied to counting methods, as one could either count 
changes in the number of IR positive neurons (which was done in the present 
study), or the intensity of already delta FosB positive neurons could be 
counted. 
Based on the findings of the present study, an alternative hypothesis for the 
regulation of delta FosB (and c-fos) can be proposed (Atkins et al., 1999). The 
results of the present study demonstrated that the in vitro and in vivo regulation 
of both c-fos mRNA and delta FosB were only associated with dopaminergic 
(and1 or sigma) receptor blocking neuroleptics and did so only at doses which 
would produce significant Dp or sigma receptor binding (Schotte et al., 1993; 
1996). On the other hand, serotonin receptor blocking neuroleptics did not 
seem to alter the expression of either early immediate gene, which is not 
surprising given that serotonergic agonism (and not 5-HT2 receptor blockade) 
increases c-fos mRNA (Humblot et al., 1 997). 
Although the clozapine-induced induction of c-fos mRNA in the mPFC is 
short lived. its induction may be indicative of the activation of pathways other 
than those induced by the blockade of D2 receptor containing pathways. Long 
term changes in early immediate gene expression in the mPFC for clozapine 
may either not exist or may translate into the regulation of an entirely different 
set of early immediate genes. It is quite intriguing, therefore, that a statistically 
significant increase in mPFC BDNF mRNA upon acute injection of clozapine 
was found in the present study. Nevertheless, induction of delta FosB IR by 
chronic neuroleptic administration may provide researchers with a useful map 
to unravel the molecular mechanisms of antipsychotic drugs. Future studies 
would do well to elucidate the target proteins of delta FosB. 
4.3 Neuroleptics demonstrate neuroprotective potential by positively 
regulating genes involved in neuroprotection and neurodegeneration 
As previously discussed, neuroanatomical studies of schizophrenia 
suggest that progressive neuropathological changes (such as neuronal 
atrophy andlor cell death) occur over the lifetime course of the disease (DeLisi, 
1997). Early intervention with atypical neuroleptics has been shown to prevent 
progression of at least some symptoms, although the mechanisms by which 
neuroleptics may do this remain unknown. 
Not only is it concluded that untreated schizophrenia progresses into a less 
treatable state, but it has been proposed that long term improvement of 
outcome in schizophrenia can occur throughout the entire course of neuroleptic 
treatment (Edwards et al., 1999; Ende et al., 2000). It is unknown, however, if 
these changes require continuous neuroleptic treatment or, if the 
neuropathology will return to its initial state after the discontinuation of 
medication. If schizophrenia is characterized by ongoing neuronal atrophy, it is 
possible that the atrophied neurons can be induced to rebuild and strengthen 
their processes by the appropriate treatment, and could go on to form 
strengthened synaptic connections. The present investigator would argue that 
the findings of the current studies support this notion. It is even possible that 
some neuroprotective genes are target genes of delta FosB (Nikam et al., 
1995: Hayes et al., 1997), and it was of interest to determine if any of the 
following neuroprotective factors were regulated in a manner similar to delta 
FosB. 
4.3.1 Superoxide dismutase (SOD1) and the low affinity nerve growth 
factor receptor p75 
In the present study, PC12 cells were used to determine the effects of a 
number neuroleptics on the gene expression of superoxide disrnutase (SOD) 
and the low affinity nerve growth factor receptor (p75). As previously 
discussed, the free radical scavenging enzyme SOD1 is widely distributed in 
the CNS, including many regions reported to be atrophied in schizophrenia, 
such as the hippocampus and cerebral cortex (Lohr et al., 1990; Selemon et 
al., 1995) . It is therefore conceivable that upregulation of this enzyme by 
neuroleptics could prevent further free radical induced neurotoxicityl 
neurodegeneration in schizophrenia. The p75 or low affinity nerve growth 
factor receptor, which binds all neurotrophins with an equal affinity, must be 
occupied with neurotrophin in order for its "host" neuron to survive. Its mRNA 
expression in adults is primarily limited to the medial septa1 nucleus and the 
nucleus of Broca's diagonal band (Vazquez and Ebendal, 1991 ). These nuclei 
of the basal forebrain contain cholinergic neurons which project to the 
hippocampus and cerebral cortex (Ebendal, 1992). The atrophy of these 
neurons would result in decreased input to the hippocampus and cortex, which 
could either exacerbate symptoms of schizophrenia, or contribute to the 
degeneration and death of target neurons. Interestingly, the increased 
expression of p75 in cholinergic neurons is associated with Alzheimer's 
disease (Woolf et al., 1989) and R-amyloid toxicity (Rabizadeh et al., 1994). 
While no effects on SOD mRNA in PC12 cells were observed for 
remoxipride, ritanserin, or haloperidol; clozapine. olanzapine and risperidone 
did upregulate this neuroprotective enzyme. No effects on SOD or p75 rnRNA 
were seen for remoxipride or ritanserin, suggesting that neither the D2 nor the 
5-HT2 receptor are specifically involved in the SOD and1 or p75 response. 
However, at 12 hours, haloperidol seemed to upregulate, while clozapine 
seemed to downregulate p75 mRNA (Figure 3.26), although these trends did 
not reach statistical significance. At 24 and 48 hours, both haloperidol and 
clozapine down regulated p75 mRNA. This differential regulation of p75 mRNA 
by haloperidol vs. clozapine is quite interesting, given that haloperidol has 
been found to be neurotoxic in many experimental paradigms (Fang and 
Gorrod, 1991; Fang and Yu, 1997) and that elevated p75 receptors could 
possibly facilitate cell death. It is possible that if haloperidol is neurotoxic, the 
initial upregulation of p75 by haloperidol may reflect its propensity to increase 
cell death, and the ability of the PC12 cells to attenuate the upregulation of 
p75 at a later time point may reflect a compensation of the initial upregulation. 
These results suggest that since atypical neuroleptics such as clozapine and 
risperidone more favorably regulate genes involved in neuroprotection and 
neurodegeneration, they would be more likely than haloperidol to reduce any 
clinical signs of pathology due to neurodegeneration in schizophrenia. Further 
studies at longer time points would be necessary to confirm this hypothesis. 
After becoming available for laboratory investigation approximately two 
years ago, olanzapine was included in later PC12 studies. The PC12 cultures 
were treated with olanzapine for a longer time than the other neuroleptics used 
in order to observe its effects at lower doses over a longer period of time. The 
results showed that olanzapine increases SOD and decreases p75 gene 
expression at concentrations of 10 and 100 pM after 48 hours of incubation in 
PC1 2 cultures. It is interesting that olanzapine, clozapine, and risperidone 
significantly upregulated SOD mRNA, while olanzapine, haloperidol and 
clozapine (but not risperidone) significantly downregulated p75 mRNA. It is 
difficult to interpret the meaning of the differential stimulation by neuroleptics in 
this paradigm, but it may involve differences in receptor binding profiles. The 
role of cell death and perhaps the p75 receptor in schizophrenia is supported 
by the finding that there is altered death of neurons in neuronal cultures from 
adults with schizophrenia (Feron et al., 1999). 
PC12 cells have been widely used as a model for the study of 
catecholamine synthesis, release, and metabolism; and neuronal differentiation 
and cell death (reviewed by Greene and Tischler, 1982). The present 
investigation shows for the first time that some neuroleptics increase SOD1 
and decrease p75 gene expression in PC1 2 cells. The results support the 
hypothesis that neuroleptics could protect neurons by upregulating the 
expression of genes coding for a neuroprotective enzyme (SOD1 ) and 
downregulating the expression of neurodegenerative genes that code for a 
receptor (p75) associated with programmed cell death. Since, as suggested 
by several investigators, one of the mechanisms by which stress-induced cell 
damage and/ or death is via oxidative damage. then stress experienced prior to 
the onset of schizophrenia may produce greater cell damage in a system that 
is already neurodevelopmentally compromised. Since stress increases 
glucocorticoid secretion and glucocorticoids downregulate SOD1 activity (Cvijic 
et al., 1995), SOD might protect against such damage. 
4.3.2 BDNF mRNA 
It was the hypothesis of the present study that disruptions of BDNF may 
play a role in the etiology of schizophrenia by compromising neuroplasticity or 
altering normal neurotransmission. and that neuroleptics may in part restore 
the balance of this neurotrophin. As previously mentioned, BDNF is the most 
abundant neurotrophin in the brain (Marty et at., 1996; Maisonpierre et al., 
1991 b; Philips et al., 1990). Not only is it decreased in the hippocampus of 
persons with schizophrenia (Brouha et al., 1996) but an allele variant of this 
gene has been found in persons with schizophrenia (Vahid-Anisari et al., 
1996). BDNF is decreased by factors associated with the exacerbation of 
schizophrenia such as stress (Smith et al., 1995) and estrogen withdrawal 
(Singh et al., 1995), and is elevated by treatments for schizophrenia, including 
~ - H T ~ A  receptor antagonists and ECT treatment (Vaidya et al., 7997). 
It was initially expected in the present study that atypical neuroleptics would 
upregulate hippocampal BDNF rnRNA, while typical neuroleptics would not 
regulate this neurotrophin. In addition, it was hypothesized that chronic, but 
not acute, neuroleptic treatment would upregulate BDNF mRNA. While the 
present study demonstrated that chronic, but not acute, neuroleptic 
administration altered BDNF mRNA (see Figures 3.31 and 3.32), it was not in 
the hypothesized pattern. Chronic haloperidol administration siginifcantly 
downregulated hippocampal BDNF mRNA in the dentate gyms and CAI 
region, while ritanserin significantly upregulated BDNF mRNA in the CA1. 
Although the atypical neuroleptics clozapine and risperidone modestly 
upregulated hippocampal BDNF mRNA, this effect did not reach statistical 
significance; the other atypical neuroleptic, rernoxipride, tended to 
downregulate hippocampal BDNF mRNA. 
These findings led to the revision of the initial working hypothesis and a 
subsequent dose-response study to elucidate the effects of varying the 0 2  to 
5-HT2 blocking ratio of atypical neuroleptics. It was expected that the atypical 
neuroleptics risperidone and clozapine would upregulate hippocampal BDNF 
mRNA at lower doses where their DA 02 blocking potencies did not outweigh 
their 5-HT2 receptor blocking properties. This hypothesis was based on the 
aforementioned findings that the D2 blockers haloperidol and remoxipride 
downregulated, while the 5-HT2 blocker ritanserin upregulated BDNF mRNA. 
The dose-response study demonstrated that while the lower doses of 
risperidone and clozapine did not produce statistically significant increases in 
BDNF mRNA levels over controls, they showed a consistent trend to 
upregulate this neurotrophin in the hippocampus, while the single dose of 
haloperidol used consistently decreased BDNF mRNA throughout the 
hippocampus (see Figures 3.33-3.36). Conversely, high doses of clozapine, 
and especially risperidone, caused a reduction of BDNF mRNA which almost 
reached statistical significance by ANOVA (p< 0.07). These findings have 
been supported by other investigators, including Khaing et al. (1999) and 
Molteni et al. (1999). If regulation of BDNF mRNA by atypical neuroleptics is 
truly indicative of the.neuroprotection they can afford, more (a higher dose) is 
not necessarily better. 
In conclusion, the present experiments showed that when the dose of 
atypical neuroleptics such as risperidone and clozapine theoreticalIy reaches a 
50% D2 receptor occupancy (as estimated from neuroleptic ex vivo receptor 
occupancies determined by Schotte et al.. 1993), the effects D2 receptor 
inhibition overrides any effect that 5-HT2 receptor blockade might have on the 
elevation of hippocampal BDNF mRNA and will cause downregulation of 
BDNF mRNA that approaches that of haloperidol. In addition, the results of 
the present study would suggest that it is unlikely that any neuroleptic which 
blocks only D2 receptors will significantly upregulate BDNF mRNA levels 
beyond controls. It is difficult to ascertain whether or not these findings have 
clinical relevance, but it is of interest that both the clinical use of haloperidol 
and the reduction of hippocampal BDNF mRNA in BDNF-deficient mice are 
associated with memory loss. decreased learning, and decreased motor 
activity (Neeper et al., 1996; Ma et al., 1998; Beuzen et al., 1999). 
Since ~ - H T ~ A  blockers can block stress-induced decreases in BDNF 
mRNA (Vaidya et al., 1997), this may be quite important in the function of 
atypical neuroleptics - especially since stress has been associated with the 
exacerbation of schizophrenia and itself can cause atrophy of neurons (Smith 
et al., 1995). It is conceivable that in a person predisposed to schizophrenia, 
impaired neuronal circuitry is more vulnerable to deficiencies in neurotrophin 
levels which could be caused by stress (Smith et al., 1995), estrogen 
withdrawal (Singh et al., 1995), or other insults, and early intervention with a 5- 
HT2 receptor-blocking neuroleptic could at least prevent trophin decreases 
induced by these events. Stress (Magarinos et al., 1996) and glucocorticoids 
(Sapolsky et al., 1985), both of which have been implicated in the etiology and 
exacerbation of schizophrenia, cause dendritic atrophy (Sapolsky et al.. 1990) 
and reduction of BDNF and NT3 in the hippocampus (Smith et al., 1995), 
Thus, it would be of considerable value to study the effects of typical and 
atypical neuroleptics on BDNF mRNA in models of "onset" of schizophrenia by 
determining if atypical neuroleptics have the ability to block decreases in 
BDNF mRNA during these critical periods associated with first episode onset 
of schizophrenia. 
4.3.3 Summary of the effects of neuroleptics on neuroprotective and 
neurodegenerative factors 
Many clinical studies have shown that some of the symptoms of 
schizophrenia not only worsen over time, but that untreated schizophrenia can 
eventually develop into a more permanent and less treatable state (Wyatt et 
al., 1995). This would imply that in addition to a probable neurodevelopmental 
defect in schizophrenia , there is a neurodegenerative component (such as 
neuronal atrophy or cell death) to the disorder associated with symptom onset 
(Coyle et al., 1996), and it is most likely that the developmental and 
degenerative components significantly interact and are not mutually exclusive. 
Increasing evidence that the early treatment of schizophrenics with 
neuroleptics can improve long term outcome demands that the molecular 
mechanism(s) by which neuroleptics do this be elucidated, as we have 
attempted to do in the present study. 
Neuroanatomically, it is likely that neurodegeneration does occur long 
before the observation of overt clinical symptoms, but the exact time is difficult 
to determine. Ventricular enlargement suggesting neuronal atrophy in 
schizophrenia has been known for years (Weinberger et al., 1979). but it is 
unknown if this neuronal atrophy is static or ongoing. According to Woods et 
al. (Woods et al., 1996, Woods, 1 998), any increase in extracerebral CSF 
caused by an earlier non-progressive lesion would tend to be masked by 
subsequent "outward growth", as brain volume more than triples between birth 
and five years (Wood et al.. 1998). This would suggest that ventricular 
enlargements observed in schizophrenia must result from a diffuse lesion 
resulting in a loss of brain tissue and a reduction in its volume that occurs after 
maximal brain volume expansion. Since ventricles can enlarge with both early 
and late tissue volume loss, cross-sectional studies (which only look at the 
ratio of lateral ventricular volume to total brain tissue volume) can detect tissue 
loss but cannot distinguish between early and later time of occurrence. Only 
volume measurements that include extracerebral CSF volumes can determine 
whether or not there has been later volume loss. Findings by Nopoulos et al. 
(1995) that patients with schizophrenia had less brain tissue, more 
extracerebral CSF, and more ventricular CSF suggest that the patients' brain 
volume loss occurred in the time period after maximum brain volume 
expansion but before onset of overt illness. 
Presently, there are ongoing studies attempting to demonstrate the abilities 
of neuroleptics to arrest some symptoms of schizpohrenia (Edwards et al., 
1999). This is a difficult theory to test for a number of reasons, including the 
anatomical ones described above. Because the prodromal symptoms of 
schizophrenia are not particularly specific to the disorder, clinicians who 
hypothesize that neuroleptics arrest the progression of some symptoms of 
schizophrenia must wait until the first clinical signs of schizophrenia are 
observed. Most people with schizophrenia have already experienced at least 
one or more psychotic episodes before seeking medical treatment (Wyatt et 
al., 1991 a, b). Although the course of schizophrenia varies between patients, a 
short prodromal phase of general psychopathology (one to two years) 
generally precedes the onset of the illness, characterized by a non-specific 
signs of psychopathology such as social withdrawal, poor hygiene, and 
changes in sleep patterns. Some researchers would argue that this is the point 
where individuals at risk must be targeted for treatment (Parnas, 1999). 
As stated by Waddington et al. (1997a): "One fundamental issue is the 
extent to which the new antipsychotics might shift materially the risk benefit 
balance towards intervention, not just at the earliest possible stage following 
the onset of psychosis but at a yet earlier, 'prodromal' phase of the disorder 
where there is a considerably greater likelihood of 'treating' behavioural 
disturbances that prove not to be the harbingers of psychotic illness". 
McGlashan (1998a,b) states that the urgency of treatment, however, comes 
from the belief that "it is likely these deficit processes begin some time before 
the first manifest signs and symptoms of illness in the prodromal phase and 
are time limited, diminishing in activity at or shortly after onset in the majority of 
cases" and that "currently these processes appear irreversible, but anecdotal 
experience with treatment in the very early phase of schizophrenia suggests 
that brain plasticity may be retained and that efforts at preventing deterioration 
should become a focus of active scientific clinical research". Since it is thought 
that this treatment must occur early in the active phase of the illness to prevent 
progression, it is this time point of neurodegeneration in schizophrenia that 
researchers should target, which makes the identification of vulnerability 
markers imperative (Matsuoka et al., 1999). Further studies are required to 
determine if such progression is specific to schizophrenia, or if it also 
characterizes other psychiatric disorders. 
There are obvious ethical problems with testing such a theory (Falloon, 
1992) since it is not acceptable to delay treatment in order to determine if 
patients will have additional long term brain damage. Mahadik and Scheffer 
(1996) and Mahadik and Gouda (1996b) propose that if schizophrenia is 
characterized by neurodegenerative processes involving oxidative stress, 
pretreatment in individuals with a high risk to develop schizophrenia may 
include the addition of vitamin E to their diets. In addition, it is not wise to 
initiate treatment with antipsychotics whose mechanisms of action are not fully 
understood unless it has been consistently demonstrated that these drugs will 
arrest some sort of neurodegenerative process. 
Usually, negative and cognitive symptoms increase over time, while 
positive symptoms can lessen in severity (Ende et al., 2000). Not only do 
these findings suggest that some symptoms progress over the course of the 
illness, but they further demonstrate the heterogeneity of this disease. This 
would be supported by clinical observations that the degree, ratio, and type of 
positive, negative, and cognitive symptoms varies greatly among patients. 
Since the ratio of positive to negative symptoms varies among patients, people 
with a predominance of negative and cognitive symptoms may be at greater 
risk for further deterioration. Since cognitive decline is integral to many post 
pubertal neurodegenerative disorders such as Alzheimer's disease, 
Huntington's disease, and even Parkinson's disease (which also affect brain 
circuitry purported to be altered in schizophrenia), it would not be surprising if 
the cognitive deficits accompanying schizophrenia are also characterized by 
neurodegeneration. Arnold et al. (1995) found that "patients with marked 
cognitive deterioration over time showed more gliosis restricted to the 
subiculum and orbitofrontal cortex than did otherwise similar patients without 
such cognitive impairment", suggesting that there are specific subtypes of 
schizophrenia which are more likely to be characterized by neurodegeneration. 
4.4 Limitations of present research 
There were several limitations in the present studies, some of which 
included the use of tissue culture. Although cell culture is an excellent means 
by which to analyse the effects of drugs at a cellular level, it does not provide 
information about what treatments do in vivo. In addition, the animals used in 
these studies do not have the brain abnormalities present in schizophrenia, 
making it possible that the biocheminical substrates regulated by neuroleptics 
might only become apparent in the schizophrenic neuroanatomy. It is probable 
that massive upregulation of BDNF by neuroleptics would not be desirable, as 
increased seizure activity is associated with elevated BDNF mRNA and protein 
(Ernfors et al., 1991; Rocamora et al., 1992; Nawa et al., 1995; Salin et al., 
1995), while decreased seizure suseptibilities are seen in BDNF-deficient, 
mutant mice (Kokaia et at., 1995). In addition, a low n (ranging between 3 and 
4 for each culture condition or animal group tested) was used for the majority 
of the studies. A higher n may have led to more statistically significant results, 
and therefore the ability to draw more definite conclusions. 
4.5 Suggestions for future research 
Given the role of stress, estrogen, and NMOA receptor fuction (Mohn et al., 
1994; Deutsch et a!., 1997; Woolley; 1998) in both schizophrenia and the 
regulation of BDNF, it would be of interest to further examine these factors in 
the neuroleptic response. It is still unknown if neuroleptics could protect 
against stress-induced or estrogen withdrawal- induced decreases in BDNF 
mRNA. Studies need to be done to confirm that: a) stress- or estrogen 
withdrawal-induced decreases in BDNF mRNA cause neuronal damage or 
death, b) neuroleptics can prevent stress- or estrogen-induced decreases in 
BDNF mRNA, and that this action specifically leads to neuroprotection. Future 
studies will test the ability of neuroleptics to prevent stress-induced decreases 
in BDNF mRNA and additional markers of neuroprotection. 
4.6 General conclusions 
The causes, etiology, and treatment of schizophrenia are poorly 
understood. The relative 02 to 5-HT2 blocking ratios of neuroleptics seem to 
predict neuroleptic differences in efficacy and side effect profiles, but we found 
in our studies that this was not always the best way to characterize the 
molecular effects of typical vs. atypical neuroleptics. 
As no common mechanism of action of all neuroleptics has been found to 
date, we had hoped that we would elucidate some mechanisms of action of 
neuroleptics that were both characteristic of all neuroleptics and that 
differentiated among the various classes of neuroleptics. We generally found 
that early immediate gene regulation correlated with D2 blocking activity, and 
that the neuroprotective properties of neuroleptics were associated with doses 
that produced lesser Dp blockade. We found out very little about the 
contribution of serotonergic blockade in the neuroleptic response at the 
molecular level, except to say that perhaps 5-HT2 blockade upregulates 
BDNF. Future studies will be needed to truly understand the role of 5-HT2 
receptor blockade in the neuroleptic response. 
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Appendix A: List of Chemicals and Reagents 
Abbott Laboratories (Montreal, Quebec, Canada) 
sodium pentobarbital 
Aldrich Chemical Company (Milwaukee, Wisconsin, USA) 
D.P.X. mounting medium 
American Type Culture Collection (Rockville, Maryland, USA) 
PC1 2 cells 
Amersham Phamacica Biotech (Baie dgUrfe, Quebec, Canada) 
ACS (Aqueous counting scintillant) 
dextran sulfate 
Hybond N Nylon paper 
Astra Pharmaceutical Inc. (Mississauga, Ontario, Canada) 
remoxipride HCl 
Baker (J.T.) Chemical Co. (Phillipsburg, NJ) 
CaC12 
Triton X-100 
Beckman Instruments (Mississauga, Ontario, Canada) 
polyallomer tubes 
BDH (Toronto, Ontario, Canada) 
aristar alcohol 
chloral hydrate 
chloroform 
ethidum bromide 
formamide 
gelatin 
hydrogen peroxide 
isopentane 
potassium phosphate (monobasic) 
sodium chloride 
sodium hydroxide 
sucrose 
toluene 
ultraformamide 
xylene 
Becton Dickinson Canada (Missisauga, Ontario, Canada) 
Falcon@ 6 well plates 
Falcon@ cell culture flasks 
Biolcan Scientific (Missisauga, Ontario, Canada) 
glass milk 
Gene Clean IP  Kit 
BIORAD (Missisauga. Ontario, Canada) 
Biospin-30 chromatography columns 
Boehringer Manhiem Canada (Laval, Quebec, Canada) 
Hexanucteotide Mixture 
Random Primed DNA Labelling Kit 
SP6fr7 Transcription Kit 
Charles River Canada (Montreal. Quebec) 
Male Wistar rats 
Colorado Serum Co. (Denver, Colorado. USA) 
normal goat serum 
Difco Laboratories (Detroit, Michigan, USA) 
bacto-t ryptone 
bacto-yeast extract 
Eastman Kodak (Rochester, New York, USA) 
developer 
fixer 
NTB2 emulsion 
octyl sodium sulfate 
Eli Lilly 
ofanzapine 
FISHER Scientific Co. (Nepean, Ontario, Canada) 
chromium potassium sulfate 
Melvin Freed microscope slides 
Permount (metioned in thesis?) 
potassium acetate 
potassium chloride 
Premium glass cover slips 
sodium azide 
FISHER1 Promega (Madison, Wiconsin, USA) 
restriction endonucteases 
T3 RNA polymerase 
x-gal 
Gibco BRU Life Technologies (Burlington, Ontario, Canada) 
agarose (ultra-pure) 
CsCl 
GlTC (guanidium isothiocyanate) 
phenol 
ICN Biomedicals, I nc. (Costa Mesa, California, USA) 
ampicillin 
DEPC (diethylpyrocarbonate) 
GlTC (guanidium isothiocyanate) 
iodoacetamide 
N-ethyl Maleimide 
penicillin G, sodium salt 
streptomycin sulfate 
TEA (triethanolarnine HCI) 
International Biotechnologies (New Haven, Connecticut) 
ammonium acetate 
DTT (dithiothreitol) 
Tris HCI 
Janssen Pharmaceutica 
haloperidol 
risperidone 
ritanserin 
Mandel I New England Nuclear (NEN; Boston, MA, USA) 
[32P] CTP 
[32P] dCTP 
[35S] CTP 
Reflection autoradiograph film NEF 496 
Nalgene 
0.2~ and 0.8~ Millipore filters 
Novartis 
clozapine 
PDI Bioscience 
Protienase K 
Perkin-Elmer 
AmpliTaq 
DNTP's 
PCR buffer 
PIERCE (Rockford, IL, USA) 
Pharmacia Biotech. (Uppsala, Sweden?) 
DNAse I 
Nucleoside triphosphates (ATP, CTP, GTP, UTP) 
RNase A 
Research Biochemicals Inc. (RBI. Natick. MA, USA) 
dextromethorphan hydrobromide 
Santa Cruz 
FosW delta FosB antibody 
Sigma Chemical Co. (St. Louis, MO, USA) 
2-mercaptoethanoi 
acetic anhydride 
agar 
ammonium acetate 
bovine serum albumin (BSA) 
bromophenol blue 
citric acid (trisodium salt dihydrate) 
collagen solution type I 
cresyl violet acetate 
DAB (3.3'-diaminobenzidine tetrahydrochloride) 
dextran sulfate 
dithiotreitol (DTT) 
EDTA 
fetal calf serum 
Ficoli 
formamide 
glucose 
glutamine 
heparin sulfate (sodium salt) 
horse serum 
kainic acid (2-carboxy-3-carboxymethyl-4-isopropenylpyrrolidine) 
MgC12 
MOPS (3-(N-morpholino) propanesulfonic acid) 
NaCl 
NaOH 
N-lauryl-sarcoside 
paraformaldehyde (PFA) 
poly-l-lysine 
polyvinyl pyrrolidone 
potassium chloride 
potassium phosphate (monobasic) 
salmon sperm DNA 
sodium acetate 
sodium phosphate 
speridine trihydrochloride 
sucrose 
Tris 
Trizma (tris base) 
Vector Laboratories 
ABC Vectastain Elite kit 
avidin-biotin peroxidase complex 
goat-anti rabbit 2" antiserum 
